

# CITATION REPORT

List of articles citing

## Edoxaban versus warfarin in patients with atrial fibrillation

DOI: 10.1056/nejmoa1310907

New England Journal of Medicine, 2013, 369, 2093-104.

**Source:** <https://exaly.com/paper-pdf/55159140/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2208	Human U1 small nuclear RNA pseudogenes do not map to the site of the U1 genes in 1p36 but are clustered in 1q12-q22. <b>1985</b> , 5, 2172-80		41
2207	Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease. <b>2005</b> , 62, 281-92		34
2206	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European College of Intensive Cardiology (ECIC). <b>2012</b> , 13, 157-339		1314
2205	Edoxaban noninferior to warfarin, lower rates of major bleeding. <b>2013</b> , 1482, 3-3		
2204	Management of unruptured intracranial aneurysms. <b>2013</b> , 3, 99-108		51
2203	ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation. <b>2013</b> , 2013, 354-6		4
2202	Research Roundup. <b>2014</b> , 9, 10-10		
2201	Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients. <b>2014</b> , 10, 841-50		6
2200	New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. <b>2014</b> , 8, 789-98		80
2199	Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials. <b>2014</b> , 9, e95354		6
2198	Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria. <b>2014</b> , 9, e99276		27
2197	Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan. <b>2014</b> , 9, e113641		17
2196	Stroke and bleeding risk in atrial fibrillation. <b>2014</b> , 44, 281-90		29
2195	A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?. <b>2014</b> , 10, 507-22		14
2194	Novel oral anticoagulants in non-valvular atrial fibrillation. <b>2014</b> , 12, 3-8		17
2193	Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. <b>2014</b> , 112, 918-23		46
2192	Update in Cardiology: Evidence Published in 2013. <b>2014</b> , 160, 847		

2191 Epistaxis and antithrombotic treatment. **2014**, 26, 109-121

2190 The target-specific oral anticoagulants: practical considerations. **2014**, 2014, 510-3

5

2189 Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke. **2014**, 45, 2983-8

24

2188 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. **2014**, 30, 1114-30

305

2187 Consistency of safety profile of new oral anticoagulants in patients with renal failure. **2014**, 12, 337-43

24

2186 Vorhofflimmern â¼iertes NOAK reiht sich ein. **2014**, 15, 10-10

2185 NOAK bei Herzinsuffizienz. **2014**, 17, 4-9

2184 Stroke prevention in Asian patients with atrial fibrillation. **2014**, 45, 1608-9

10

2183 Atrial fibrillation in the elderly: a review. **2014**, 10, 745-58

9

2182 Pericardial endoscopy-guided left atrial appendage ligation: a pilot study in a canine model. **2014**, 7, 844-50

2

2181 [Consensus statement: Stroke prevention in nonvalvular atrial fibrillation in special consideration of the new direct oral anticoagulants]. **2014**, 126, 792-808

2

2180 Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers. **2014**, 34, 743-52

17

2179 Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. **2014**, 70, 1339-51

52

2178 Patient self-testing and self-management of oral anticoagulation with vitamin K antagonists: guidance from the British Committee for Standards in Haematology. **2014**, 167, 600-7

19

2177 Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. **2014**, 4, 619-639

1

2176 When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world-a problem or a myth ?. **2014**, 40, 852-9

13

2175 Direct oral anticoagulants: integration into clinical practice. **2014**, 90, 529-39

13

2174 Left ventricular diastolic dysfunction: a new foe in the management of atrial fibrillation?. **2014**, 14, 261-4

2173	Anticoagulation in the older adult: optimizing benefit and reducing risk. <b>2014</b> , 40, 688-94	6
2172	New oral anticoagulants for non-valvular atrial fibrillation: harder to handle than expected. <b>2014</b> , 35, 1825-36	3
2171	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <b>2014</b> , 35, 3377-85	127
2170	Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. <b>2014</b> , 4, e005379	1
2169	Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation. <b>2014</b> , 1, e000080	9
2168	Clinician's guide to the updated ABCs of cardiovascular disease prevention. <b>2014</b> , 3, e001098	17
2167	Anticoagulation therapy: Edoxaban noninferior to warfarin in patients with AF. <b>2014</b> , 11, 66	1
2166	Bleeding complications of targeted oral anticoagulants: what is the risk?. <b>2014</b> , 2014, 504-9	5
2165	Ischämischer Schlaganfall â Orale Antikoagulation in der Sekundärprävention. <b>2014</b> , 43, 36-40	
2164	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?. <b>2014</b> , 42, 153-62	1
2163	Vorhofflimmerablation und Antikoagulation â Welches Patientenkollektiv kann profitieren?. <b>2014</b> , 43, 48-52	
2162	Perioperative management of target-specific oral anticoagulants. <b>2014</b> , 42, 38-45	3
2161	Strategies for urgent reversal of target-specific oral anticoagulants. <b>2014</b> , 42, 108-25	
2160	Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?. <b>2014</b> , 10, 153-5	
2159	Praktische Anwendung der neuen Antikoagulanzen bei Patienten mit TIA und Schlaganfall und Vorhofflimmern bei absoluter Arrhythmie. <b>2014</b> , 41, 146-155	1
2158	Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention. <b>2014</b> , 35, 3323-5	6
2157	Direct oral anticoagulants: new drugs and new concepts. <b>2014</b> , 7, 1333-51	67
2156	Left atrial appendage occlusion addresses the tremendous unmet needs of stroke prevention in atrial fibrillation that persist despite recent advances in anticoagulation therapy. <b>2014</b> , 130, 1516-23	5

2155	Oral anticoagulants for Asian patients with atrial fibrillation. <b>2014</b> , 11, 290-303	27
2154	The use of oral anticoagulants for the treatment of venous thromboembolic events in an ED. <b>2014</b> , 32, 1526-33	4
2153	Antithrombotics in atrial fibrillation and coronary disease. <b>2014</b> , 12, 977-86	4
2152	Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence. <b>2014</b> , 12, 933-47	5
2151	What is 'valvular' atrial fibrillation? A reappraisal. <b>2014</b> , 35, 3328-35	123
2150	Improving anticoagulant prescribing for AF. <b>2014</b> , 25, 8-12	1
2149	Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. <b>2014</b> , 134, 1198-204	93
2148	Anticoagulants oraux directs, fibrillation atriale et accidents vasculaires cfrbraux. <b>2014</b> , 5, 269-276	
2147	Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment. <b>2014</b> , 54, 910-6	18
2146	Qualit^ della terapia con dicumarolici, nuovi anticoagulanti orali, e ruolo dei centri per la terapia anticoagulante. <b>2014</b> , 10, 204-211	
2145	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. <b>2014</b> , 12, 24	37
2144	Management of hemorrhage with the target-specific oral anticoagulants. <b>2014</b> , 42, 75-83	
2143	Which drug should we use for stroke prevention in atrial fibrillation?. <b>2014</b> , 29, 293-300	6
2142	'New' direct oral anticoagulants in the perioperative setting. <b>2014</b> , 27, 409-19	35
2141	Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis. <b>2014</b> , 15, 873-9	30
2140	Meta-analysis of efficacy and safety of the new anticoagulants versus warfarin in patients with atrial fibrillation. <b>2014</b> , 64, 368-74	27
2139	Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban. <b>2014</b> , 77, 486-94; quiz 486-94	10
2138	A pint of sweat will save a gallon of blood: a call for randomized trials of anticoagulation in end-stage renal disease. <b>2014</b> , 129, 1190-2	15

2137	Novel anticoagulants eliminate the need for left atrial appendage exclusion devices. <b>2014</b> , 130, 1505-14	6
2136	Target-specific oral anticoagulants: practice issues for the clinician. <b>2014</b> , 42, 48-61	1
2135	New oral anticoagulant agents - general features and outcomes in subsets of patients. <b>2014</b> , 111, 575-82	42
2134	Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. <b>2014</b> , 45, 2372-8	43
2133	Switching between oral anticoagulants. <b>2014</b> , 42, 68-74	1
2132	Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. <b>2014</b> , 3, e000515	73
2131	Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. <b>2014</b> , 111, 783-8	34
2130	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. <b>2014</b> , 111, 798-807	38
2129	Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute. <b>2014</b> , 2014, 901586	5
2128	Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation - patient considerations. <b>2014</b> , 5, 25-30	1
2127	Non-vitamin-K oral anticoagulants reduce mortality, stroke and intracranial haemorrhage when compared with warfarin in randomised trials of patients with non-valvular atrial fibrillation. <b>2014</b> , 19, 182	
2126	Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: a survey of Canadian physicians. <b>2014</b> , 12, 13	10
2125	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. <b>2014</b> , 130, e199-267	1016
2124	Direct oral anticoagulants--pharmacology, drug interactions, and side effects. <b>2014</b> , 51, 89-97	31
2123	Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. <b>2014</b> , 174, 471-83	14
2122	Net clinical benefit outcome should be standardized in trials evaluating antithrombotic drugs: the example of NOACs in atrial fibrillation. <b>2014</b> , 174, 405-6	4
2121	Direct oral anticoagulants in atrial fibrillation. <b>2014</b> , 51, 139-46	2
2120	Left Atrial Appendage Closure with Transcatheter-Delivered Devices. <b>2014</b> , 3, 209-218	14

2119	Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. <b>2014</b> , 168, 239-247.e1	41
2118	Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice. <b>2014</b> , 14, 111-27	17
2117	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <b>2014</b> , 64, e1-76	2768
2116	Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. <b>2014</b> , 7, 113-24	54
2115	Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies. <b>2014</b> , 133, 705-13	30
2114	Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned?. <b>2014</b> , 16, 480	51
2113	Perioperative management of patients on new oral anticoagulants. <b>2014</b> , 101, 742-9	58
2112	Edoxaban: a focused review of its clinical pharmacology. <b>2014</b> , 35, 1844-55	90
2111	[New direct oral anticoagulants : Many advantages, but open questions]. <b>2014</b> , 55, 537-8, 540-5	2
2110	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <b>2014</b> , 383, 955-62	2823
2109	The NOACs (novel oral anticoagulants) have landed!. <b>2014</b> , 127, 1027-1028	3
2108	Balancing ischaemia and bleeding risks with novel oral anticoagulants. <b>2014</b> , 11, 693-703	20
2107	Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. <b>2014</b> , 35, 3346-55	278
2106	Edoxaban: Review of pharmacology and key phase I to III clinical trials. <b>2014</b> , 19, 409-16	17
2105	Edoxaban ist so wirksam wie Warfarin, aber sicherer. <b>2014</b> , 16, 31-31	
2104	Use of PER977 to reverse the anticoagulant effect of edoxaban. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 2141-2	59.2 361
2103	Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis. <b>2014</b> , 25, 1411-8	9
2102	Individualizing treatment choices using quantitative methods. <b>2014</b> , 168, 607-10	7

2101	Antithrombotic and anticoagulant therapy for atrial fibrillation. <b>2014</b> , 32, 585-99	5
2100	PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing body of the American Heart Association (AHA) and the American College of Cardiology (ACC).	153
2099	A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. <b>2014</b> , 134, 1253-64	42
2098	New advances in the treatment of atrial fibrillation: focus on stroke prevention. <b>2014</b> , 15, 2193-204	3
2097	Erratum: Management of unruptured intracranial aneurysms. <b>2014</b> , 4, 98	
2096	Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. <b>2014</b> , 4, e004301	80
2095	Nuevos anticoagulantes orales en fibrilaci3n auricular valvular: ¿Hasta d3nde llegan?. <b>2014</b> , 49, 99-101	0
2094	Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion. <b>2014</b> , 16, 626-30	30
2093	Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. <b>2014</b> , 17, 587-98	52
2092	Evolution of stroke prevention in nonvalvular atrial fibrillation patients. <b>2014</b> , 64, 13-5	2
2091	[Novel oral anticoagulants in patients with atrial fibrillation, how to avoid accidents?]. <b>2014</b> , 43, 775-83	
2090	New oral anticoagulants in patients with atrial fibrillation. <b>2014</b> , 384, 23	1
2089	New oral anticoagulants in patients with atrial fibrillation - Authors' reply. <b>2014</b> , 384, 25-6	12
2088	Gestion pfi-opfatoire des anticoagulants : vers de nouvelles recommandations ?. <b>2014</b> , 6, 110-119	
2087	The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey. <b>2014</b> , 16, 1720-5	50
2086	Fibrilaci3n auricular no valvular: el problema de una definici3n indefinida. <b>2014</b> , 67, 670-671	3
2085	Nonvalvular atrial fibrillation: the problem of an undefined definition. <b>2014</b> , 67, 670-1	
2084	Percutaneous closure of baffle leaks in patients with atrial switch operation for D-transposition of the great arteries. <b>2014</b> , 67, 671-4	1



2083	Oral anticoagulants for stroke prevention in atrial fibrillation. <b>2014</b> , 39, 319-44	4
2082	Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?. <b>2014</b> , 3,	33
2081	Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays. <b>2014</b> , 34, 479-501	26
2080	Cierre percutáneo de comunicaciones interauriculares en pacientes con cirugía de switch auricular para la D-transposición de grandes arterias. <b>2014</b> , 67, 671-674	
2079	Pharmacology and laboratory testing of the oral Xa inhibitors. <b>2014</b> , 34, 503-17	21
2078	Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. <b>2014</b> , 64, 576-84	35
2077	Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. <b>2014</b> , 64, 565-72	161
2076	Switching patients from blinded study drug to warfarin at the end of the ENGAGE AF-TIMI 48 trial: setting a new standard. <b>2014</b> , 64, 585-7	6
2075	Edoxaban: an update on the new oral direct factor Xa inhibitor. <b>2014</b> , 74, 1209-31	75
2074	Advances in clinical cardiology. <b>2014</b> , 31, 837-60	4
2073	Ex vivo reversal of the anticoagulant effects of edoxaban. <b>2014</b> , 134, 909-13	41
2072	Interventioneller Vorhofohrverschluss zur Schlaganfallprophylaxe bei Vorhofflimmern. <b>2014</b> , 8, 327-340	
2071	Personalized approach to primary and secondary prevention of ischemic stroke. <b>2014</b> , 5, 9	7
2070	Stroke prevention in atrial fibrillation: Commentary regarding the AAN's evidence-based guideline update. <b>2014</b> , 4, 96-98	1
2069	Anticoagulation in atrial fibrillation. <b>2014</b> , 348, g2116	49
2068	Evidence-to-practice gaps in post-stroke management: a focus on care in a stroke unit and anticoagulation to prevent death, disability and recurrent stroke. <b>2014</b> , 9, 449-459	
2067	Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials. <b>2014</b> , 12, 1419-24	23
2066	Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. <b>2014</b> , 90, 520-8	21

2065	Do current clinical trials meet society's needs?: a critical review of recent evidence. <b>2014</b> , 64, 1615-28	44
2064	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (EACC) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society. <b>2014</b> , 33, 1533-9	413
2063	[Direct anticoagulants for atrial fibrillation. Update 2014]. <b>2014</b> , 39, 357-67; quiz 368	2
2062	[New pharmaceuticals in cardiology. Heart failure, anticoagulation, dyslipidemia]. <b>2014</b> , 55, 382-9	1
2061	Potential use of NOACs in developing countries: pros and cons. <b>2014</b> , 70, 817-28	12
2060	Novel anticoagulants for stroke prevention in patients with atrial fibrillation. <b>2014</b> , 28, 247-62	4
2059	Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice. <b>2014</b> , 40, 261-8	2
2058	Left atrial appendage closure to prevent stroke in patients with atrial fibrillation. <b>2014</b> , 130, 202-12	27
2057	Comment évaluer le risque ischémique et hémorragique cérébral dans la fibrillation atriale ? Place des approches morphologiques et biologiques. <b>2014</b> , 6, 120-131	
2056	Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat?. <b>2014</b> , 15, 1991-2001	9
2055	Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. <b>2014</b> , 45, 1739-47	106
2054	Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians. <b>2014</b> , 37, 372-9	9
2053	The clinical impact of different coagulometers on patient outcomes. <b>2014</b> , 31, 639-56	6
2052	Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation. <b>2014</b> , 37, 295-307	2
2051	Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage. <b>2014</b> , 14, 1019-28	11
2050	External validity of the ARISTOTLE trial in real-life atrial fibrillation patients. <b>2014</b> , 32, 214-8	13
2049	Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups. <b>2014</b> , 25, 600-6	17
2048	Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding. <b>2014</b> , 51, 102-11	13

2047	Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation. <b>2014</b> , 19, 190-204	10
2046	Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. <b>2014</b> , 168, 160-7	53
2045	Resultados de los nuevos anticoagulantes orales en fibrilaci3n auricular no valvular. <b>2014</b> , 49, 91-94	0
2044	PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS) and the International Society for Adult Congenital Heart Disease. <b>2014</b> , 117, 102-85	374
2043	Vascular response after percutaneous sympathectomy: not all devices are equal. <b>2014</b> , 174, 406-7	9
2042	Critique of Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation trial. <b>2014</b> , 45, 2151-3	1
2041	Acquired bleeding disorders. <b>2014</b> , 32, 691-713	7
2040	Vitamin K antagonists and risk of subdural hematoma: meta-analysis of randomized clinical trials. <b>2014</b> , 45, 1672-8	27
2039	Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. <b>2014</b> , 127, 1075-1082.e1	167
2038	Mechanical closure devices for atrial fibrillation. <b>2014</b> , 24, 225-31	2
2037	Potential antidotes for reversal of old and new oral anticoagulants. <b>2014</b> , 133 Suppl 2, S158-66	35
2036	¿Qu3 aportan los nuevos anticoagulantes en la prevenci3n del tromboembolismo venoso y arterial?. <b>2014</b> , 31, 102-109	
2035	Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. <b>2014</b> , 29, 2439-46	40
2034	New oral anticoagulants--what the cardiothoracic surgeon needs to know. <b>2014</b> , 148, 1794-1801.e1	7
2033	[Stroke in atrial fibrillation patients already on oral anticoagulant: What more can be done?]. <b>2014</b> , 43, 784-8	1
2032	Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. <b>2014</b> , 30, 888-97	59
2031	PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: Executive Summary. <b>2014</b> , 11, e81-e101	22
2030	Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. <b>2014</b> , 111, 981-8	77

2029	Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. <b>2014</b> , 111, 1167-76	320
2028	Report of the American Heart Association (AHA) Scientific Sessions 2013, Dallas. <b>2014</b> , 78, 51-6	3
2027	Inappropriate use of oral anticoagulants for patients with atrial fibrillation. <b>2014</b> , 78, 2166-72	102
2026	Which score should be used for risk stratification of ischemic stroke in patients with atrial fibrillation. <b>2014</b> , 78, 1331-2	3
2025	New era of oral anticoagulation for Japanese non-valvular atrial fibrillation patients. <b>2014</b> , 78, 1317-9	3
2024	Clinical research and the development of medical therapeutics. <b>2014</b> , 78, 1267-71	3
2023	Report of the American Heart Association (AHA) Scientific Sessions 2014, Chicago. <b>2015</b> , 79, 34-40	15
2022	Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). <b>2014</b> , 78, 1997-2021	322
2021	The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. <b>2014</b> , 124, 2450-8	237
2020	Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory. <b>2014</b> , 71, 158-67	11
2019	Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study. <b>2015</b> , 10, 836-42	77
2018	Quality control of oral anticoagulant therapy in Primary Care in Madrid City, Spain: CHRONOS-TAO study. <b>2015</b> , 145, 192-197	1
2017	ERRATUM. <b>2015</b> , 12, 2520	
2016	Epidemiology of Intracranial Haemorrhages Associated with Vitamin K Antagonist Oral Anticoagulants in Spain: TAC Registry. <b>2015</b> , 4, 52-8	10
2015	Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai. <b>2015</b> , 1, 203-209	2
2014	Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study. <b>2015</b> , 201, 693-8	13
2013	Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. <b>2015</b> , 15, 143	40
2012	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <b>2015</b> , 1, 86-94	44

2011	Why do we need observational studies of everyday patients in the real-life setting?. <b>2015</b> , 17, D2-D8	67
2010	Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature. <b>2015</b> , 41, 774-87	13
2009	Neues bei der Therapie intrazerebraler Blutungen. <b>2015</b> , 42, 581-595	1
2008	Vorhofflimmern: welches Antikoagulans für welchen Patienten?. <b>2015</b> , 4, 104-109	
2007	What's new in stroke? Phase III randomized clinical trials of 2012-2014. <b>2015</b> , 10, 790-5	1
2006	An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. <b>2015</b> , 55, 1395-405	33
2005	Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives. <b>2015</b> , 95, 389-404	56
2004	New strategies for effective treatment of vitamin K antagonist-associated bleeding. <b>2015</b> , 13 Suppl 1, S180-6	10
2003	Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review. <b>2015</b> , 38, 684-91	6
2002	Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation. <b>2015</b> , 69, 743-56	5
2001	Triple therapy for percutaneous coronary intervention in atrial fibrillation: standard of care, or a nightmare soon to end?. <b>2015</b> , 13 Suppl 1, S332-5	2
2000	Clinical significance of non-vitamin K antagonist oral anticoagulants in the management of atrial fibrillation. <b>2015</b> , 79, 914-23	10
1999	Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. <b>2015</b> , 79, 1486-95	44
1998	Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients - Insight From the Fushimi AF Registry. <b>2015</b> , 79, 1009-17	44
1997	Oral anticoagulation in Japanese patients with atrial fibrillation –insight to the use of non-vitamin K antagonist oral anticoagulants. <b>2015</b> , 79, 292-4	4
1996	Timing of anticoagulation therapy in patients with acute cardioembolic stroke. <b>2015</b> , 79, 763-5	2
1995	Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation. <b>2015</b> , 79, 2584-90	20
1994	Use of Oral Anticoagulants According to the Degree of Renal Impairment in Japanese Patients With Atrial Fibrillation--Which Non-Vitamin K Antagonist Oral Anticoagulant to Select?. <b>2015</b> , 79, 1441-3	1

1993	Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin--Insights From the ENGAGE AF-TIMI 48 Trial. <b>2015</b> , 79, 2560-7	29
1992	Effect of Renal Function on Anticoagulation Therapy in Asian Patients. <b>2015</b> , 79, 2098-9	5
1991	Message from the editor-in-chief. <b>2015</b> , 79, 2285-6	
1990	Cardiological aspects of stroke prevention. <b>2015</b> , 79, 271-7	6
1989	New Oral Anticoagulants (NOAC) Studies in the Ideal and the Real World - Needs of Prospective Observational Studies. <b>2015</b> , 79, 962-3	1
1988	A review of novel oral anticoagulants in the prevention of stroke for non-valvular atrial fibrillation. <b>2015</b> , 11, 279-285	
1987	Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation â€”meta-analysis. <b>2015</b> , 79, 339-45	30
1986	How can we bridge the results of global clinical trials and region/country specific clinical practice by region/country specific registry data?. <b>2015</b> , 79, 287-8	0
1985	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. <b>2015</b> , 113, 625-32	158
1984	Choosing appropriate patients for anticoagulation. 53-61	
1983	59 Does CHA <sub>2</sub> DS <sub>2</sub> -VASc Score Correlate with Point-of-Care Global Thrombotic Status in Atrial Fibrillation Patients?. <b>2015</b> , 101, A32.2-A33	
1982	Anticoagulants for stroke prevention in patients with atrial fibrillation. <b>2015</b> , 11, 31-37	
1981	Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation. <b>2015</b> , 37, 2476-2488.e27	5
1980	Direkte orale Antikoagulantien: Welche Patienten eignen sich zur Behandlung mit diesen Substanzen?. <b>2015</b> , 10, 1-13	
1979	Vorhofflimmern: orale Antikoagulation. <b>2015</b> , 15, 52-56	
1978	Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study. <b>2015</b> , 31, 339-44	41
1977	Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial. <b>2015</b> , 2, e231-40	17
1976	Sekund�prophylaxe mit oralen Antikoagulanzen. <b>2015</b> , 16, 36-43	

1975 Apixaban for A-fib. **2015**, 13, 50-53

1974 Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ? 2. **2015**, 3, 2050312115613350 10

1973 Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. **2015**, 13, 22 29

1972 A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. **2015**, 13, 29 1

1971 Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. **2015**, 16, 393 54

1970 Novel antidotes for target specific oral anticoagulants. **2015**, 4, 25 23

1969 Edoxaban: Efficacy, Laboratory Monitoring, and Approach to Reversal. **2015**, 139, 1479

1968 Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study. **2015**, 55, 1268-79 31

1967 Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. **2015**, 33, 177-83 48

1966 The new oral anticoagulants: clinical use and reversal agent development. **2015**, 10, 324-331 8

1965 A New Generation of Antiplatelet, and Anticoagulant Medication and the Implications for the Dental Surgeon. **2015**, 42, 840-2, 845-6, 849-50 passim 7

1964 Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis. **2015**, 114, 403-9 11

1963 Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. **2015**, 17, 1192-200 82

1962 Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. **2015**, 42, 1239-49 42

1961 Warfarin pharmacogenetics in the era of new oral anticoagulants. **2015**, 88, 135-6 2

1960 Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage. **2015**, 122, 387-98 47

1959 Novel oral anticoagulants in atrial fibrillation: which novel oral anticoagulant for which patient?. **2015**, 16, 512-9 10

1958 Myths and Legends. **2015**, 22, 255-257

1957	The Impact of Novel Anticoagulants: Should All AF Patients Now Be Anticoagulated?. <b>2015</b> , 66, 530-9	1
1956	Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. <b>2015</b> , 35, 560-8	27
1955	Update in hospital medicine: Evidence you should know. <b>2015</b> , 10, 817-26	2
1954	Triple therapy for atrial fibrillation and percutaneous coronary intervention. <b>2015</b> , 30, 690-6	1
1953	Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study. <b>2015</b> , 36, 1290-8	2
1952	Duraõ dos Episõdios de Fibrilhaõ Auricular e Implicaõs no Risco Tromboembõlico. <b>2015</b> , 28, 766	
1951	Economic Evaluations of Medical Cost Differences: Use of Targeted-Specific Oral Anticoagulants vs. Warfarin among Patients with Nonvalvular Atrial Fibrillation and Venous Thromboembolism in the U.S.. <b>2015</b> , 03,	
1950	Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity?. <b>2015</b> , 8, 217-28	11
1949	Anticoagulation in Atrial Fibrillation - Current Concepts. <b>2015</b> , 4, 100-7	4
1948	Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. <b>2015</b> , 10, 1431-44	14
1947	Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care. <b>2015</b> , 8, 283-91	6
1946	Evaluaciõ positiva de medicamentos: marzo/abril/mayo 2015. <b>2015</b> , 71, 186-195	
1945	The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society. <b>2015</b> , 45, 9-19	33
1944	Preventing bleeding and thromboembolic complications in atrial fibrillation patients undergoing surgery. <b>2015</b> , 73, 704-13	1
1943	The Use of Novel Oral Anticoagulants in Atrial Fibrillation. <b>2015</b> , 15, 97-100	1
1942	Anti-coagulation for Patients with Acute Coronary Syndrome. <b>2015</b> , 21, 272-277	
1941	Management of Antithrombotic Agents in Oral Surgery Maria Martinez and Dimitrios A. Tsakiris. <b>2015</b> , 3, 93-101	2
1940	A Study of the Management of Patients Taking Novel Oral Antiplatelet or Direct Oral Anticoagulant Medication Undergoing Dental Surgery in a Rural Setting. <b>2015</b> , 3, 102-110	3



1939	Epidemiology, diagnosis, and management of atrial fibrillation in women. <b>2015</b> , 7, 605-14	23
1938	An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. <b>2015</b> , 10, 63-73	2
1937	Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. <b>2015</b> , 11, 317-32	9
1936	The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. <b>2015</b> , 10, e0124719	38
1935	Characteristics of Symptomatic Intracranial Hemorrhage in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulant Therapy. <b>2015</b> , 10, e0132900	23
1934	Lyso-Sulfatide Binds Factor Xa and Inhibits Thrombin Generation by the Prothrombinase Complex. <b>2015</b> , 10, e0135025	2
1933	Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis. <b>2015</b> , 10, e0137444	34
1932	Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study. <b>2015</b> , 10, e0140607	7
1931	Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation. <b>2015</b> , 10, e0144314	12
1930	Secondary stroke prevention: challenges and solutions. <b>2015</b> , 11, 437-50	64
1929	Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. <b>2015</b> , 114, 1113-26	52
1928	Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options. <b>2015</b> , 8, 231-42	29
1927	Adherence to oral anticoagulant therapy in secondary stroke prevention - impact of the novel oral anticoagulants. <b>2015</b> , 9, 1695-705	19
1926	Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. <b>2015</b> , 114, 826-34	77
1925	Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. <b>2015</b> , 113, 719-27	92
1924	Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. <b>2015</b> , 2015, 920361	8
1923	Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management. <b>2015</b> , 2015, 424031	6
1922	Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany. <b>2015</b> , 2015, 876923	16

1921	Cancer after intense and prolonged antiplatelet therapies--fact or fiction?. <b>2015</b> , 114, 1100-3	4
1920	Edoxaban. <b>2015</b> , 50, 619-34	3
1919	Left atrial appendage closure devices for cardiovascular risk reduction in atrial fibrillation patients. <b>2015</b> , 47	
1918	Management of direct oral anticoagulants in the perioperative setting. <b>2015</b> , 29, 741-8	10
1917	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. <b>2015</b> , 36, 1470-7	42
1916	NUEVOS ANTICOAGULANTES ORALES EN FIBRILACION AURICULAR. <b>2015</b> , 26, 223-233	0
1915	Reversal of anticoagulants: an overview of current developments. <b>2015</b> , 113, 931-42	126
1914	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. <b>2015</b> , 75, 979-98	9
1913	TIA Management: Should TIA Patients be Admitted? Should TIA Patients Get Combination Antiplatelet Therapy?. <b>2015</b> , 5, 151-60	6
1912	Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. <b>2015</b> , 17, 840-54	25
1911	Edoxaban and the need for outcomes-based NOAC dosing. <b>2015</b> , 385, 2232-3	3
1910	Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation. <b>2015</b> , 15, 323-35	8
1909	Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. <b>2015</b> , 17, 530-8	113
1908	Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. <b>2015</b> , 36, 2239-45	58
1907	Novel oral anticoagulants and reversal agents: Considerations for clinical development. <b>2015</b> , 169, 751-7	62
1906	To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort. <b>2015</b> , 10, 795-804	17
1905	Antithrombotic treatment in elderly patients with atrial fibrillation. <b>2015</b> , 215, 171-181	
1904	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <b>2015</b> , 385, 2288-95	275

1903	Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. <b>2015</b> , 132, 194-204	167
1902	Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. <b>2015</b> , 13, 811-24	5
1901	Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials. <b>2015</b> , 8, 103-14	7
1900	Harnessing the power of real-life data. <b>2015</b> , 17, D9-D14	4
1899	Drug updates and approvals: 2015 in review. <b>2015</b> , 40, 34-43; quiz 43-4	3
1898	Stroke prevention in atrial fibrillation: changing concepts. <b>2015</b> , 1, 76-9	1
1897	Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. <b>2015</b> , 13, 2119-26	528
1896	New oral anticoagulants for patients with nonvalvular atrial fibrillation. <b>2015</b> , 28, 28-34	
1895	Control de la anticoagulaci3n en pacientes con fibrilaci3n auricular no valvular asistidos en atenci3n primaria en Espa1a. Estudio PAULA. <b>2015</b> , 68, 769-776	94
1894	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <b>2015</b> , 17, 1747-69	94
1893	Contemporary measures to reduce the risk of embolic events in patients with atrial fibrillation. <b>2015</b> , 11, 635-43	1
1892	Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry. <b>2015</b> , 170, 1234-42	3
1891	Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. <b>2015</b> , 170, 1140-50	22
1890	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <b>2015</b> , 36, 3268-75	30
1889	New Insights into Nonvitamin K Antagonist Oral Anticoagulants' Reversal of Intracerebral Hemorrhage. <b>2015</b> , 37, 93-106	4
1888	Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials. <b>2015</b> , 66, 2648-2662	57
1887	Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. <b>2015</b> , 8, 1925-1932	61
1886	Saving and Improving Lives in the Information Age: Presidential Address at the American Heart Association 2014 Scientific Sessions. <b>2015</b> , 131, 2238-42	2

1885	Conundrums for Atrial Fibrillation Management in Older Adults. <b>2015</b> , 4, 368-376		
1884	The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines. <b>2015</b> , 31, 1207-18		36
1883	Antidote for Factor Xa Anticoagulants. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2471-2	59.2	31
1882	Asian strategy for stroke prevention in atrial fibrillation. <b>2015</b> , 17 Suppl 2, ii31-9		21
1881	Management of Bleeding Associated with New Oral Anticoagulants. <b>2015</b> , 41, 788-801		14
1880	New Oral Anticoagulants: Clinical Parameters and Uses in Practice. <b>2015</b> , 30, 329-45		3
1879	A multicenter, prospective, observational study of warfarin-associated intracerebral hemorrhage: The SAMURAI-WAICH study. <b>2015</b> , 359, 72-7		8
1878	Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves. <b>2015</b> , 30, 644-56		7
1877	The WATCHMAN device for stroke prophylaxis in atrial fibrillation: an evolving niche. <b>2015</b> , 43, 13-21		1
1876	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <b>2017</b> , 38, 1710-1716		38
1875	Left Atrial Appendage Ligation in Nonvalvular Atrial Fibrillation Patients at High Risk for Embolic Events With Ineligibility for Oral Anticoagulation: Initial Report of Clinical Outcomes. <b>2015</b> , 1, 465-474		26
1874	Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation. <b>2015</b> , 43, 258-67		2
1873	Progress of anticoagulation therapy in atrial fibrillation. <b>2015</b> , 145, 124-130		
1872	Direct factor Xa inhibitor edoxaban: from bench to clinical practice. <b>2015</b> , 8, 707-25		1
1871	Percutaneous left atrial appendage closure: a review of the WATCHMAN clinical trial experience. <b>2015</b> , 7, 333-344		
1870	The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. <b>2015</b> , 67 Suppl 2, S13-34		9
1869	A novel approach indirectly comparing benefit-risk balance across anti-thrombotic therapies in patients with atrial fibrillation. <b>2015</b> , 1, 15-28		11
1868	Real-World Experience with Insertable Cardiac Monitors to Find Atrial Fibrillation in Cryptogenic Stroke. <b>2015</b> , 40, 175-81		43

1867	Efficacy, safety and tolerability of rivaroxaban for the secondary prevention of stroke in patients with atrial fibrillation in clinical practice. <b>2015</b> , 10, 529-536	6
1866	Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter. <b>2015</b> , 115, 635-40	30
1865	Antithrombotic treatment in elderly patients with atrial fibrillation. <b>2015</b> , 215, 171-81	14
1864	Antithrombotic management of atrial fibrillation in the elderly. <b>2015</b> , 99, 417-30	9
1863	Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation. <b>2015</b> , 17, 331	1
1862	Update in cardiac arrhythmias and pacing. <b>2015</b> , 68, 226-33	
1861	Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?. <b>2015</b> , 65, 635-42	187
1860	Data strengthen to support recommending anticoagulant therapy for all atrial fibrillation patients with a CHA2DS2-VASc score ≥2. <b>2015</b> , 65, 643-4	4
1859	[Quality control of oral anticoagulant therapy in Primary Care in Madrid City, Spain: CHRONOS-TAO study]. <b>2015</b> , 145, 192-7	11
1858	Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials. <b>2015</b> , 47, 429-31	28
1857	Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm. <b>2015</b> , 16, 358-64	33
1856	Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?. <b>2015</b> , 66, 241-53	18
1855	Pericardial bleeding risk with non-vitamin K oral anticoagulants: a meta-analysis. <b>2015</b> , 182, 187-8	5
1854	Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation. <b>2015</b> , 14, 45-62	5
1853	New oral anticoagulants for nonvalvular atrial fibrillation in the elderly: Limited applicability in primary care. <b>2015</b> , 21, 145-9	5
1852	Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. <b>2015</b> , 18, 399-409	23
1851	Recent advances in the development of specific antidotes for target-specific oral anticoagulants. <b>2015</b> , 35, 198-207	26
1850	Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. <b>2015</b> , 33, 395-408	37

1849	Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?. <b>2015</b> , 25, 315-36	15
1848	Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?. <b>2015</b> , 10, 21-4	4
1847	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. <b>2015</b> , 36, 281-7a	196
1846	Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. <b>2015</b> , 39, 149-54	28
1845	Left atrial appendage occlusion debate revisited. <b>2015</b> , 131, 756-61	17
1844	The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in nonvalvular atrial fibrillation patients already on vitamin K antagonist. <b>2015</b> , 10, 157-63	8
1843	Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. <b>2015</b> , 39, 288-94	83
1842	Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. <b>2015</b> , 143, 241-7	55
1841	Practical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolism treatment. <b>2015</b> , 39, 295-303	6
1840	Temas de actualidad en arritmias y estimulaci3n cardiaca. <b>2015</b> , 68, 226-233	4
1839	Evidencias actuales de los nuevos anticoagulantes orales en el tratamiento de la fibrilaci3n auricular no valvular: comparaci3n de subestudios. <b>2015</b> , 68, 185-189	5
1838	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <b>2015</b> , 385, 2280-7	126
1837	Restarting oral anticoagulants after intracerebral hemorrhage: pros. <b>2015</b> , 10, 3-4	7
1836	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. <b>2015</b> , 278, 1-18	53
1835	Actualizaci3n 2014 en cardiolog3a cl3nica, cardiolog3a geri3trica e insuficiencia cardiaca y trasplante. <b>2015</b> , 68, 317-323	4
1834	Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. <b>2015</b> , 41, 146-53	14
1833	Target-specific oral anticoagulants and the hospitalist. <b>2015</b> , 43, 1-12	0
1832	New Oral Anticoagulants: How Do We Use Them Wisely?. <b>2015</b> , 17, 626	0

1831	Protocol for Cerebral Microbleeds during the Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients with Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial. <b>2015</b> , 24, 2143-8	8
1830	The case against using hypertension as the only criterion for oral anticoagulation in atrial fibrillation. <b>2015</b> , 31, 576-9	4
1829	Severity and Functional Outcome of Patients with Cardioembolic Stroke Occurring during Non-vitamin K Antagonist Oral Anticoagulant Treatment. <b>2015</b> , 24, 1430-7	20
1828	Left Atrial Appendage Occlusion Device and Novel Oral Anticoagulants Versus Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2015</b> , 8, 1057-64	21
1827	Risk Factors of Ischemic Stroke and Subsequent Outcome in Patients Receiving Hemodialysis. <b>2015</b> , 46, 2477-81	41
1826	HRS/NSA 2014 survey of atrial fibrillation and stroke: Gaps in knowledge and perspective, opportunities for improvement. <b>2015</b> , 12, e105-13	19
1825	A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention. <b>2015</b> , 22, 261-8	13
1824	Innovative designs of point-of-care comparative effectiveness trials. <b>2015</b> , 45, 61-8	14
1823	Are direct oral anticoagulants effective in reducing systemic embolism in patients with atrial fibrillation? A systematic review and meta-analysis of the literature. <b>2015</b> , 180, 192-5	1
1822	Left atrial appendage closure is preferred to chronic warfarin therapy: the pro perspective. <b>2015</b> , 7, 403-13	3
1821	Atrial fibrillation and heart failure: update 2015. <b>2015</b> , 58, 126-35	36
1820	Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding. <b>2015</b> , 135, 554-60	36
1819	Dosing of Target-Specific Oral Anticoagulants in Special Populations. <b>2015</b> , 49, 1031-45	14
1818	Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic. <b>2015</b> , 12, 2332-43	21
1817	Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight. <b>2015</b> , 46, 5-6	4
1816	New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. <b>2015</b> , 196, 133-8	16
1815	Antidotes to non-vitamin K oral anticoagulants: necessary or not?. <b>2015</b> , 16, 1573-6	7
1814	Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. <b>2015</b> , 13, 907-14	2

1813	Patients with atrial fibrillation and CHA2DS2-VASc score 1: "To anticoagulate or not to anticoagulate? That is the question!". <b>2015</b> , 12, 2515-20	4
1812	Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. <b>2015</b> , 138, 2126-39	208
1811	How to define valvular atrial fibrillation?. <b>2015</b> , 108, 530-9	74
1810	Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke. <b>2015</b> , 85, 1078-84	10
1809	Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. <b>2015</b> , 58, 177-94	26
1808	Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies. <b>2015</b> , 66, 466-74	28
1807	Review of anticoagulation options for mechanical valve prosthesis. <b>2015</b> , 7, 273-281	
1806	60 Anticoagulation in AF: Is Time in Therapeutic Range Nice?. <b>2015</b> , 101, A33.1-A33	
1805	Peri-procedural management of patients taking oral anticoagulants. <b>2015</b> , 351, h2391	34
1804	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <b>2015</b> , 36, 3238-49	129
1803	Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. <b>2015</b> , 65, 2614-2623	328
1802	The new or non-vitamin K antagonist oral anticoagulants: what have we learned since their debut. <b>2015</b> , 41, 188-94	11
1801	Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. <b>2015</b> , 41, 178-87	22
1800	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 823-33	59.2 719
1799	Venous thromboembolism prophylaxis in critically ill patients. <b>2015</b> , 41, 68-74	36
1798	Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants?. <b>2015</b> , 41, 195-207	15
1797	Should patients on vitamin K antagonists be treated differently?. <b>2015</b> , 36, 1431-3	3
1796	Tolerability and Acceptability of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Meta-Analysis. <b>2015</b> , 15, 259-65	8



1795	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. <b>2015</b> , 17, 1007-17	40
1794	Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <b>2015</b> , 132, 624-32	159
1793	New oral anticoagulants in severe trauma patients: Enemy at the gates?. <b>2015</b> , 39, 167-171	
1792	Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. <b>2015</b> , 13, 341-53	7
1791	New oral anticoagulants: their role in stroke prevention in high-risk patients with atrial fibrillation. <b>2015</b> , 99, 759-80	3
1790	[Oral anticoagulation for non-valvular atrial fibrillation in the elderly]. <b>2015</b> , 50, 134-42	5
1789	New oral anticoagulants: a practical guide for physicians. <b>2015</b> , 1, 134-45	40
1788	Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. <b>2015</b> , 128, 1007-14.e2	29
1787	[Management of new oral anticoagulants in gastrointestinal bleeding and endoscopy]. <b>2015</b> , 38, 501-10	1
1786	New oral anticoagulants in severe trauma patients: enemy at the gates?. <b>2015</b> , 39, 167-71	7
1785	Current evidence for new oral anticoagulants in the treatment of nonvalvular atrial fibrillation: comparison of substudies. <b>2015</b> , 68, 185-9	2
1784	Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists. <b>2015</b> , 135, 958-62	5
1783	[Not Available]. <b>2015</b> , 58, 634-5	1
1782	Variability in the benefit of the novel oral anticoagulant agents in patients with non-valvular atrial fibrillation. <b>2015</b> , 10, 395-6	
1781	Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis. <b>2015</b> , 135, 1117-23	15
1780	Management of atrial fibrillation: What is new in the 2014 ACC/AHA/HRS guideline?. <b>2015</b> , 127, 396-404	1
1779	Edoxaban, a Novel Oral Factor Xa Inhibitor. <b>2015</b> , 49, 843-50	12
1778	Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. <b>2015</b> , 113, 1247-57	114

1777	Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. <b>2015</b> , 65, 2239-51	129
1776	Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient? <b>2015</b> , 169, 603-5	0
1775	A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UnderRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. <b>2015</b> , 169, 597-604.e5	30
1774	Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. <b>2015</b> , 386, 303-10	97
1773	Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation. <b>2015</b> , 34, 179-191	17
1772	The year in cardiology 2014: arrhythmias and device therapy. <b>2015</b> , 36, 270-8	4
1771	Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs). <b>2015</b> , 15, 235-42	8
1770	Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation. <b>2015</b> , 11, 937-48	4
1769	Update for 2014 on clinical cardiology, geriatric cardiology, and heart failure and transplantation. <b>2015</b> , 68, 317-23	0
1768	2015 update. <b>2015</b> , 46, 16-22	5
1767	Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. <b>2015</b> , 131, 82-90	202
1766	Novel anticoagulants and antiplatelet agents; a guide for the urologist. <b>2015</b> , 116, 687-96	15
1765	Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. <b>2015</b> , 386, 281-91	156
1764	Anticoagulant therapy in atrial fibrillation: vitamin K antagonists or novel oral anticoagulant drugs?. <b>2015</b> , 16, 139-41	3
1763	Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study. <b>2015</b> , 12, 1162-8	127
1762	Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. <b>2015</b> , 14, 683-95	9
1761	Practical management of anticoagulation in patients with atrial fibrillation. <b>2015</b> , 65, 1340-1360	67
1760	Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. <b>2015</b> , 170, 141-8, 148.e1	152

1759	Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation. <b>2015</b> , 10, 555-60	9
1758	Using new oral anticoagulants in patients undergoing major orthopedic surgery. <b>2015</b> , 17, 25	3
1757	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. <b>2015</b> , 104, 418-29	77
1756	New oral anticoagulants versus vitamin K antagonists before cardioversion of atrial fibrillation: a meta-analysis of data from 4 randomized trials. <b>2015</b> , 13, 577-83	5
1755	[Stroke prevention with direct oral anticoagulants in patients with non-valvular atrial fibrillation]. <b>2015</b> , 140, 750-5	1
1754	Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. <b>2015</b> , 24, 2710-9	4
1753	Percutaneous Left Atrial Appendage Ligation for Stroke Prevention in Atrial Fibrillation. <b>2015</b> , 11, 94-9	1
1752	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. <b>2015</b> , 13, 1155-63	1
1751	Atrial fibrillation and chronic kidney disease: focus on rivaroxaban. <b>2015</b> , 4, 651-64	12
1750	Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?. <b>2015</b> , 4, e001573	17
1749	[New therapeutic approaches to pulmonary embolism: trials' results and significance of direct oral anticoagulants]. <b>2015</b> , 69, 99-110	1
1748	Edoxaban: a review in nonvalvular atrial fibrillation. <b>2015</b> , 15, 351-61	4
1747	Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation. <b>2015</b> , 17, 64	1
1746	Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. <b>2015</b> , 75, 1627-44	30
1745	Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study. <b>2015</b> , 68, 769-76	15
1744	[Which place for direct oral anticoagulants in routine hospital medical practice?]. <b>2015</b> , 36, 813-7	0
1743	Discontinuation of anticoagulant treatment: from clinical trials to medication persistence. <b>2015</b> , 31, 1841-4	9
1742	Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis. <b>2015</b> , 46, 2555-61	141

1741	HRS/NSA 2014 Survey of Atrial Fibrillation and Stroke: Gaps in Knowledge and Perspective, Opportunities for Improvement. <b>2015</b> , 24, 1691-700	23
1740	Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants. <b>2015</b> , 13, 1213-23	1
1739	Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan. <b>2015</b> , 66, 1339-47	92
1738	[Non-vitamin K oral anticoagulants and cardioversion]. <b>2015</b> , 64, 368-71	
1737	[The use of the new direct oral anticoagulants among older subjects: The limits of the evidence-based medicine?]. <b>2015</b> , 36, 840-2	0
1736	The evolving role of dabigatran etexilate in clinical practice. <b>2015</b> , 16, 2053-72	
1735	Stroke prevention in atrial fibrillation: evidence from real-life studies: Table 1. <b>2015</b> , 17, D42-D52	4
1734	Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation. <b>2015</b> , 17, 61	11
1733	Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation. <b>2015</b> , 4, 367-76	1
1732	Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. <b>2015</b> , 170, 669-74	14
1731	The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. <b>2015</b> , 35, 447-53	51
1730	Medikamentöse Rhythmuskontrolle und orale Antikoagulation bei Patienten mit Vorhofflimmern: Bedeutung pharmakokinetischer Interaktionen für die klinische Praxis. <b>2015</b> , 4, 114-119	
1729	Medikamentöse Sekundärprävention des ischämischen Schlaganfalls â Empfehlungen für den klinischen Alltag. <b>2015</b> , 44, 346-350	2
1728	Atrial fibrillation in heart failure: what should we do?. <b>2015</b> , 36, 3250-7	172
1727	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <b>2015</b> , 17, 1467-507	803
1726	Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. <b>2015</b> , 46, 2830-7	5
1725	Edoxaban and amiodarone: interactions on multiple levels. <b>2015</b> , 36, 2210-1	1
1724	Les anticoagulants oraux directs en 2015 chez le patient âgé: focus chez le sujet fragile. <b>2015</b> , 7, 122-137	

1723 Prevention of Cardiovascular Diseases. **2015,**

1722 Sample size adjustment based on promising interim results and its application in confirmatory clinical trials. **2015, 12, 584-95** 9

1721 Poor Anticoagulation Control in Atrial Fibrillation: How Much Longer?. **2015, 68, 740-2** 1

1720 Mal control de la anticoagulación en la fibrilación auricular. ¿Hasta cuándo?. **2015, 68, 740-742** 10

1719 [Therapeutic equivalence of the new oral anticoagulants]. **2015, 41, 382-6**

1718 Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation. **2015, 34, 179-91** 23

1717 A case of Trousseau syndrome caused by pulmonary adenocarcinoma that was controlled for one year and 10 months with thrombosis treatment using an EGFR tyrosine kinase inhibitor and chemotherapy. **2015, 15, 101-5** 7

1716 Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. **2015, 16, 2661-78** 2

1715 Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. **2015, 66, 2271-2281** 127

1714 Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure. **2015, 66, 2728-2739** 64

1713 Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism. **2015, 75, 2025-34** 4

1712 Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-analysis. **2015, 16, 1103.e1-19** 29

1711 Major publications in the critical care pharmacotherapy literature: January-December 2014. **2015, 72, 1974-85** 4

1710 Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives. **2015, 136, 1074-81** 21

1709 Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. *New England Journal of Medicine*, **2015, 373, 2413-24** 59.2 754

1708 Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials. **2015, 40, 1-11** 5

1707 Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis. **2015, 181, 247-54** 5

1706 Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemma. **2015, 39, 203-8** 12

1705	Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <b>2015</b> , 169, 25-30	51
1704	Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding. <b>2015</b> , 169, 1-3	3
1703	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <b>2015</b> , 36, 1264-72	99
1702	Selecting an oral anticoagulant for patients with nonvalvular atrial fibrillation. <b>2015</b> , 39, 129-38	2
1701	Management of Atrial Fibrillation. <b>2015</b> , 30, 484-98	5
1700	[Progress of anticoagulation therapy in atrial fibrillation]. <b>2015</b> , 145, 124-30	5
1699	Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation. <b>2015</b> , 10, 128-33	33
1698	Cardiac Drug Therapy. <b>2015</b> ,	2
1697	Controversies in cardioembolic stroke. <b>2015</b> , 17, 358	11
1696	[Anticoagulation in atrial fibrillation in the elderly: the geriatrician point of view with a focus on the direct oral anticoagulants]. <b>2015</b> , 36, 22-30	7
1695	Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. <b>2015</b> , 262, 516-22	65
1694	Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach. <b>2015</b> , 14, 7-20	19
1693	Pharmacology and mechanisms of action of new oral anticoagulants. <b>2015</b> , 29, 10-20	27
1692	Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Pharmacology and Phase III Clinical Trials. <b>2016</b> ,	
1691	Implications of the NICE technology appraisal of edoxaban. <b>2016</b> , 22, 297-299	
1690	Targeting stroke risk and improving outcomes in patients with atrial fibrillation in Latin America. <b>2016</b> , 134, 534-542	1
1689	New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials. <b>2016</b> , 16, 178	1
1688	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. <b>2016</b> , 115, 257-70	11

- 1687 Atrial fibrillation management in older heart failure patients: a complex clinical problem. **2016**, 11, e41-e49 8
- 1686 Evaluating the benefits of home-based management of atrial fibrillation: current perspectives. **2016**, 7, 41-53
- 1685 Recent advances in ischemic stroke management. **2016**, 59, 775
- 1684 Edoxaban in venous thromboembolism and stroke prevention: an appraisal. **2016**, 12, 45-51 4
- 1683 Stroke Prevention in Atrial Fibrillation: Focus on Latin America. **2016**, 107, 576-589 10
- 1682 Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease. **2016**, 10, 110-6 5
- 1681 Antithrombotic Usage Patterns in the Era of New Oral Anticoagulant Options for Atrial Fibrillation. **2016**, 51, 564-71 4
- 1680 Renal Function and Treatment Persistence with Non-Vitamin K Antagonist Oral Anticoagulants in Japanese Patients with Atrial Fibrillation: A Single-Center Experience. **2016**, 47, 115-122 1
- 1679 Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients. **2016**, 37, 361-8 2
- 1678 Individualising Anticoagulant Therapy in Atrial Fibrillation Patients. **2016**, 5, 102-9 4
- 1677 Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians. **2016**, 2016, 1781684 17
- 1676 Direct Oral Anticoagulants in Emergency Trauma Admissions. **2016**, 113, 575-82 20
- 1675 Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. **2016**, 115, 685-711 21
- 1674 Treatment. 145-216 1
- 1673 Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. **2016**, 115, 856-63 26
- 1672 Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. **2016**, 116, S33-S40 7
- 1671 Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism. **2016**, 12, 667-74
- 1670 [Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation]. **2016**, 144, 1103-1111

1669	Primary prevention of cardiovascular disease. <b>2016</b> , 19, 90-94	
1668	Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. <b>2016</b> , 116, 544-53	20
1667	Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAf) in the US. <b>2016</b> , 8, 215-26	13
1666	Economic evaluation of the new oral anticoagulants for the prevention of thromboembolic events: a cost-minimization analysis. <b>2016</b> , 134, 322-9	10
1665	Efficacy and safety of oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. <b>2016</b> , 71, 349-357	2
1664	Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy. <b>2016</b> , 17, 954-70	33
1663	Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. <b>2016</b> , 115, 622-31	21
1662	The Use of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Pharmacist's Perspective. <b>2016</b> , 51, 26-34	
1661	Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. <b>2016</b> , 116, 1003-1010	36
1660	The Specific Direct Oral Anticoagulant Reversal Agents: Their Current Status and Future Place in Gastroenterology Practice. <b>2016</b> , 3, 36-44	2
1659	Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention. <b>2016</b> , 9, 337-347	12
1658	Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. <b>2016</b> , 8, 93-107	23
1657	Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. <b>2016</b> , 12, 35-44	67
1656	NOAC or Warfarin for Atrial Fibrillation: Does Time in Therapeutic Range Matter?. <b>2015</b> , 10, 60-4	
1655	Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide. <b>2016</b> , 115, 368-81	50
1654	Non-Vitamin K Antagonist Oral Anticoagulants, Clinical Use, Real-World Data, and Reversal of Anticoagulant Effect. <b>2016</b> ,	
1653	Controversy Surrounding ROCKET-AF: A Call for Transparency, But Should We Be Changing Practice?. <b>2016</b> , 5, 12-3	3
1652	Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. <b>2016</b> , 24, 218-23	31



1651	Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. <b>2016</b> , 179, 59-68	29
1650	Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents. <b>2016</b> , 786, 246-252	10
1649	Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice. <b>2016</b> , 220, 602-7	17
1648	Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients. <b>2016</b> , 36, 488-95	13
1647	Warfarin Treatment and All-Cause Mortality in Community-Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study. <b>2016</b> , 64, 1416-24	26
1646	Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. <b>2016</b> , 33, 42-6	14
1645	Renal Function in Atrial Fibrillation: A Multifaceted Dilemma. <b>2016</b> , 134, 48-51	8
1644	Clinical Applications of Aspirin. <b>2016</b> , 263-446	
1643	Novel anticoagulants - an update on the latest developments and management for clinicians treating patients on these drugs. <b>2016</b> , 45, 551-6	12
1642	Reversal of Target-Specific Oral Anticoagulants. <b>2016</b> , 47-54	
1641	[New oral anticoagulants for prophylaxis of stroke : Results of an expert conference on practical use in geriatric patients]. <b>2016</b> , 49, 460-1	0
1640	Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. <b>2016</b> , 31, 541-61	15
1639	Vitamin K antagonists, direct oral anticoagulants, and the rationale for reversal agents. <b>2016</b> , 73, S3-4	1
1638	Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. <b>2016</b> , 12, 419-33	4
1637	Resolution of Internal Carotid Arterial Thrombus by the Thrombolytic Action of Dabigatran: A first case report. <b>2016</b> , 95, e3215	2
1636	Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights. <b>2016</b> , 34, 100-6	9
1635	Management of direct oral anticoagulants-associated bleeding in the trauma patient. <b>2016</b> , 29, 220-8	14
1634	Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism. <b>2016</b> , 24, 205-10	

1633	Novel oral anticoagulants in the management of coronary artery disease. <b>2016</b> , 27, 412-9	4
1632	Anticoagulation in atrial fibrillation and chronic heart failure: the risk and drug of choice. <b>2016</b> , 31, 229-34	9
1631	Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. <b>2016</b> , 13, 549-59	59
1630	Anticoagulation and population risk of stroke and death in incident atrial fibrillation: a population-based cohort study. <b>2016</b> , 4, E1-6	5
1629	A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma. <b>2016</b> , 14, 1043-53	8
1628	Stroke Prevention in Atrial Fibrillation: Current Strategies and Recommendations. <b>2016</b> , 1, 157-164	
1627	Causes of Death in Anticoagulated Patients With Atrial Fibrillation. <b>2016</b> , 68, 2508-2521	142
1626	Anticoagulant-Related Bleeding and Mortality. <b>2016</b> , 68, 2522-2524	9
1625	Has the Safety of Edoxaban 60 mg Among East Asian Atrial Fibrillation Patients Been Truly Proven by the ENGAGE AF-TIMI 48 Subanalysis? - Reply. <b>2016</b> , 80, 2057	
1624	Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. <b>2016</b> , 8, 367ra168	27
1623	The Direct Oral Anticoagulants. <b>2016</b> , 253-268	
1622	Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. <b>2016</b> , 5,	12
1621	Anticoagulation Therapy and NOACs in Heart Failure. <b>2017</b> , 243, 515-535	4
1620	Rationale and design of the Chinese Atrial Fibrillation Registry Study. <b>2016</b> , 16, 130	37
1619	[Direct oral anticoagulants: what is the exact assessment of coagulation tests and plasma levels by laboratory tests in clinical practice?]. <b>2016</b> , 74, 69-77	
1618	Periprocedural anticoagulation in patients undergoing cryoballoon ablation for atrial fibrillation. <b>2016</b> , 57, 338-339	1
1617	What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation?. <b>2016</b> , 18, I18-I24	2
1616	When to stop, how to reverse, and when to restart antithrombotic drugs periendoscopically in nonvariceal upper gastrointestinal bleeding. <b>2016</b> , 18, 177-186	

1615	What are the effects of edoxaban in the general population and in the elderly?. <b>2016</b> , 18, 113-117	
1614	How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?. <b>2016</b> , 18, 11-16	1
1613	Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry. <b>2016</b> , 16, 254	16
1612	How I use anticoagulation in atrial fibrillation. <b>2016</b> , 128, 2891-2898	8
1611	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. <b>2016</b> , 68, 2597-2604	291
1610	2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. <b>2016</b> , 115, 893-952	76
1609	Non vitamin K anticoagulation drugs will win the race. <b>2016</b> , 24, 571-3	
1608	Radiation therapy and stroke. 113-122	
1607	Stroke after discontinuation of preventive medications. 144-154	
1606	Los nuevos anticoagulantes orales. <b>2016</b> , 23, 541-549	
1605	Renal function and venous thromboembolic diseases. <b>2016</b> , 41, 389-395	2
1604	Validation of satisfaction questionnaire ACTS in outpatients with atrial fibrillation treated with oral anticoagulants in Spain. ALADIN Study. <b>2016</b> , 147, 192-198	
1603	Tratamiento periprocedimiento en pacientes con fibrilaci3n auricular que reciben anticoagulantes. <b>2016</b> , 23, 73-77	
1602	Anticoagulantes orales directos para el tratamiento de los pacientes con fibrilaci3n auricular no valvular. <b>2016</b> , 23, 82-88	1
1601	Uso de anticoagulantes directos en situaciones especiales. <b>2016</b> , 23, 89-94	
1600	Gu3a ESC 2016 sobre el diagn3stico y tratamiento de la insuficiencia cardiaca aguda y cr3nica. <b>2016</b> , 69, 1167.e1-1167.e85	91
1599	Introducci3n. <b>2016</b> , 16, 1	
1598	Tratamiento farmacol3gico de la fibrilaci3n auricular. Antiarr3tmicos y anticoagulantes orales. <b>2016</b> , 16, 33-39	

1597	Tratamiento no farmacológico de la fibrilación auricular. Ablación, cardioversión eléctrica, marcapasos y cierre de la orejuela. <b>2016</b> , 16, 40-46	
1596	Acceso a los anticoagulantes de acción directa en España. <b>2016</b> , 16, 55-59	0
1595	Edoxabán. Propiedades farmacocinéticas y farmacodinámicas. <b>2016</b> , 16, 60-66	2
1594	Estudios en fase III del edoxabán. <b>2016</b> , 16, 70-77	
1593	Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. <b>2016</b> , 5,	42
1592	Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data. <b>2016</b> , 214, 292-8	66
1591	Safety and efficacy of oral factor-Xa inhibitors versus Vitamin K antagonist in patients with non-valvular atrial fibrillation: Meta-analysis of phase II and III randomized controlled trials. <b>2016</b> , 218, 235-239	5
1590	Pharmacologic Therapies in Anticoagulation. <b>2016</b> , 100, 695-718	7
1589	Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. <b>2016</b> , 5,	102
1588	Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. <b>2016</b> , 55, 641-55	117
1587	Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <b>2016</b> , 5,	144
1586	Physician and Patient Preferences for Nonvalvular Atrial Fibrillation Therapies. <b>2016</b> , 19, 451-9	11
1585	Optimal antithrombotic treatment in patients with atrial fibrillation and coronary stents: an update. <b>2016</b> , 31, 356-65	1
1584	Clinical considerations on the posology of direct oral anticoagulants. <b>2016</b> , 216, 384-392	
1583	SCAI/ACC/HRS Institutional and Operator Requirements for Left Atrial Appendage Occlusion. <b>2016</b> , 67, 2295-2305	12
1582	Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. <b>2016</b> , 118, 210-4	92
1581	Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. <b>2016</b> , 5,	43
1580	Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants. <b>2016</b> , 73, S14-26	15

1579	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <b>2016</b> , 37, 2129-2200	7751
1578	The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review. <b>2017</b> , 19, 937-947	12
1577	Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants. <b>2016</b> , 35, 148-55	10
1576	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. <b>2016</b> , 48, 385-402	137
1575	Use of Direct-Acting Oral Anticoagulants in Nonagenarians: A Call for More Data. <b>2016</b> , 33, 315-20	11
1574	The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation. <b>2016</b> , 16, 47	3
1573	Commentary on the Cervical Artery Dissection in Stroke Study Trial. <b>2016</b> , 47, 1413-5	9
1572	Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease. <b>2016</b> , 133, 1512-5	24
1571	Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation. <b>2016</b> , 18, D7-D15	2
1570	Efficacy and Safety of Novel Oral Anticoagulants for Atrial Fibrillation Ablation: An Updated Meta-Analysis. <b>2016</b> , 5, 85-100	12
1569	Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. <b>2016</b> , 47, 1555-61	37
1568	Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism. <b>2016</b> , 5, 1-18	49
1567	Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. <b>2016</b> , 15, 566-73	216
1566	Overview of direct oral anticoagulant therapy reversal. <b>2016</b> , 73, S5-S13	11
1565	Management of novel oral anticoagulants in emergency and trauma surgery. <b>2016</b> , 14, 234-9	5
1564	North American Thrombosis Forum, AF Action Initiative Consensus Document. <b>2016</b> , 129, S1-S29	19
1563	Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. <b>2016</b> , 118, 1409-24	76
1562	NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. <b>2016</b> , 177, 74-86	34

1561	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. <b>2016</b> , 29, 537-44	22
1560	Update on Anticoagulation: What the Interventional Radiologist Needs to Know. <b>2016</b> , 33, 122-31	4
1559	Minimizing the Risk of Bleeding with NOACs in the Elderly. <b>2016</b> , 33, 491-500	25
1558	SCAI/ACC/HRS institutional and operator requirements for left atrial appendage occlusion. <b>2016</b> , 13, e241-e250	2
1557	Direct oral anticoagulants: a practical guide for the emergency physician. <b>2016</b> , 23, 330-6	4
1556	Establishing Edoxaban's Role in Anticoagulation. <b>2016</b> , 29, 228-38	3
1555	Standard dose versus low dose non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials. <b>2016</b> , 13, 2340-2347	23
1554	Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. <b>2016</b> , 129, S33-S40	54
1553	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. <b>2016</b> , 68, 1169-1178	99
1552	Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. <b>2016</b> , 129, S47-S53	14
1551	Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols. <b>2016</b> , 129, S89-S96	11
1550	Transient Ischemic Attacks: Advances in Diagnosis and Management in the Emergency Department. <b>2016</b> , 34, 811-835	9
1549	Resolving Thrombus in the Left Atrial Appendage by Edoxaban Treatment after Acute Ischemic Stroke: Report of 2 Cases. <b>2016</b> , 25, e188-91	7
1548	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <b>2016</b> , 32, 1170-1185	212
1547	[Validation of satisfaction questionnaire ACTS in outpatients with atrial fibrillation treated with oral anticoagulants in Spain. ALADIN Study]. <b>2016</b> , 147, 192-198	15
1546	New Oral Anticoagulants in Nonvalvular Atrial Fibrillation. <b>2016</b> , 39, 739-746	10
1545	Pitfalls in the Acute Management of Atrial Fibrillation. <b>2016</b> , 145-173	
1544	Anticoagulation for Atrial Fibrillation in the Emergency Department or Observation Unit. <b>2016</b> , 87-100	

1543	Direct Oral Anticoagulants: A Patient-centered Review. <b>2016</b> , 12, 523-529	
1542	Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. <b>2016</b> , 20, 273	16
1541	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <b>2016</b> , 50, e1-e88	589
1540	Current treatment of heart failure with reduction of left ventricular ejection fraction. <b>2016</b> , 9, 1619-1631	5
1539	Direct Oral Anticoagulants: Monitoring Anticoagulant Effect. <b>2016</b> , 30, 995-1006	1
1538	Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events. <b>2016</b> , 87, 1856-1862	72
1537	An update on the pharmaceutical management of thrombosis. <b>2016</b> , 17, 2149-2164	6
1536	Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. <b>2016</b> , 30, 1019-34	7
1535	New Oral Anticoagulants and Their Reversal Agents. <b>2016</b> , 18, 47	12
1534	Preclinical and clinical data for factor Xa and "universal" reversal agents. <b>2016</b> , 34, 39-45	14
1533	Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. <b>2016</b> , 34, 46-51	14
1532	Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: Focus on apixaban. <b>2016</b> , 225, 77-81	14
1531	Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. <b>2016</b> , 34, 19-25	1
1530	Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report. <b>2016</b> , 10, 269	22
1529	Bleeding with direct oral anticoagulants vs warfarin: clinical experience. <b>2016</b> , 34, 3-8	17
1528	Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. <b>2016</b> , 150, 1302-1312	165
1527	Composite Scores and Other Outcome Measures in Stroke Trials. <b>2016</b> , 39, 60-70	6
1526	Direct oral anticoagulants: unique properties and practical approaches to management. <b>2016</b> , 102, 1620-6	15

1525	Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants. <b>2016</b> , 11, 950-967	2
1524	New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban. <b>2016</b> , 225, 154-158	
1523	Discontinuation and management of direct-acting anticoagulants for emergency procedures. <b>2016</b> , 34, 14-18	26
1522	Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. <b>2016</b> , 3, e379-87	93
1521	Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. <b>2016</b> , 182, 28-35	7
1520	Fiix-prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix-warfarin or direct oral anticoagulants to standard PT-warfarin. <b>2016</b> , 38 Suppl 1, 78-90	6
1519	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). <b>2016</b> , 47, 2075-82	57
1518	A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome. <b>2016</b> , 4, 107-118	10
1517	Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand. <b>2016</b> , 222, 615-619	4
1516	Clinical considerations on the posology of direct oral anticoagulants. <b>2016</b> , 216, 384-392	
1515	Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). <b>2016</b> , 134, 589-98	116
1514	Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. <b>2016</b> , 18, 1153-61	59
1513	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. <b>2016</b> , 388, 1161-9	157
1512	Outpatient Medications in Atrial Fibrillation. <b>2016</b> , 195-217	
1511	Anticoagulation Therapy Considerations in Factor VII Deficiency. <b>2016</b> , 3, 8	9
1510	Reversal agents for direct oral anticoagulants: A focused review. <b>2016</b> , 223, 244-250	9
1509	Short Stay Management of Atrial Fibrillation. <b>2016</b> ,	1
1508	Early Initiation of Anticoagulation with Direct Oral Anticoagulants in Patients after Transient Ischemic Attack or Ischemic Stroke. <b>2016</b> , 25, 2317-21	24



1507	Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. <b>2016</b> , 39, 345-6	46
1506	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <b>2016</b> , 18, 891-975	4036
1505	Anesthesia and Transesophageal Echocardiography for WATCHMAN Device Implantation. <b>2016</b> , 30, 1685-1692	10
1504	The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. <b>2016</b> , 82, 285-300	28
1503	Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients. <b>2016</b> , 82, 633-44	14
1502	Novel oral anticoagulant management issues for the stroke clinician. <b>2016</b> , 11, 759-67	4
1501	The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation. <b>2016</b> , 34, 94-9	3
1500	A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. <b>2016</b> , 81, 569-78	19
1499	Novel anticoagulants: general overview and practical considerations for dental practitioners. <b>2016</b> , 22, 23-32	36
1498	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <b>2016</b> , 37, 2893-2962	4465
1497	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <b>2016</b> , 18, 1609-1678	1293
1496	Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. <b>2016</b> , 14, 2194-2201	51
1495	Patient satisfaction with extended-interval warfarin monitoring. <b>2016</b> , 42, 486-93	7
1494	Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. <b>2016</b> , 388, 1995-2003	173
1493	A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation. <b>2016</b> , 18, 101	2
1492	[Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation]. <b>2016</b> , 27, 295-306	2
1491	Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed. <b>2016</b> , 129, S54-S63	9
1490	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. <b>2016</b> , 5,	79

1489	Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents. <b>2016</b> , 129, S80-S88	19
1488	Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants. <b>2016</b> , 64, 1996-2002	21
1487	Major bleeding complications in patients treated with direct oral anticoagulants: One-year observational study in a Paris Hospital. <b>2016</b> , 64, 129-133	2
1486	[Catheter-based closure of the left atrial appendage : Stroke prevention in atrial fibrillation]. <b>2016</b> , 57, 844-55	2
1485	Use of Direct Oral Anticoagulants in Special Populations. <b>2016</b> , 30, 1053-71	3
1484	Upstream versus downstream thrombin inhibition. <b>2016</b> , 14, 1273-1282	3
1483	Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation. <b>2016</b> , 42, 573-8	22
1482	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. <b>2016</b> , 9, 1694-702	19
1481	Reduced dose and reduced exposure to non-vitamin K-antagonist oral anticoagulants: Some considerations on this relationship. <b>2016</b> , 223, 519-520	1
1480	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. <b>2017</b> , 19, 4-15	88
1479	Drug-drug interactions of non-vitamin K oral anticoagulants. <b>2016</b> , 12, 1445-1461	24
1478	Efficacy and Safety of Rivaroxaban and Warfarin in the Perioperative Period of Catheter Ablation for Atrial Fibrillation - Outcome Analysis From a Prospective Multicenter Registry Study in Japan. <b>2016</b> , 80, 2295-2301	24
1477	[Anticoagulation and new therapeutic options in atrial fibrillation]. <b>2016</b> , 141, 1618-1623	0
1476	Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation - An ENGAGE AF-TIMI 48 Subanalysis. <b>2016</b> , 80, 860-9	64
1475	Nine-Year Trend of Anticoagulation Use, Thromboembolic Events, and Major Bleeding in Patients With Non-Valvular Atrial Fibrillation - Shinken Database Analysis. <b>2016</b> , 80, 639-49	36
1474	Distribution of Anti-Factor Xa Activity in Patients on Edoxaban Therapy for Non-Valvular Atrial Fibrillation. <b>2016</b> , 80, 745-7	2
1473	Beneficial Effect of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation - Results of the J-RHYTHM Registry 2. <b>2016</b> , 80, 843-51	35
1472	Innovative Edoxaban Overcomes Undesirable Characteristics of Warfarin in East Asian Patients. <b>2016</b> , 80, 811-3	2

1471	Regional Differences in Frequency of Warfarin Therapy and Thromboembolism in Japanese Patients With Non-Valvular Atrial Fibrillation - Analysis of the J-RHYTHM Registry. <b>2016</b> , 80, 1548-55	3
1470	Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. <b>2016</b> , 32, 2047-2053	75
1469	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. <b>2016</b> , 18, 1162-71	21
1468	The C of CHADS: Historical perspective and clinical applications for anticoagulation in patients with non valvular atrial fibrillation and congestive heart failure. <b>2016</b> , 224, 431-436	3
1467	Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease. <b>2016</b> , 68, 1452-1464	80
1466	Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation. <b>2016</b> , 68, 1389-1401	117
1465	Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding. <b>2016</b> , 151, 1105-1112.e10	48
1464	Stroke: New Developments and Their Application in Clinical Practice. <b>2016</b> , 36, 317-23	8
1463	Ablation of Atrial Fibrillation: Patient Selection, Periprocedural Anticoagulation, Techniques, and Preventive Measures After Ablation. <b>2016</b> , 134, 339-52	27
1462	Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries. <b>2016</b> , 179, 10-8	9
1461	Management of Bleeding Patients. <b>2016</b> ,	2
1460	Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?. <b>2016</b> , 11, 748-58	33
1459	Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis. <b>2016</b> , 36, 857-62	6
1458	Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. <b>2016</b> , 134, 248-61	82
1457	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. <b>2016</b> , 134, 24-36	174
1456	Vitamin K antagonists after all, or possibly not?. <b>2016</b> , 35, 467-8	
1455	Vitamin K antagonists after all, or possibly not?. <b>2016</b> , 35, 467-468	
1454	Neue Einsichten durch Real-World-Daten zu oralen Non-Vitamin-K-Antikoagulanzen. <b>2016</b> , 18, 46-60	

1453	Betrixaban - the next direct factor Xa inhibitor?. <b>2016</b> , 9, 1111-1117	12
1452	Pharmacist Interventions Regarding the Appropriateness of Apixaban, Rivaroxaban, Dabigatran, and Warfarin in a University-Affiliated Outpatient Clinic. <b>2016</b> , 32, 245-252	5
1451	Nuevos anticoagulantes orales ¿cuñelegir?. <b>2016</b> , 23, 95-99	
1450	Non-vitamin K antagonist oral anticoagulants and heart failure. <b>2016</b> , 109, 641-650	10
1449	DOACs - advances and limitations in real world. <b>2016</b> , 14, 17	53
1448	Effect of rivaroxaban on prothrombin fragment 1+2 compared with warfarin in patients with acute cardioembolic stroke: Insight from its serial measurement. <b>2016</b> , 148, 9-14	6
1447	Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro. <b>2016</b> , 11, 2079-2084	17
1446	Oral Anticoagulant Agents in Patients With Atrial Fibrillation and Heart Failure: Does Heart Failure Status Influence Efficacy and Safety?. <b>2016</b> , 4, 881-884	
1445	Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. <b>2016</b> , 13, 319-328	17
1444	The State of the Art: Atrial Fibrillation Epidemiology, Prevention, and Treatment. <b>2016</b> , 91, 1778-1810	82
1443	Antiplatelet and Anticoagulant Agents. <b>2016</b> , 227-238	
1442	Patent foramen ovale. <b>2016</b> , 2, 15086	47
1441	Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. <b>2016</b> , 18, 1507-1513	7
1440	Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey. <b>2016</b> , 18, 1593-1598	12
1439	Assessment and Management of Gastrointestinal Hemorrhage in the Setting of Direct Oral Anticoagulants: The Hematology Perspective. <b>2016</b> , 3, 29-35	2
1438	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. <b>2016</b> , 9,	73
1437	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. <b>2016</b> , 18, 74	60
1436	Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. <b>2016</b> , 116, 747-53	21

1435	Intracranial hemorrhage during administration of a novel oral anticoagulant. <b>2016</b> , 11, 69-72	3
1434	Introduction and perspective. 1-18	
1433	Brain embolism. 312-363	0
1432	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <b>2016</b> , 353, i3189	280
1431	Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. <b>2016</b> , 115, 1056-63	27
1430	Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension. <b>2016</b> , 91, 307-15	15
1429	Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. <b>2016</b> , 116, 410-6	31
1428	Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. <b>2016</b> , 115, 31-9	113
1427	Comparative registries of atrial fibrillation from Japan and the UK: is there a difference between the east and west ends of the Eurasian continent?. <b>2016</b> , 102, 1857-1858	
1426	Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review. <b>2016</b> , 9, 25-36	19
1425	Anticoagulantiebehandeling bij voorkamerfibrillatie. <b>2016</b> , 45, 211-215	
1424	A Review on the Reversal of the Old and New Anticoagulants. <b>2016</b> , 38, 279-294	0
1423	Intracerebral hemorrhage. 477-510	1
1422	Total Thrombus-Formation Analysis System (T-TAS) Can Predict Periprocedural Bleeding Events in Patients Undergoing Catheter Ablation for Atrial Fibrillation. <b>2016</b> , 5,	23
1421	Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy. <b>2016</b> , 36, 1525-33	55
1420	Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study. <b>2016</b> , 2, 2	5
1419	Therapie tachykarder Herzrhythmusstörungen. <b>2016</b> , 13, 9-20	
1418	A Summary of the Literature Evaluating Adherence and Persistence with Oral Anticoagulants in Atrial Fibrillation. <b>2016</b> , 16, 349-63	39

1417	Detecting nonvalvular atrial fibrillation and anticoagulant therapy in cardioembolic ischemic stroke. <b>2016</b> , 128, 620-8	3
1416	2016 New Drug Update. <b>2016</b> , 31, 186-98	
1415	Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. <b>2016</b> , 9,	10
1414	Defining nonvalvular atrial fibrillation: A quest for clarification. <b>2016</b> , 178, 161-7	15
1413	Paroxysmal Atrial Fibrillation: Novel Strategies for Monitoring and Implications for Treatment in Stroke. <b>2016</b> , 18, 52	5
1412	Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. <b>2016</b> , 32, 1108-16	6
1411	Efficacy Study of the COmbination of Edoxaban and Physiotherapy on the PREvention of Venous-Thromboembolism in patients after Total Knee Arthroplasty (ESCORT-TKA Trial): Study protocol for a randomized controlled trial. <b>2016</b> , 19, 1-4	2
1410	Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect. <b>2016</b> , 103, 665-72	5
1409	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. <b>2016</b> , 129, 1117-1123.e2	12
1408	Anticoagulation in Elderly Patients With Chronic Kidney Disease: How Safe Is It?. <b>2016</b> , 32, 941.e3-5	
1407	Intracerebral Hematoma Occurring During Warfarin Versus Non-Vitamin K Antagonist Oral Anticoagulant Therapy. <b>2016</b> , 118, 222-5	32
1406	Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation. <b>2016</b> , 32, 1355.e9-1355.e14	15
1405	Net Clinical Benefit of Edoxaban for Stroke, Mortality, and Bleeding Risk: Modeling Projections for a European Population. <b>2016</b> , 2, 47-54	2
1404	Evaluating the Importance of Heterogeneity of Treatment Effect: Variation in Patient Utilities Can Influence Choice of the "Optimal" Oral Anticoagulant for Atrial Fibrillation. <b>2016</b> , 19, 661-9	2
1403	How much does the choice of new oral anticoagulant matter for reducing the burden of stroke in atrial fibrillation?. <b>2016</b> , 35, 149-151	
1402	Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. <b>2016</b> , 37, 2455-64	27
1401	[How much does the choice of new oral anticoagulant matter for reducing the burden of stroke in atrial fibrillation?]. <b>2016</b> , 35, 149-51	
1400	Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences. <b>2016</b> , 4, 19	30

1399	Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. <b>2016</b> , 14, 14	27
1398	Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. <b>2016</b> , 67, 2888-99	117
1397	Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. <b>2016</b> , 5,	261
1396	Targeted Anticoagulation for Atrial Fibrillation Guided by Continuous Rhythm Assessment With an Insertable Cardiac Monitor: The Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) Pilot Study. <b>2016</b> , 27, 264-70	70
1395	Anticoagulation-related nephropathy. <b>2016</b> , 14, 461-7	57
1394	Non-vitamin K oral anticoagulants in patients with atrial fibrillation after cardiac surgery: the results of the European Heart Rhythm Association Survey. <b>2016</b> , 18, 1113-6	9
1393	Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution. <b>2016</b> , 31, 957-62	7
1392	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. <b>2016</b> , 30, 201-14	15
1391	NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. <b>2016</b> , 3, e000279	55
1390	Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. <b>2016</b> , 41, 206-32	210
1389	Over 1-year efficacy and safety of left atrial appendage occlusion versus novel oral anticoagulants for stroke prevention in atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials and observational studies. <b>2016</b> , 13, 1203-14	19
1388	Individualized approaches to thromboprophylaxis in atrial fibrillation. <b>2016</b> , 173, 143-58	9
1387	Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure: Systematic Review and Meta-Analysis of Randomized Trials. <b>2016</b> , 149, 1516-24	35
1386	Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. <b>2016</b> , 204, 88-94	62
1385	Intracerebral Hemorrhage. <b>2016</b> , 466-515.e12	2
1384	Cardiac Diseases. <b>2016</b> , 563-575.e5	
1383	Prevalence of auricular thrombosis before atrial flutter cardioversion: a 17-year transoesophageal echocardiographic study. <b>2016</b> , 18, 450-6	20
1382	Underuse of anticoagulation in patients with atrial fibrillation. <b>2016</b> , 128, 191-200	26

1381	Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation. <b>2016</b> , 10, 37-49	6
1380	Direct Oral Anticoagulants for the Management of Thromboembolic Disorders: The Importance of Adherence and Persistence in Achieving Beneficial Outcomes. <b>2016</b> , 22, 605-16	16
1379	European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. <b>2016</b> , 23, 460-73	44
1378	Comorbidity of atrial fibrillation and heart failure. <b>2016</b> , 13, 131-47	88
1377	Non-vitamin K oral anticoagulants in 'valvular' atrial fibrillation: a call for action. <b>2016</b> , 18, 1-3	37
1376	Secondary Prevention After Cardioembolic Stroke. <b>2016</b> , 111-135	
1375	Intracranial hemorrhage with target specific oral anticoagulants in patients with atrial fibrillation: An updated meta-analysis of randomized controlled trials. <b>2016</b> , 203, 1000-2	8
1374	Rapport coû/efficacit'des traitements m'dicamenteux et interventionnels dans la fibrillation atriale. <b>2016</b> , 8, 144-156	
1373	Efficacy of non-vitamin K antagonist oral anticoagulants for Lemierre syndrome. <b>2016</b> , 34, 2059.e3-2059.e5	3
1372	Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. <b>2016</b> , 129, 850-857.e2	40
1371	How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. <b>2016</b> , 95, 437-49	47
1370	Emerging Tools for Stroke Prevention in Atrial Fibrillation. <b>2016</b> , 4, 26-39	9
1369	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. <b>2016</b> , 81, 1-14	6
1368	Vascular Engineering of Blood Coagulation. <b>2016</b> , 211-219	
1367	Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study. <b>2016</b> , 25, 1342-8	9
1366	SCAI/ACC/HRS institutional and operator requirements for left atrial appendage occlusion. <b>2016</b> , 87, 351-62	5
1365	Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <b>2016</b> , 14, 1308-13	253
1364	Prior bleeding, future bleeding and stroke risk with oral anticoagulation in atrial fibrillation: What new lessons can ARISTOTLE teach us?. <b>2016</b> , 175, 168-71	1



1363	Why switch from warfarin to NOACs?. <b>2016</b> , 11, 289-93	32
1362	Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review. <b>2016</b> , 95, e2895	33
1361	Pharmacogenetics and oral antithrombotic drugs. <b>2016</b> , 27, 38-42	19
1360	The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. <b>2016</b> , 37, 1591-602	190
1359	The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. <b>2016</b> , 14, 177-87	15
1358	Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?. <b>2016</b> , 118, 607-19	22
1357	Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?. <b>2016</b> , 16, 183-200	52
1356	Anticoagulation in Older Adults with Multimorbidity. <b>2016</b> , 32, 331-46	10
1355	Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. <b>2016</b> , 137, 178-183	105
1354	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <b>2017</b> , 38, 852-859	50
1353	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <b>2017</b> , 38, 860-868	75
1352	Rivaroxaban: can we trust the evidence?. <b>2016</b> , 352, i575	18
1351	Management of antithrombotic therapy during cardiac implantable device surgery. <b>2016</b> , 32, 163-9	12
1350	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. <b>2016</b> , 16, 221-35	16
1349	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. <b>2016</b> , 65, 374-89	161
1348	Assessing generalizability of trial results in general practice. <b>2016</b> , 37, 1154-7	8
1347	Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. <b>2016</b> , 22, 412-22	21
1346	Atrial Fibrillation and Stroke: Making Sense of Recent Observations on Anticoagulation. <b>2016</b> , 34, 317-28	5

1345	Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions. <b>2016</b> , 5,	42
1344	Intracranial Hemorrhage Risk in the Era of Antithrombotic Therapies for Ischemic Stroke. <b>2016</b> , 18, 29	12
1343	Study design of J-ELD AF: A multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients. <b>2016</b> , 68, 554-558	17
1342	The Evolution and Application of Cardiac Monitoring for Occult Atrial Fibrillation in Cryptogenic Stroke and TIA. <b>2016</b> , 18, 17	4
1341	Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. <b>2016</b> , 16, 171-82	2
1340	[Local experience with the use of direct-acting oral anticoagulants in patients with atrial fibrillation and significant valvulopathy or biological prosthesis]. <b>2016</b> , 216, 234-6	0
1339	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <b>2016</b> , 18, 973-8	16
1338	Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation. <b>2016</b> , 18, 1319-27	27
1337	Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. <b>2016</b> , 5,	232
1336	Persistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials. <b>2016</b> , 5,	5
1335	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. <b>2016</b> , 12, 257-71	5
1334	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <b>2016</b> , 5, e002197	94
1333	Safety of non-vitamin K antagonist oral anticoagulants - coronary risks. <b>2016</b> , 15, 731-40	5
1332	Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAf) study. <b>2016</b> , 11, 565-74	58
1331	Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial. <b>2016</b> , 55, 1079-90	21
1330	Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <b>2016</b> , 24, 6-46	422
1329	The year in cardiology 2015: arrhythmias and device therapy. <b>2016</b> , 37, 587-93	
1328	Non-Vitamin K Antagonist Oral Anticoagulants. <b>2016</b> ,	1

1327	Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort. <b>2016</b> , 133, 265-72	56
1326	Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population. <b>2016</b> , 5, 19-41	38
1325	Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician. <b>2016</b> , 30, 823-30	9
1324	Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis. <b>2016</b> , 205, 17-22	23
1323	[Treatment safety of non-vitamin K oral anticoagulants in patients with atrial fibrillation]. <b>2016</b> , 41, 37-47	2
1322	Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation. <b>2016</b> , 117, 69-75	52
1321	An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery. <b>2016</b> , 45, 618-30	36
1320	Who, when, and how to reverse non-vitamin K oral anticoagulants. <b>2016</b> , 41, 253-72	24
1319	Use of Warfarin at Discharge Among Acute Ischemic Stroke Patients With Nonvalvular Atrial Fibrillation in China. <b>2016</b> , 47, 464-70	41
1318	Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. <b>2016</b> , 172, 144-51	13
1317	Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <b>2016</b> , 31, 1327-36	12
1316	The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use. <b>2016</b> , 14, 163-76	6
1315	Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?. <b>2016</b> , 41, 279-84	
1314	Ischemic Stroke Therapeutics. <b>2016</b> ,	1
1313	The Quandary of Oral Anticoagulation in Patients With Atrial Fibrillation and Chronic Kidney Disease. <b>2016</b> , 117, 477-82	15
1312	Preventing a First Stroke. <b>2016</b> , 280-291	1
1311	Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures. <b>2016</b> , 202, 578-85	28
1310	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. <b>2016</b> , 37, 1145-53	319

1309	Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves. <b>2016</b> , 105, 268-72	43
1308	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. <b>2016</b> , 18, 6-11	27
1307	Novel oral anticoagulants and the 73rd anniversary of historical warfarin. <b>2016</b> , 28, 31-45	11
1306	Coagulation assessment with the new generation of oral anticoagulants. <b>2016</b> , 33, 423-30	49
1305	The Trends in Utilizing Nonvitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A Real-Life Experience. <b>2016</b> , 22, 785-791	12
1304	Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. <b>2016</b> , 18, 955-64	53
1303	Edoxaban in patients with atrial fibrillation. <b>2017</b> , 11, 81-90	3
1302	Patient Characteristics and Antithrombotic Prescribing Patterns in Patients With Atrial Fibrillation in Tasmania. <b>2017</b> , 23, 438-444	4
1301	Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation. <b>2017</b> , 23, 5-19	9
1300	Direct Oral Anticoagulants for Very Elderly People With Atrial Fibrillation: Efficacy and Safe Enough?. <b>2017</b> , 23, 58-63	6
1299	Apixaban to prevent stroke in patients with atrial fibrillation: a review. <b>2017</b> , 11, 91-104	6
1298	Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. <b>2017</b> , 23, 685-695	0
1297	Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation. <b>2017</b> , 69, 11-15	19
1296	Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect. <b>2017</b> , 23, 677-684	11
1295	Benefits of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation go beyond stroke prevention. <b>2017</b> , 14, 606-607	
1294	Is there a 'therapeutic window' for antiplatelet therapy?. <b>2017</b> , 3, 18-20	
1293	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. <b>2017</b> , 69, 409-419	46
1292	Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. <b>2017</b> , 70, 50.e1-50.e84	6

1291	[Use of non-vitamin K antagonist oral anticoagulants in Primary Care: ACTUA study]. <b>2017</b> , 43, 477-485	10
1290	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. <b>2017</b> , 38, 888-896	29
1289	Risk of gastrointestinal bleeding with direct oral anticoagulants: a systematic review and network meta-analysis. <b>2017</b> , 2, 85-93	27
1288	2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. <b>2017</b> , 69, 871-898	234
1287	Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement. <b>2017</b> , 10, 66-74	78
1286	Pregnancy, Hormonal Treatments for Infertility, Contraception, and Menopause in Women After Ischemic Stroke: A Consensus Document. <b>2017</b> , 48, 501-506	22
1285	New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its dose. <b>2017</b> , 40, e11-e12	4
1284	National Trends in Atrial Fibrillation Hospitalization, Readmission, and Mortality for Medicare Beneficiaries, 1999-2013. <b>2017</b> , 135, 1227-1239	70
1283	[Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine]. <b>2017</b> , 112, 83-91	
1282	Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. <b>2017</b> , 103, 834-839	49
1281	[Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?]. <b>2017</b> , 112, 105-110	5
1280	Optimizing the use of oral anticoagulant therapy for atrial fibrillation in primary care: a pharmacist-led intervention. <b>2017</b> , 39, 173-180	9
1279	Management of bleeding in patients receiving non-vitamin K antagonists. <b>2017</b> , 93, 221-225	5
1278	Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): A systematic review and meta-analysis on gender differences. <b>2017</b> , 117, 274-282	13
1277	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). <b>2017</b> , 10,	94
1276	Relation of Stroke and Major Bleeding to Creatinine Clearance in Patients With Atrial Fibrillation (from the Fushimi AF Registry). <b>2017</b> , 119, 1229-1237	27
1275	Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. <b>2017</b> , 135, 1024-1035	36
1274	Atrial Fibrillation. <b>2017</b> , 258-277	

1273	[Vitamin K antagonists : Is their prescription really "medical malpractice" today?]. <b>2017</b> , 58, 90-99	2
1272	Edoxaban: A direct oral anticoagulant. <b>2017</b> , 74, 117-129	23
1271	Management strategies for atrial fibrillation. <b>2017</b> , 110, 13-22	9
1270	Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. <b>2017</b> , 34, 620-637	6
1269	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <b>2017</b> , 135, 1273-1275	94
1268	The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. <b>2017</b> , 69, 777-785	193
1267	Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs. <b>2017</b> , 52, 1211-1220	26
1266	Clinical implications of reversal agents for direct oral anticoagulants. <b>2017</b> , 13, 153-159	7
1265	Mitos y realidades de los nuevos anticoagulantes orales en fibrilaci3n auricular. <b>2017</b> , 24, 1-4	1
1264	Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. <b>2017</b> , 103, 623-628	30
1263	Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when?. <b>2017</b> , 177, 185-197	17
1262	Is There an Obesity Paradox for Outcomes in Atrial Fibrillation? A Systematic Review and Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulant Trials. <b>2017</b> , 48, 857-866	79
1261	Management of atrial fibrillation in patients taking targeted cancer therapies. <b>2017</b> , 3, 2	9
1260	Laboratory Assessment of Direct Oral Anticoagulants. <b>2017</b> , 43, 277-290	60
1259	Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data. <b>2017</b> , 26, 1171-1181	7
1258	The anticoagulation choices of internal medicine residents for stroke prevention in non-valvular atrial fibrillation. <b>2017</b> , 93, 308-312	6
1257	Stroke Risk Factors, Genetics, and Prevention. <b>2017</b> , 120, 472-495	459
1256	Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. <b>2017</b> , 135, e604-e633	153

- 1255 Novel oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) and diabetes-Good or excellent?. **2017**, 33, e2893
- 1254 Health literacy and warfarin therapy at two anticoagulation clinics in Brazil. **2017**, 103, 1089-1095 16
- 1253 Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. **2017**, 27, 2622-2628
- 1252 Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?. **2017**, 130, 900-906 4
- 1251 During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time. **2017**, 15, 131-139 5
- 1250 The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. **2017**, 106, 565-572 40
- 1249 The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation. **2017**, 120, 75-82 4
- 1248 Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients. **2017**, 44, 38-47 15
- 1247 Managing the perioperative patient on direct oral anticoagulants. **2017**, 64, 656-672 13
- 1246 Real-world stroke prevention strategies in nonvalvular atrial fibrillation in patients with renal impairment. **2017**, 47, 428-438 5
- 1245 Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. **2017**, 15, 1322-1333 36
- 1244 Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention. **2017**, 18, 875-883 8
- 1243 [Oral anticoagulant-associated intracerebral haemorrhage]. **2017**, 112, 475-488
- 1242 Renal Function Considerations for Stroke Prevention in Atrial Fibrillation. **2017**, 130, 1015-1023 25
- 1241 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. **2017**, 14, e275-e444 878
- 1240 Replacing warfarin with a novel oral anticoagulant: Risk of recurrent bleeding and stroke in patients with warfarin ineligible or failure in patients with atrial fibrillation (The ROAR study). **2017**, 28, 853-861 6
- 1239 Antithrombotic treatment for patients with paroxysmal atrial fibrillation and a low CHA2DS2-VASc score. **2017**, 18 Suppl 1, e94-e99
- 1238 Percutaneous Interventions for Structural Heart Disease. **2017**,

1237	Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. <b>2017</b> , 155, 38-47	24
1236	Anticoagulation Bridge Therapy in Patients with Atrial Fibrillation: Recent Updates Providing a Rebalance of Risk and Benefit. <b>2017</b> , 37, 712-724	17
1235	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. <b>2017</b> , 189, 137-145	170
1234	Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis. <b>2017</b> , 15, 1674-1683.e3	84
1233	Direct anticoagulants and nursing: An approach from patient's safety. <b>2017</b> , 27, 106-112	1
1232	Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. <b>2017</b> , 34, 332-395	416
1231	Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. <b>2017</b> , 190, 12-18	143
1230	Risk of gastrointestinal bleeding during anticoagulant treatment. <b>2017</b> , 16, 673-685	31
1229	The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue. <b>2017</b> , 39 Suppl 1, 37-40	18
1228	Thromboembolic risk and effect of oral anticoagulation according to atrial fibrillation patterns: A systematic review and meta-analysis. <b>2017</b> , 40, 641-647	10
1227	Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <b>2017</b> , 189, 40-47	40
1226	Ischemic Stroke in Nonvalvular Atrial Fibrillation at Warfarin Initiation: Assessment via a Large Insurance Database. <b>2017</b> , 48, 1487-1494	7
1225	[Stroke prophylaxis in atrial fibrillation : When, how and for whom?]. <b>2017</b> , 42, 373-379	
1224	Intracerebral haemorrhage risk in microbleed-positive ischaemic stroke patients with atrial fibrillation: Preliminary meta-analysis of cohorts and anticoagulation decision schema. <b>2017</b> , 378, 102-109	17
1223	Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. <b>2017</b> , 43, 365-379	62
1222	Atrial Fibrillation and Percutaneous Coronary Intervention. <b>2017</b> ,	
1221	New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention. <b>2017</b> , 17, 539-552	1
1220	Percutaneous closure of the left atrial appendage in patients with diabetes mellitus. <b>2017</b> , 14, 407-414	2



1219	Management of acute stroke in patients on oral anticoagulants. <b>2017</b> , 30, 1-7	13
1218	Indications and appropriate selection of novel oral anticoagulants in patients with atrial fibrillation. <b>2017</b> , 103, 1129-1137	6
1217	In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking. <b>2017</b> , 7, 249-256	3
1216	Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer. <b>2017</b> , 120, 213-217	36
1215	No Difference with NOACs in Women with Nonvalvular Atrial Fibrillation: One Less Gender Gap!. <b>2017</b> , 26, 197-198	1
1214	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <b>2017</b> , 31, 295-301	2
1213	Lessons in Bridge-Building: A Multidisciplinary Approach to Heart Failure Care. <b>2017</b> , 23, 574-575	1
1212	New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation: an appraisal. <b>2017</b> , 35, 689-695	3
1211	Analytical Management of Patients Undergoing Oral Anticoagulant Therapy Could Have a Strong Impact on Clinical Outcomes: A Follow-up Study. <b>2017</b> , 6, 261-271	
1210	Novel Oral Anticoagulants in the Peri-Endoscopic Period. <b>2017</b> , 25, 223-229	
1209	Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective. <b>2017</b> , 12, 74-83	6
1208	Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. <b>2017</b> , 33, 1595-1604	42
1207	Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). <b>2017</b> , 3, 225-250	34
1206	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). <b>2017</b> , 13, 891-911	58
1205	Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. <b>2017</b> , 27, 567-572	4
1204	The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). <b>2017</b> , 13, 725-739	14
1203	Current challenges and future prospects in oral anticoagulant therapy. <b>2017</b> , 178, 838-851	21
1202	Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. <b>2017</b> , 69, 2779-2790	289

1201	Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: A focused review. <b>2017</b> , 243, 263-269	8
1200	Cancer, atrial fibrillation, and stroke. <b>2017</b> , 155, 101-105	23
1199	Antikoagulation bei Risikopatienten. <b>2017</b> , 46, 236-240	
1198	Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay. <b>2017</b> , 155, 121-127	16
1197	Heart Failure Complicating Acute Myocardial Infarction. <b>2017</b> , 13, 513-525	4
1196	Oral Anticoagulation Therapy. <b>2017</b> ,	1
1195	e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thromBEVAL study. <b>2017</b> , 15, 1375-1385	11
1194	Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention. <b>2017</b> , 26, 2102-2110	9
1193	The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis. <b>2017</b> , 39, 1291-1312.e8	1
1192	Causes of death in atrial fibrillation: Challenges and opportunities. <b>2017</b> , 27, 494-503	10
1191	Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study. <b>2017</b> , 2, 872-881	34
1190	Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults. <b>2017</b> , 13, 467-483	2
1189	Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). <b>2017</b> , 119, 1590-1595	26
1188	Bleeding Complications and Management on anticoagulant therapy. <b>2017</b> , 43, 886-892	7
1187	Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. <b>2017</b> , 12, 589-596	67
1186	Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection. <b>2017</b> , 12, 383-391	70
1185	Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. <b>2017</b> , 3, 147-150	14
1184	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. <b>2017</b> , 32, 1967-1976	11

1183	Intracranial complications after minor head injury (MHI) in patients taking vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs). <b>2017</b> , 35, 1317-1319	24
1182	Direct anticoagulants and nursing: an approach from patient's safety. <b>2017</b> , 27, 106-112	1
1181	Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry. <b>2017</b> , 33, 289-296	55
1180	Direct acting oral anticoagulant: Bench to bedside. <b>2017</b> , 73, 274-281	
1179	Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. <b>2017</b> , 83, 1835-1843	9
1178	Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal. <b>2017</b> , 130, 773-779	4
1177	Efficacy and safety of the drugs used to reverse direct oral anticoagulants: a systematic review and meta-analysis. <b>2017</b> , 57, 1834-1846	9
1176	Rapid and well tolerated action of idarucizumab for antagonizing dabigatran in a patient needing urgent thrombolysis: a case report. <b>2017</b> , 28, 576-579	13
1175	Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin?. <b>2017</b> , 7, 62-71	23
1174	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. <b>2017</b> , 4, CD008600	31
1173	Gender differences in the effects of cardiovascular drugs. <b>2017</b> , 3, 163-182	126
1172	Novel Anticoagulant Agents in the Perioperative Setting. <b>2017</b> , 35, 305-313	7
1171	Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence. <b>2017</b> , 41, 18-27	18
1170	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. <b>2017</b> , 129, 2980-2987	70
1169	Scoring Systems for Estimating the Risk of Anticoagulant-Associated Bleeding. <b>2017</b> , 43, 514-524	9
1168	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. <b>2017</b> , 69, 1372-1382	87
1167	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. <b>2017</b> , 69, 1363-1371	84
1166	NOACs for Stroke Prevention in Atrial Fibrillation With Valve Disease: Filling the Gaps. <b>2017</b> , 69, 1383-1385	1

1165	Cardiac Management in the Frail Elderly Patient and the Oldest Old. <b>2017</b> ,	1
1164	2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <b>2017</b> , 70, 252-289	1681
1163	Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. <b>2017</b> , 106, 618-628	41
1162	The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial. <b>2017</b> , 189, 68-74	58
1161	Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection. <b>2017</b> , 29, 686-694	26
1160	2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <b>2017</b> , 135, e1159-e1195	1261
1159	2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack. <b>2017</b> , 12, 302-320	52
1158	Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study. <b>2017</b> , 153, 19-27	25
1157	Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. <b>2017</b> , 15, 237-245	10
1156	Reversal of direct oral anticoagulants. <b>2017</b> , 78, 165-169	1
1155	Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. <b>2017</b> , 26, 657-665	14
1154	Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. <b>2017</b> , 227, 261-266	39
1153	Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation. <b>2017</b> , 18, 67-77	5
1152	POST-NOAC: Portuguese observational study of intracranial hemorrhage on non-vitamin K antagonist oral anticoagulants. <b>2017</b> , 12, 623-627	13
1151	Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review. <b>2017</b> , 40, 407-412	14
1150	Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials. <b>2017</b> , 33, e2876	38
1149	Population Pharmacokinetics of Edoxaban in Japanese Atrial Fibrillation Patients With Severe Renal Impairment. <b>2017</b> , 6, 484-491	8
1148	Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials. <b>2017</b> , 103, 139-147	31

1147	Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. <b>2017</b> , 34, 357-377	10
1146	Update on Direct Oral Anticoagulants and Their Uses. <b>2017</b> , 6, 193-203	
1145	Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. <b>2017</b> , 14, 501-507	43
1144	Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. <b>2017</b> , 130, 449-456	16
1143	New oral anticoagulants in patients with chronic kidney disease. <b>2017</b> , 37, 244-252	9
1142	Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know. <b>2017</b> , 37, 236-248	67
1141	Catheter Ablation for Atrial Fibrillation in Patients With Watchman Left Atrial Appendage Occlusion Device: Results from a Multicenter Registry. <b>2017</b> , 28, 139-146	22
1140	Anti-thrombotic therapy for atrial fibrillation in patients with chronic kidney disease: Current views. <b>2017</b> , 21 Suppl 2, S47-S56	6
1139	Acquired Bleeding Disorders. <b>2017</b> , 31, 1123-1145	12
1138	Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study. <b>2017</b> , 6,	35
1137	Patients With Atrial Fibrillation Who Are Not on Anticoagulant Treatment Due to Increased Bleeding Risk Are Common and Have a High Risk of Stroke. <b>2017</b> , 3, 1369-1376	11
1136	Reversal agents for oral anticoagulants. <b>2017</b> , 42, 8-14	1
1135	Modern Drug Discovery and Development. <b>2017</b> , 719-743	4
1134	Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban. <b>2019</b> , 26, 106-112	6
1133	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <b>2017</b> , 194, 132-140	104
1132	Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study. <b>2017</b> , 194, 99-106	25
1131	Systemic Octreotide Therapy in Prevention of Gastrointestinal Bleeds Related to Arteriovenous Malformations and Obscure Etiology in Atrial Fibrillation. <b>2017</b> , 3, 1390-1399	4
1130	WITHDRAWN: 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. <b>2017</b> ,	

1129	Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug?. <b>2017</b> , 46, e40-e41	3
1128	Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. <b>2017</b> , 4, e000682	17
1127	Anticoagulation in Patients with Atrial Fibrillation and Chronic Kidney Disease. <b>2017</b> , 283-294	
1126	Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation. <b>2017</b> , 34, 2274-2294	4
1125	Anticoagulation for Thromboembolic Risk Reduction in Adults With Congenital Heart Disease. <b>2017</b> , 33, 1597-1603	9
1124	High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy. <b>2017</b> , 44, 435-441	14
1123	Rescue Therapies. <b>2017</b> , 621-643	
1122	Deep Venous Thrombosis. <b>2017</b> , 35, 743-770	43
1121	Perioperative management of antithrombotic therapy in patients receiving cardiovascular implantable electronic devices: a network meta-analysis. <b>2017</b> , 50, 65-83	1
1120	Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence. <b>2017</b> , 31, 747-757	33
1119	Managing the Left Atrial Appendage in Atrial Fibrillation: Current State of the Art. <b>2017</b> , 104, 2111-2119	4
1118	Drug interactions with new oral anticoagulants in elderly patients. <b>2017</b> , 10, 1191-1202	23
1117	Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users. <b>2017</b> , 27, 347-355	18
1116	Rapid liquid chromatography tandem mass spectrometry determination of rivaroxaban levels in human plasma for therapeutic drug monitoring. <b>2017</b> , 25, 145-155	4
1115	Embolic Stroke of Undetermined Source in Latin America: A Review. <b>2017</b> , 22, 171-181	6
1114	Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence. <b>2017</b> , 44, 527-535	8
1113	Warfarin Use and Increased Mortality in End-Stage Renal Disease. <b>2017</b> , 46, 249-256	18
1112	Anticoagulation in Patients With Atrial Fibrillation in the Setting of Prior Hemorrhage: An Ongoing Dilemma. <b>2017</b> , 48, 2654-2659	2

1111	Highlights from the Ninth International Symposium of Thrombosis and Anticoagulation (ISTA IX), October 15, 2016, Salvador, Bahia, Brazil. <b>2017</b> , 44, 544-555	
1110	Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study. <b>2017</b> , 249, 198-203	20
1109	Pills Never Work in the Bottle. <b>2017</b> , 70, 1584-1586	1
1108	Left atrial appendage closure for prevention of death, stroke, and bleeding in patients with nonvalvular atrial fibrillation. <b>2017</b> , 249, 234-246	13
1107	Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial. <b>2017</b> , 74, 1206-1215	54
1106	Direct oral anticoagulant reversal: how, when and issues faced. <b>2017</b> , 10, 1005-1022	2
1105	Replacement of warfarin with a novel oral anticoagulant in endoscopic mucosal resection: a multicentre, open-label, randomised controlled trial. <b>2017</b> , 4, e000152	0
1104	Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. <b>2017</b> , 12, 1101-1108	10
1103	Atrial fibrillation, bleeding, and coronary intervention: current recommendations. <b>2017</b> , 28, 702-709	
1102	The safety of edoxaban for treating atrial fibrillation. <b>2017</b> , 16, 1295-1303	2
1101	Selections of Antithrombotic Agents During Acute Stage. <b>2017</b> , 135-143	
1100	Baseline characteristics and event rates among anticoagulated patients with atrial fibrillation in practice and pivotal NOAC trials. <b>2017</b> , 14, 563-565	3
1099	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. <b>2017</b> , 6,	14
1098	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. <b>2017</b> , 70, 1368-1375	50
1097	Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. <b>2017</b> , 6,	71
1096	Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making. <b>2017</b> , 245, 174-177	7
1095	2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. <b>2017</b> , 33, 345-367	93
1094	Management of antithrombotic agents in patients undergoing flexible bronchoscopy. <b>2017</b> , 26,	16

1093	Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal. <b>2017</b> , 17, 67	5
1092	Clinical profile and outcomes in octogenarians with atrial fibrillation: A community-based study in a specific European health care area. <b>2017</b> , 243, 211-215	16
1091	Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation). <b>2017</b> , 6,	93
1090	Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. <b>2017</b> , 130, 1440-1448.e1	83
1089	Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants. <b>2017</b> , 10, 833-845	1
1088	New Standards of Care in Ischemic Stroke. <b>2017</b> , 37, 320-331	2
1087	Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers. <b>2017</b> , 7, 692-701	7
1086	Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation. <b>2017</b> , 6, 549-560	4
1085	Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. <b>2017</b> , 40, 932-939	25
1084	Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients. <b>2017</b> , 33, 475-482	15
1083	Vitamin K Antagonists Versus Novel Oral Anticoagulants for Elective Electrical Cardioversion of Atrial Fibrillation. <b>2017</b> , 24, e553-e558	2
1082	Mortality and oral anticoagulants in the Food and Drug Administration Adverse Event Reporting System. <b>2017</b> , 4, e000629	6
1081	Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. <b>2017</b> , 48, 2494-2503	130
1080	New oral anticoagulants in patients with chronic kidney disease. <b>2017</b> , 37, 244-252	5
1079	Thrombo-embolic prevention after transcatheter aortic valve implantation. <b>2017</b> , 38, 3341-3350	41
1078	Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care. <b>2017</b> , 103, 210-218	31
1077	Free Fatty Acid Is Associated with Thrombogenicity in Cardioembolic Stroke. <b>2017</b> , 44, 160-168	11
1076	Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis. <b>2017</b> , 18, 567-576	12



1075	Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies. <b>2017</b> , 26, 1378-1386	25
1074	Periprocedural Anticoagulation for Catheter Ablation of Atrial Fibrillation: Practical Implications for Perioperative Management. <b>2017</b> , 31, 1519-1526	3
1073	ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives. <b>2017</b> , 19, D70-D88	4
1072	Comparison of Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Multicriteria Decision Analysis. <b>2017</b> , 20, 1394-1402	4
1071	[Atrial fibrillation: Thromboembolic risk factor or marker? From concept to therapy]. <b>2017</b> , 46, 751-757	
1070	Oral anticoagulation for stroke prevention amongst atrial fibrillation patients with valvular heart disease: an update. <b>2017</b> , 32, 174-180	5
1069	Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. <b>2017</b> , 24, 453-459	2
1068	Interventional and surgical occlusion of the left atrial appendage. <b>2017</b> , 14, 727-743	24
1067	Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System. <b>2017</b> , 7, 7399	10
1066	Edoxaban Use in Nonvalvular Atrial Fibrillation With Valvular Heart Disease-Insights from ENGAGE AF-TIMI 48. <b>2017</b> , 40, 612-613	1
1065	The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation. <b>2017</b> , 24, 1399-1406	16
1064	Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation. <b>2017</b> , 29, 551-561	4
1063	Global deregulation of ginseng products may be a safety hazard to warfarin takers: solid evidence of ginseng-warfarin interaction. <b>2017</b> , 7, 5813	12
1062	Original Abstracts from the 13th Annual Meeting of ISMPP. <b>2017</b> , 33, 5-21	15
1061	Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease. <b>2017</b> , 7, 207-217	12
1060	Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. <b>2017</b> , 18, 1325-1332	14
1059	Antithrombotic treatment for ischaemic stroke. <b>2017</b> , 13, S26-S34	
1058	Navigating the choice of oral anticoagulation therapy for atrial fibrillation in the NOAC era. <b>2017</b> , 8, 165-176	11

1057	Pharmacists' confidence when providing pharmaceutical care on anticoagulants, a multinational survey. <b>2017</b> , 39, 1282-1290	9
1056	Percutaneous Left Atrial Appendage Closure: Current Devices and Clinical Outcomes. <b>2017</b> , 10,	53
1055	Safe administration of non-vitamin K antagonist oral anticoagulants. <b>2017</b> , 15, 238-245	
1054	[Left atrial appendage closure in nonvalvular atrial fibrillation : Clinical evidence 2017]. <b>2017</b> , 28, 366-380	
1053	Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. <b>2017</b> , 70, 2621-2632	118
1052	5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. <b>2017</b> , 70, 2964-2975	407
1051	NOACs and atrial fibrillation: Incidence and predictors of left atrial thrombus in the real world. <b>2017</b> , 249, 179-183	44
1050	Steuerung der NOAK-Gabe bei invasiven oder operativen Interventionen. <b>2017</b> , 20, 146-151	
1049	Why is there still undertreatment with oral anticoagulants in elderly high risk patients with AF?. <b>2017</b> , 249, 247-248	
1048	Patients With Atrial Fibrillation: Switching Emphasis From Stroke Prevention to Stroke and Hemorrhage Prevention. <b>2017</b> , 3, 1377-1379	
1047	[Recent and upcoming randomized trials for left atrial appendage occlusion : Need for a definite assessment of the situation]. <b>2017</b> , 28, 395-402	0
1046	Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. <b>2017</b> , 11, CD011373	47
1045	Should Patients With Ischemic Stroke or Transient Ischemic Attack With Atrial Fibrillation and Microbleeds Be Anticoagulated?. <b>2017</b> , 48, 3408-3412	13
1044	Perioperativer Umgang mit Antikoagulanzen und Plättchenhemmern bei allgemein chirurgischen Eingriffen. <b>2017</b> , 11, 529-547	
1043	Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. <b>2017</b> , 33, 1583-1594	21
1042	Management of Oral Anticoagulation Therapy After Gastrointestinal Bleeding: Whether to, When to, and How to Restart an Anticoagulation Therapy. <b>2017</b> , 51, 1000-1007	19
1041	Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation. <b>2017</b> , 21, 540-550	13
1040	Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease. <b>2017</b> , 10, 789-797	4

1039	Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trials. <b>2017</b> , 116, 591-598	5
1038	[Procedures on patients receiving NOACs : What's possible?]. <b>2017</b> , 112, 117-124	1
1037	[Perioperative management of patients on NOACs]. <b>2017</b> , 112, 125-128	1
1036	Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. <b>2017</b> , 103, 1800-1805	13
1035	Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. <b>2017</b> , 25, 551-558	20
1034	Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus. <b>2017</b> , 18, 1101-1114	7
1033	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. <b>2017</b> , 16, 1051-1062	13
1032	Risk of Intraocular Bleeding With Novel Oral Anticoagulants Compared With Warfarin: A Systematic Review and Meta-analysis. <b>2017</b> , 135, 864-870	19
1031	Bleeding With Direct Oral Anticoagulants: The Gastrointestinal Tract and Beyond. <b>2017</b> , 15, 1665-1667	3
1030	First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial. <b>2017</b> , 244, 192-195	17
1029	Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. <b>2017</b> , 11, 243-256	20
1028	Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil. <b>2017</b> , 17, 148	2
1027	Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. <b>2017</b> , 39, 1456-1478.e36	81
1026	Monitoring and Reversal of Oral Anticoagulation in Hospitalized Patients. <b>2017</b> , 6, 330-347	
1025	Intensity of anticoagulation and risk of thromboembolism after elective cardioversion of atrial fibrillation. <b>2017</b> , 156, 163-167	10
1024	Anticoagulation after coronary stenting: a systemic review. <b>2017</b> , 123, 79-89	2
1023	Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. <b>2017</b> , 6,	25
1022	Dissection of Cervical and Cerebral Arteries. <b>2017</b> , 17, 59	27

1021	Drug therapy in anticoagulation: which drug for which patient?. <b>2017</b> , 17, 233-244	6
1020	Treatment of Non-vitamin K Antagonist Oral Anticoagulants. <b>2017</b> ,	
1019	Management and Outcomes of Bleeding Events in Patients in the Emergency Department Taking Warfarin or a Non-Vitamin K Antagonist Oral Anticoagulant. <b>2017</b> , 52, 1-7.e1	16
1018	Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. <b>2017</b> , 13, 113-122	4
1017	The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. <b>2017</b> , 10, 5-15	3
1016	Cardiovascular Disease. <b>2017</b> , 243-267	
1015	Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. <b>2017</b> , 43, 283-288	15
1014	Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. <b>2017</b> , 40, 46-52	15
1013	Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study. <b>2017</b> , 43, 157-165	1
1012	Comparative Efficacy of Clinical Events Prevention of Five Anticoagulants in Patients With Atrial Fibrillation (A Network Meta-Analysis). <b>2017</b> , 119, 585-593	7
1011	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. <b>2017</b> , 150, 123-130	17
1010	Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis. <b>2017</b> , 130, 457-461	16
1009	Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?. <b>2017</b> , 52, 341-347	2
1008	Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. <b>2017</b> , 40, 126-131	15
1007	Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice. <b>2017</b> , 130, 135-145	33
1006	Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. <b>2017</b> , 15, 682-690	38
1005	Intermittent vs. Continuous Anticoagulation therapy in patients with Atrial Fibrillation (iCARE-AF): a randomized pilot study. <b>2017</b> , 48, 51-60	14
1004	Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study). <b>2017</b> , 119, 268-274	10

1003	Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics. <b>2017</b> , 176, 32-39	35
1002	A pharmacotherapy review of the novel, oral antithrombotics. <b>2017</b> , 37, 62-70	3
1001	Atrial fibrillation in women: treatment. <b>2017</b> , 14, 113-124	43
1000	Intracranial Bleeding. <b>2017</b> , 25-39	
999	Causes and Outcome in Patients with Cerebral Hemorrhage Using Antithrombotic Drugs. <b>2017</b> , 53-63	
998	Pharmacological treatments of cardiovascular diseases: Evidence from real-life studies. <b>2017</b> , 118, 43-52	13
997	Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <b>2017</b> , 116, 276-286	3
996	Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. <b>2017</b> , 11, 105-120	5
995	Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke. <b>2017</b> , 23, 301-318	32
994	Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban. <b>2017</b> , 127, 716-725	2
993	Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal. <b>2017</b> , 43, 139-148	6
992	Oral Anticoagulant Use in Atrial Fibrillation-Associated Ischemic Stroke: A Retrospective, Multicenter Survey in Northwestern China. <b>2017</b> , 26, 125-131	11
991	Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa). <b>2017</b> , 33, 111-116	0
990	Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile. <b>2017</b> , 13, 49-64	0
989	Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant. <b>2017</b> , 227, 863-868	8
988	Evaluation of the antithrombotic abilities of non-vitamin K antagonist oral anticoagulants using the Total Thrombus-formation Analysis System. <b>2017</b> , 32, 309-316	4
987	Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation. <b>2017</b> , 26, 214-221	16
986	Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants. <b>2017</b> , 184, 150-155	13

985	Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. <b>2017</b> , 69, 868-876	43
984	Direct oral anticoagulant considerations in solid organ transplantation: A review. <b>2017</b> , 31, e12873	27
983	Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting. <b>2017</b> , 6, 91-117	3
982	Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation. <b>2017</b> , 23, 711-724	2
981	Practical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants. <b>2017</b> , 136, 115-124	10
980	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. <b>2017</b> , 151, 127-138	185
979	Atrial high-rate episodes and stroke prevention. <b>2017</b> , 19, 169-179	58
978	CHADS risk score and rate of stroke or systemic embolism and major bleeding in patients with non-valvular atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants. <b>2017</b> , 72, 390-396	1
977	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia	75
976	Evaluation of the Appropriateness of Direct Oral Anticoagulant Selection and Monitoring in the Outpatient Setting. <b>2017</b> , 33, 108-113 ca y. <b>2017</b> , 19, 1757-1758	2
975	Real-world incidence of efficacy and safety outcomes in patients on direct oral anticoagulants with left ventricular systolic dysfunction at a tertiary referral center. <b>2017</b> , 40, 1328-1332	3
974	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <b>2017</b> , 117, 2415-2424	45
973	Antikoagulation nach intrazerebraler Blutung. <b>2017</b> , 18, 24-27	
972	Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. <b>2017</b> , 117, 209-218	124
971	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <b>2017</b> , 7, e017157	58
970	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart	29
969	Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the Heart) GLORIA-AF Phase II Registry. <b>2017</b> , 117, 2376-2388 <b>2017</b> , 117, 2215-2236	65
968	Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation). <b>2017</b> , 6,	24

967	Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients. <b>2017</b> , 117, 1072-1082	102
966	Anticoagulation Stability Depends on CHADS Score and Hepatorenal Function in Warfarin-treated Patients, Including Those with Atrial Fibrillation. <b>2017</b> , 24, 68-76	5
965	Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults - a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing. <b>2017</b> , 17, 223	10
964	Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study. <b>2017</b> , 1, 202-215	11
963	Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS). <b>2017</b> , 37,	5
962	Pharmacological profile of non-vitamin K antagonist oral anticoagulants. <b>2017</b> , 11, 125-136	4
961	Literatur. <b>2017</b> ,	
960	. <b>2017</b> ,	4
959	Interventional Left Atrial Appendage Closure: Focus on Practical Implications. <b>2017</b> ,	
958	Update on Direct Oral AntiCoagulants (DOACs). <b>2017</b> , 37, 267-275	3
957	Direct oral anticoagulants (DOAC) - Management of emergency situations. <b>2017</b> , 37, 257-266	9
956	Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. <b>2017</b> , 1, 772-778	64
955	[Old and new oral anticoagulants in the management of atrial fibrillation. Hungarian data]. <b>2017</b> , 158, 1545-1549	
954	A case of dabigatran-induced esophagitis improved rapidly after switching medication from dabigatran to apixaban. <b>2017</b> , 39, 304-308	0
953	Antithrombotic treatment for ischaemic stroke. <b>2017</b> , 15, 345-354	
952	DOAC use in patients with chronic kidney disease. <b>2017</b> , 37, 286-294	0
951	Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. <b>2017</b> , 10, 135-143	64
950	Use of Novel Oral Anticoagulant to Treat Pulmonary Thromboembolism in Patient with Ulcerative Colitis Superinfected Cytomegalovirus Colitis. <b>2017</b> , 70, 44-49	2

949	A Multilevel Analysis of Real-World Variations in Oral Anticoagulation Initiation for Atrial Fibrillation in Valencia, a European Region. <b>2017</b> , 8, 576	2
948	Role of Antiplatelet Therapy in Stroke Prevention in Patients With Atrial Fibrillation. <b>2017</b> , 117, 761-771	4
947	A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: Comparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry. <b>2017</b> , 47, 877-887	25
946	Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. <b>2017</b> , 23, 1954-1963	92
945	Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians. <b>2017</b> , 12, 175-187	8
944	Evaluation of bleeding in patients receiving direct oral anticoagulants. <b>2017</b> , 13, 325-342	58
943	Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients. <b>2017</b> , 47, 833-841	9
942	Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran. <b>2017</b> , 4, 42	1
941	Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation. <b>2017</b> , 20, 8-14	7
940	Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. <b>2017</b> , 13, 457-467	33
939	Risk of ischemic stroke after atrial fibrillation diagnosis: A national sample cohort. <b>2017</b> , 12, e0179687	21
938	Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany. <b>2017</b> , 12, e0185642	22
937	Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed. <b>2017</b> , 17, 260	3
936	Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report. <b>2017</b> , 15, 23	16
935	The Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective. <b>2017</b> , 25, 76	19
934	Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial. <b>2017</b> , 18, 581	19
933	Nicht-Vitamin-K-abhängige orale Antikoagulanzen und Plättchenhemmer in der Herzchirurgie. <b>2017</b> , 31, 399-405	
932	Patient values and preferences for antithrombotic therapy in atrial fibrillation. A Narrative Systematic Review. <b>2017</b> , 117, 1007-1022	24



931	Kryptogener Schlaganfall: Rhythmusdetektion versus pragmatische orale Antikoagulation. <b>2017</b> , 6, 424-430	
930	Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients - Fushimi AF Registry. <b>2017</b> , 81, 1278-1285	87
929	Possible Benefits of Direct Oral Anticoagulants for the Electrophysiological Substrate Properties of Atrial Fibrillation: Can these New Agents have Antiatrial Fibrillation Actions?. <b>2017</b> , 06,	
928	Which of the Direct Oral Anticoagulants Is the Safest?: Based on Gastrointestinal Bleeding. <b>2017</b> , 69, 328	
927	Spontaneous Thyroid Hemorrhage on Chronic Anticoagulation Therapy. <b>2017</b> , 7, 932	4
926	Novel stroke risk reduction in atrial fibrillation: left atrial appendage occlusion with a focus on the Watchman closure device. <b>2017</b> , 13, 81-90	2
925	Setting priorities in the health care sector - the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark. <b>2017</b> , 9, 617-627	5
924	Clinical Stroke prevention in atrial fibrillation. <b>2017</b> , 47, 13-23	2
923	Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword. <b>2017</b> , 3,	1
922	Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials. <b>2017</b> , 87, 805	4
921	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. <b>2017</b> , 1, 1827-1838	35
920	Nuevos anticoagulantes orales: actualizaci3n. <b>2017</b> , 36, 254-263	1
919	Managing patients taking edoxaban in dentistry. <b>2017</b> , 9, e308-e311	5
918	Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide. <b>2017</b> , 13, 720-727	7
917	Direct Oral Anticoagulants: A Quick Guide. <b>2017</b> , 12, 40-45	47
916	Fibrilaci3n auricular: enfoque para el m3dico no cardiol3gico. <b>2017</b> , 30, 404-422	2
915	Dabigatran Therapy Resulting in the Resolution of Rivaroxaban-resistant Left Atrial Appendage Thrombi in Patients with Atrial Fibrillation. <b>2017</b> , 56, 1977-1980	13
914	The Dose of Direct Oral Anticoagulants and Stroke Severity in Patients with Acute Ischemic Stroke and Nonvalvular Atrial Fibrillation. <b>2018</b> , 27, 1490-1496	11

913	Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. <b>2018</b> , 3, CD008980	24
912	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <b>2018</b> , 39, 2314-2325	104
911	Impact of pre-admission treatment with non-vitamin K oral anticoagulants on stroke severity in patients with acute ischemic stroke. <b>2018</b> , 45, 529-535	10
910	Direct Oral Anticoagulant Use in Valvular Heart Disease. <b>2018</b> , 10, 1179559X1775163	2
909	Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis. <b>2018</b> , 72, 105-112	35
908	Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. <b>2018</b> , 7, 15-24	11
907	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <b>2018</b> , 39, 1672-1686f	59
906	An updated systematic review and meta-analysis of early outcomes after left atrial appendage occlusion. <b>2018</b> , 31, 197-206	15
905	Pharmacologic Reversal of Direct Oral Anticoagulants. <b>2018</b> , 41, 121-128	1
904	Race and stroke in an atrial fibrillation inception cohort: Findings from the Penn Atrial Fibrillation Free study. <b>2018</b> , 15, 487-493	9
903	Registry of Japanese patients with atrial fibrillation focused on anticoagulant therapy in the new era: The RAFFINE registry study design and baseline characteristics. <b>2018</b> , 71, 590-596	9
902	Direct Oral Anticoagulants. <b>2018</b> , 87-103	
901	GI Bleeding Risk of DOACs Versus Warfarin: Is Newer Better?. <b>2018</b> , 63, 1675-1677	9
900	Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. <b>2018</b> , 34, 1945-1957	2
899	Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. <b>2018</b> , 29, 835-843	8
898	Transitioning Between Anticoagulants. <b>2018</b> , 133-150	
897	Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry. <b>2018</b> , 32, 191-196	5
896	Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis. <b>2018</b> , 35, 1105-1110	21

895	Current State of Left Atrial Appendage Closure. <b>2018</b> , 20, 42	7
894	Diagnóstico, tratamiento y seguimiento de la fibrilación auricular en atención primaria. <b>2018</b> , 25, 4-31	0
893	Antithrombotic Therapy for Patients with Atrial Fibrillation. <b>2018</b> , 217-238	
892	Anticoagulation for Cardiac Prosthetic Devices: Prosthetic Heart Valves, Left Ventricular Assist Devices, and Septal Closure Devices. <b>2018</b> , 253-295	
891	Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe. <b>2018</b> , 39, 2932-2941	19
890	Gender Differences in Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis. <b>2018</b> , 52, 1135-1142	24
889	Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature. <b>2018</b> , 2, 251-265	23
888	State of play and future direction with NOACs: An expert consensus. <b>2018</b> , 106, 9-21	7
887	What Surgeons Should Know About Non-Vitamin K Oral Anticoagulants: A Review. <b>2018</b> , 153, 577-585	21
886	Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study. <b>2018</b> , 41, 440-449	11
885	Advances in Stroke 2017. <b>2018</b> , 49, e174-e199	19
884	Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system. <b>2018</b> , 46, 1-6	7
883	NOAKs zur Schlaganfallprävention bei Vorhofflimmern. <b>2018</b> , 14, 87-97	
882	Antithrombotic Management of Patients With Prosthetic Heart Valves. <b>2018</b> , 26, 177-186	11
881	PAR1 contribution in acute electrophysiological properties of oral anticoagulants in rabbit pulmonary vein sleeve preparations. <b>2018</b> , 32, 378-391	5
880	Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. <b>2018</b> , 16, 842-848	74
879	Epidemiology of Intracranial Hemorrhage Associated with Oral Anticoagulants in Spain: Trends in Anticoagulation Complications Registry - The TAC 2 Study. <b>2018</b> , 7, 284-295	5
878	Antiplatelet and anticoagulation regimen in patients with mechanical valve undergoing PCI - State-of-the-art review. <b>2018</b> , 264, 39-44	1

877	Contemporary approach to stroke prevention in atrial fibrillation: Risks, benefits, and new options. <b>2018</b> , 28, 469-480	0
876	Novel oral anticoagulant use in adult Fontan patients: A single center experience. <b>2018</b> , 13, 541-547	26
875	Use of direct oral anticoagulants in antiphospholipid syndrome. <b>2018</b> , 16, 1028-1039	31
874	Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation. <b>2018</b> , 7,	85
873	Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease. <b>2018</b> , 7,	19
872	Venous thromboembolism controversies. <b>2018</b> , 64, 408-444	2
871	Anticoagulation Management After Transcatheter and Surgical Valve Replacement. <b>2018</b> , 20, 42	3
870	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. <b>2018</b> , 23, 822-839	13
869	Multi-disciplinary decision making in general practice. <b>2018</b> , 32, 146-156	2
868	Managing atrial fibrillation to prevent stroke. <b>2018</b> , 16, 71-77	
867	Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. <b>2018</b> , 2, 282-290	22
866	Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). <b>2018</b> , 7,	104
865	Usefulness of the CHADS-VASc and HAS-BLED Scores in Predicting the Risk of Stroke Versus Intracranial Bleeding in Patients With Atrial Fibrillation (from the FibStroke Study). <b>2018</b> , 121, 1182-1186	6
864	Emergency medicine considerations in atrial fibrillation. <b>2018</b> , 36, 1070-1078	10
863	The Waxing and Waning of Antithrombotic Therapy in Cardiovascular Disease - Where Is the Moon Now?. <b>2018</b> , 60, 457-459	
862	Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <b>2018</b> , 60, 524-530	4
861	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. <b>2018</b> , 20, e1-e160	461
860	Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. <b>2018</b> , 257, 102-107	14

859	Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis. <b>2018</b> , 45, 550-556	14
858	Atrial Fibrillation for the Neurologist: Preventing both Ischemic and Hemorrhagic Strokes. <b>2018</b> , 18, 6	4
857	International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <b>2018</b> , 118, 437-450	159
856	Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus. <b>2018</b> , 35, 548-556	13
855	Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation. <b>2018</b> , 48, e12907	9
854	Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation. <b>2018</b> , 100, 488-493	44
853	Periprocedural Anticoagulation Management for Atrial Fibrillation Ablation: Current Knowledge and Future Directions. <b>2018</b> , 20, 3	6
852	Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. <b>2018</b> , 319, 463-473	129
851	Management of the Trauma Patient on Direct Oral Anticoagulants. <b>2018</b> , 8, 107-118	
850	Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. <b>2018</b> , 8, e019638	22
849	Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants. <b>2018</b> , 7,	14
848	Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis. <b>2018</b> , 118, 229-250	32
847	Reversal of Anticoagulation: Therapeutic Advances and Clinical Guidelines. <b>2018</b> , 25, e44-e52	2
846	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. <b>2018</b> , 4, 75-81	4
845	Incidence of intracardiac thrombus formation prior to electrical cardioversion in respect to the mode of oral anticoagulation. <b>2018</b> , 29, 537-547	7
844	Advances in anticoagulation therapy. <b>2018</b> , 31, 30-35	3
843	Principles and nursing management of anticoagulation. <b>2018</b> , 32, 50-63	0
842	Exploration of adherence and patient experiences with DOACs one year after switching from vitamin-K antagonists- insights from the switching study. <b>2018</b> , 162, 62-68	12

841	The challenges of antithrombotic therapy in patients with left ventricular thrombosis. <b>2018</b> , 39, 209-211	2
840	Novel oral anticoagulants in the preoperative period: a meta-analysis. <b>2018</b> , 45, 386-396	4
839	Management of atrial fibrillation in diabetes. <b>2018</b> , 35, 27-31	4
838	Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). <b>2018</b> , 163, 100-104	7
837	Anesthesia for Cardiac Ablation. <b>2018</b> , 32, 1892-1910	9
836	[S1 guideline - Austrian consensus for anticoagulation in the context of atrial fibrillation ablation]. <b>2018</b> , 130, 1-8	
835	Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France. <b>2018</b> , 111, 370-379	8
834	Risk of Recurrent Ischemic Stroke with Unintended Low-Dose Oral Anticoagulant Therapy and Optimal Timing of Review. <b>2018</b> , 27, 1546-1551	16
833	Neues beim Schlaganfall. <b>2018</b> , 08, 61-84	
832	Hypertension and Atrial Fibrillation: Doubts and Certainties From Basic and Clinical Studies. <b>2018</b> , 122, 352-368	76
831	Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?. <b>2018</b> , 20, 4	6
830	Modelling projections for the risks related with atrial fibrillation in East Asia: a focus on ischaemic stroke and death. <b>2018</b> , 20, 1584-1590	7
829	Anticoagulation. <b>2018</b> , 535-546	
828	Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. <b>2018</b> , 17, 251-258	1
827	Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation. <b>2018</b> , 118, 526-538	45
826	Outcome of Secondary Stroke Prevention in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants. <b>2018</b> , 27, 1174-1177	3
825	Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation. <b>2018</b> , 131, 573.e1-573.e8	13
824	Discrepancies between the use of MDRD-4 IDMS and CKD-EPI equations, instead of the Cockcroft-Gault equation, in the determination of the dosage of direct oral anticoagulants in patients with non-valvular atrial fibrillation. <b>2018</b> , 150, 85-91	

823	Direct oral anticoagulants: An update. <b>2018</b> , 151, 198-206	15
822	Quantifying Time in Atrial Fibrillation and the Need for Anticoagulation. <b>2018</b> , 60, 537-541	7
821	Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. <b>2018</b> , 196, 105-112	69
820	[Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?]. <b>2018</b> , 43, 214-221	2
819	Reintroduction of anticoagulant therapy after intracranial haemorrhage: If and when?. <b>2018</b> , 32, 256-263	6
818	Actualizaci3n ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboraci3n con la EACTS. <b>2018</b> , 71, 42.e1-42.e58	2
817	Direct Oral Anticoagulants in End-Stage Renal Disease. <b>2018</b> , 44, 353-363	12
816	Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa. <b>2018</b> , 215, 775-779	9
815	Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. <b>2018</b> , 104, 301-310	11
814	Clinical Trials for Atrial Fibrillation—What Do We Know?. <b>2018</b> , 630-642	
813	Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. <b>2018</b> , 60, 514-523	7
812	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. <b>2018</b> , 198, 169-177	6
811	Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. <b>2018</b> , 33, 1683-1689	17
810	The year in cardiology 2017: arrhythmias and cardiac devices. <b>2018</b> , 39, 434-441	3
809	Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIA Registry. <b>2018</b> , 20, 1577-1583	61
808	Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience. <b>2018</b> , 44, 364-369	27
807	Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban. <b>2018</b> , 118, 72-81	19
806	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials. <b>2018</b> , 93, 1065-1073	18

805	Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With CKD: Pragmatic Considerations for the Clinician. <b>2018</b> , 72, 717-727	10
804	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. <b>2018</b> , 118, 1001-1008	11
803	Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. <b>2018</b> , 360, k342	50
802	What Constitutes an Independent Statistical Analysis?. <b>2018</b> , 33, 786-788	
801	Design and rationale of the non-interventional, edoxaban treatment in routine clinical practice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. <b>2018</b> , 16, 9	11
800	Reversal of direct oral anticoagulants. <b>2018</b> , 79, C70-C73	
799	Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study. <b>2018</b> , 265, 108-112	19
798	Optimal long-term antithrombotic management of atrial fibrillation: life cycle management. <b>2018</b> , 26, 311-320	5
797	A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants. <b>2018</b> , 16, 1296-1306	24
796	Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism. <b>2018</b> , 2, 69-76	6
795	Managing atrial fibrillation to prevent stroke. <b>2018</b> , 14, 84-90	
794	A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice. <b>2018</b> , 46, 95-101	1
793	Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis. <b>2018</b> , 72, 284-291	7
792	Initial apixaban dosing in patients with atrial fibrillation. <b>2018</b> , 41, 671-676	10
791	Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. <b>2018</b> , 34, 1839-1847	7
790	Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants. <b>2018</b> , 151, 210.e1-210.e13	1
789	Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. <b>2018</b> , 50, 288-302	10
788	Antithrombotic Therapy in Nonvalvular Atrial Fibrillation: Consensus and Challenges. <b>2018</b> , 355, 467-476	5



787	Left Atrial Appendage Occlusion, Shared Decision-Making, and Comprehensive Atrial Fibrillation Management. <b>2018</b> , 7, 267-283	
786	An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <b>2018</b> , 200, 17-23	56
785	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. <b>2018</b> , 14, 337-351	50
784	Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants. <b>2018</b> , 52, 156-162	6
783	Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation. <b>2018</b> , 20, 32	16
782	Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Retrospective Population Study. <b>2018</b> , 56, 410-415	2
781	Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran. <b>2018</b> , 63, 1878-1889	14
780	Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. <b>2018</b> , 25, 158-168	45
779	Interventions and Strategies to Improve Oral Anticoagulant Use in Patients with Atrial Fibrillation: A Systematic Review of Systematic Reviews. <b>2018</b> , 38, 579-591	1
778	Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. <b>2018</b> , 118, 842-851	114
777	Novel oral anticoagulants in chronic kidney disease: ready for prime time?. <b>2018</b> , 27, 201-208	4
776	[The efficacy and safety of edoxaban in non-valvular atrial fibrillation]. <b>2018</b> , 159, 466-469	
775	Anticoagulation in atrial fibrillation with heart failure. <b>2018</b> , 23, 563-571	7
774	Oral anticoagulants for atrial fibrillation and acute coronary syndrome with or without stenting. <b>2018</b> , 19 Suppl 1, e40-e45	1
773	Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program. <b>2018</b> , 41, 744-751	14
772	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <b>2018</b> , 20, 1231-1242	148
771	Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil. <b>2018</b> , 45, 578-587	
770	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <b>2018</b> , 39, 1330-1393	1094

769	Evaluation and management of Non-variceal upper gastrointestinal bleeding. <b>2018</b> , 64, 333-343	24
768	Comparison of Aspirin and Naoxintong Capsule () with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase. <b>2018</b> , 24, 247-253	4
767	Prognostic factors and analysis of mortality due to brain haemorrhages associated with vitamin K antagonist oral anticoagulants. Results from the TAC registry. <b>2018</b> , 33, 419-426	5
766	Transcatheter closure of the left atrial appendage: A focused update on the Watchman closure device. <b>2018</b> , 92, E28-E34	1
765	New developments in clinical ischemic stroke prevention and treatment and their imaging implications. <b>2018</b> , 38, 1533-1550	10
764	[Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper]. <b>2018</b> , 168, 133-143	1
763	Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. <b>2018</b> , 48, 51-58	69
762	An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure. <b>2018</b> , 18, 153-159	15
761	Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management. <b>2018</b> , 59, 311-320	29
760	Management of Direct-Acting Oral Anticoagulants Surrounding Dental Procedures With Low-to-Moderate Risk of Bleeding. <b>2018</b> , 31, 202-207	10
759	Current Evidence-Based Understanding of the Epidemiology, Prevention, and Treatment of Atrial Fibrillation. <b>2018</b> , 43, 241-283	7
758	Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery. <b>2018</b> , 20, e105-e114	46
757	Triple therapy with dual antiplatelet treatment and direct oral anticoagulants. <b>2018</b> , 47, e20	
756	Percutaneous left atrial appendage closure is not ready for routine clinical use. <b>2018</b> , 15, 298-301	16
755	Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. <b>2018</b> , 21, 244-253	12
754	2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. <b>2018</b> , 53, 5-33	183
753	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). <b>2018</b> , 39, 213-260	1475
752	Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. <b>2018</b> , 20, 1-11	35

751	Safe Burr Hole Surgery for Chronic Subdural Hematoma Using Dabigatran with Idarucizumab. <b>2018</b> , 109, 432-435	11
750	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <b>2018</b> , 53, 34-78	149
749	Atrial fibrillation in kidney transplant recipients: is there a place for the novel drugs?. <b>2018</b> , 33, 1304-1309	10
748	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. <b>2018</b> , 121, 131-140	15
747	Acute Management of Atrial Fibrillation: From Emergency Department to Cardiac Care Unit. <b>2018</b> , 36, 141-159	7
746	Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. <b>2018</b> , 197, 1-8	5
745	One decade of oral anticoagulation in stroke patients: Results from a large country-wide hospital-based registry. <b>2018</b> , 13, 308-312	9
744	Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective. <b>2018</b> , 24, 22-32	9
743	Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. <b>2018</b> , 199, 59-67	15
742	Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence. <b>2018</b> , 52, 277-284	11
741	Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke. <b>2018</b> , 27, 338-345	5
740	Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients. <b>2018</b> , 111, 85-94	22
739	Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. <b>2018</b> , 283, 45-55	61
738	Rationale and design of a global registry to evaluate real-world clinical outcomes in patients with atrial fibrillation and high risk of stroke treated with left atrial appendage occlusion using the AMPLATZER amulet device-Perspective of available/ongoing registries of catheter-based LAA occlusion. <b>2018</b> , 91, 540-547	5
737	Atrial Fibrillation. <b>2018</b> , 724-735	
736	Prevention of Stroke in Atrial Fibrillation. <b>2018</b> , 1092-1100	
735	Left Atrial Appendage Closure. <b>2018</b> , 1337-1344	
734	Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis. <b>2018</b> , 36, 396-402	14

733	Decision Algorithms for Direct Oral Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation: A Practical Guide for Neurologists. <b>2018</b> , 24, 396-404	2
732	[Fine-tuning of antithrombotic therapy in patients with non-valvular atrial fibrillation. The AFINVA register]. <b>2018</b> , 50, 340-349	2
731	[Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?]. <b>2018</b> , 44, 297-303	0
730	Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. <b>2018</b> , 137, 1117-1129	33
729	Safety of Uninterrupted Periprocedural Edoxaban Versus Phenprocoumon for Patients Who Underwent Left Atrial Catheter Ablation Procedures. <b>2018</b> , 121, 445-449	14
728	Stroke Prevention for High-Risk Atrial Fibrillation in the Emergency Setting: The Emergency Physician Perspective. <b>2018</b> , 34, 125-131	11
727	Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. <b>2018</b> , 131, 573.e9-573.e15	19
726	Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?. <b>2018</b> , 43, 20-25	2
725	Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]). <b>2018</b> , 121, 584-589	12
724	Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism. <b>2018</b> , 14, 89-99	
723	Overview of Anticoagulation Agents. <b>2018</b> , 275-289	
722	Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. <b>2018</b> , 34, 487-498	27
721	Left atrial appendage closure: Six reasons why I wouldn't choose a percutaneous closure for my appendage. <b>2018</b> , 251, 42-44	3
720	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in 'real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. <b>2018</b> , 254, 125-131	15
719	Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. <b>2018</b> , 197, 133-141	16
718	Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation. <b>2018</b> , 45, 250-256	16
717	Nonpharmacological Management of Atrial Fibrillation in Patients at High Intracranial Hemorrhage Risk. <b>2018</b> , 49, 247-254	22
716	Perioperative management of anticoagulant and antiplatelet therapy. <b>2018</b> , 104, 1461-1467	35

715	Sex Differences in Atrial Fibrillation. <b>2018</b> , 34, 429-436	33
714	European guidelines on perioperative venous thromboembolism prophylaxis: Patients with preexisting coagulation disorders and after severe perioperative bleeding. <b>2018</b> , 35, 96-107	7
713	[New oral anticoagulants (NOAC) in stroke treatment]. <b>2018</b> , 86, 117-124	
712	Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study. <b>2018</b> , 27, 174-181	17
711	Tranexamic Acid Failed to Reverse the Anticoagulant Effect and Bleeding by an Oral Direct Factor Xa Inhibitor Edoxaban. <b>2018</b> , 101, 92-95	6
710	Anticoagulation in atrial fibrillation : Current evidence and guideline recommendations. <b>2018</b> , 43, 2-10	5
709	Clinical manifestations and outcomes of severe warfarin overanticoagulation: from the EWA study. <b>2018</b> , 50, 164-171	
708	Empirical anticoagulation for patients in sinus rhythm at high risk of ischaemic stroke: A review of current literature. <b>2017</b> , 9, 422-428	0
707	Acute Stroke Emergency Management. <b>2017</b> , 303-314	
706	Patient with Concomitant Mitral Valve Stenosis. <b>2017</b> , 81-85	
705	Patient with Concomitant Aortic Valve Stenosis. <b>2017</b> , 87-90	
704	Male with Priority of Ischemic Stroke Reduction. <b>2017</b> , 15-18	
703	Acute VTE in a Patient with Moderate Chronic Kidney Disease. <b>2017</b> , 143-149	
702	Percutaneous Left Atrial Appendage Closure: Rational, Patient Selection, and Preoperative Evaluation. <b>2017</b> , 191-198	
701	Anticoagulants for Atrial Fibrillation. <b>2017</b> , 105-114	
700	Role of anticoagulation for ischemic stroke patients. <b>2017</b> , 28, 335-344	
699	Oral Anticoagulants in Severe Renal Dysfunction. <b>2017</b> , 53-59	
698	Cardiac Evaluation and Management After Ischemic Cerebral Stroke. <b>2017</b> , 85-97	

- 697 Patient with Concomitant Stable Coronary Artery Disease. **2017**, 69-73
- 696 Patient with Prior History of GI Hemorrhage. **2017**, 25-29
- 695 Defibrillation Testing During ICD Implantation - Should we or Should we Not?. **2017**, 9, 1508 1
- 694 Cardioembolic Stroke. **2017**, 23, 111-132 9
- 693 Prevalence and Characteristic Features of Deep Vein Thrombosis in Patients with Severe Motor and Intellectual Disabilities. **2017**, 28, 29-34
- 692 Rivaroxaban in high-risk patients. **2017**, 63, 424-430 2
- 691 Approaches to Left Atrial Appendage Closure: Device Design, Performance, and Limitations. **2017**, 13, 106-113 1
- 690 Bleeding Risk under Oral Factor Xa Inhibitors: Meta-analysis of the randomized comparison with Vitamin K Antagonists and Meta-Regression analysis. 038-048
- 689 Riesgo diferencial de hemorragia intracraneana en pacientes con fibrilaci3n auricular no valvular con el uso de nuevos anticoagulantes orales vs. warfarina. Revisi3n sistem3tica de la literatura y an3lisis de subpoblaciones. **2017**, 58,
- 688 1) Selection of Suitable Antithrombotic Therapy Based upon Precise Pathophysiological Understanding. **2017**, 106, 1843-1850
- 687 New anticoagulants. **2017**, 10, 1-9 2
- 686 Early Anticoagulation for Recurrent Ischemic Stroke despite the Presence of Ventricular Bleeding. **2017**, 7,
- 685 Direct Oral Anticoagulants and their Clinical Management. **2017**, 5,
- 684 Use of Rivaroxaban and Apixaban, Two Non-Vitamin K Antagonist Oral Anticoagulants (NOACs), in Renally Impaired Patients - the limits of our knowledge. **2018**, 3, 049-051 1
- 683 OBSOLETE: Clinical Trials for Atrial Fibrillation - What do we know?. **2018**,
- 682 Therapie von tachykarden Herzrhythmusst3rungen. **2018**, 128-153
- 681 Stratifying Thromboembolic Risk: Why Is Your Patient on Antithrombotic Medications?. **2018**, 73-89
- 680 Anticoagulants and Therapeutic Endoscopy. **2018**, 107-113

- 679 Primary Prevention and Secondary Prevention des Hirninfarkts. **2018**, 1-31
- 678 Possibility of novel monitoring system for thrombus formation in patients with coronary artery disease. **2018**, 24, 156-160
- 677 Intracranial hemorrhage associated with direct oral anticoagulant developing at three days after clipping for unruptured cerebral aneurysm through craniotomy. **2018**, 40, 275-279
- 676 Survey of Direct-Acting Oral Anticoagulants for Non-Valvular Atrial Fibrillation. **2018**, 67, 58-64
- 675 4. Efficacy and Safety of DOAC Versus Warfarin in Chronic Kidney Disease. **2018**, 107, 856-864
- 674 Novel Oral Anticoagulants, A Subject in Continuing Debate. **2018**, 15, 43-52
- 673 MERKEZİNDE NON- VALVÜLER ATRİYAL FİBRİLYASYON TANISI ALMI HASTALARIN DEMOGRAFİK ÖZELLİKLERİNE ORAL ANTIKOAGÜLYASYON TERCİHLERİNİN RETROSPEKTİF OLARAK DEĞERLENDİRİLMESİ  
RETROSPECTIVE EVALUATION OF ORAL ANTICOAGULATION PREFERENCES AND DEMOGRAPHIC CHARACTERISTICS OF THE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN OUR CENTER
- 672 Hemorragia grave en el paciente anticoagulado. **2018**, 150, 30-37
- 671 Edoxaban. **2018**, 40, ○
- 670 Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation. **2018**, 9, 3274-3281
- 669 EFFICACY OF ISCHEMIC STROKE PREVENTION IN PATIENTS WITH IMPLANTED OCCLUDER OF THE LEFT ATRIUM. FIVE YEAR FOLLOW-UP. **2018**, 16-20 1
- 668 Risky Business: Judging the Use of Non-Vitamin K Antagonist Oral Anticoagulants for Non-Valvular Atrial Fibrillation in Patients with Renal Dysfunction. **2018**, 11, 2071 ○
- 667 Edoxaban - its properties and role in antithrombotic prophylaxis in atrial fibrillation. **2018**, 17, 169-172
- 666 Edoxaban. **2018**, 20, 207-210
- 665 Stroke in the Elderly Population. **2019**, 121-135
- 664 Safety of concomitant treatment with Non-Vitamin K Oral Anticoagulants and SSRI/SNRI antidepressants. **2018**, 19, 267-278 1
- 663 Influence of Epidemiologic and Clinical Trends on Risk Stratification and Net Clinical Benefit of Long-term Oral Anticoagulation for Nonvalvular Atrial Fibrillation. **2018**, 2, 22-25
- 662 New oral anticoagulants.

- 661 The Impact of Cancer on Major Bleeding and Stroke/Systemic Emboli in Patients Using Direct Oral Anticoagulants:From the Database of a Single-Center Registry. **2018**, 11, 2105 3
- 660 A novel rationale for targeting FXI: Insights from the hemostatic miRNA targetome for emerging anticoagulant strategies.
- 659 Beneficios y riesgos de los anticoagulantes orales en la fibrilaci3n auricular. **2019**, 18, 9-14
- 658 Updates on Direct Oral Anticoagulants in the Management of Atrial Fibrillation. **2019**, 5, 24
- 657 Efficacy and safety of anticoagulation therapy in patients with non-valvular atrial fibrillation in actual clinical setting. **2019**, 41, 85-92 0
- 656 Recent Advances for Stroke Prevention in Patients With Atrial Fibrillation and Advanced Kidney Disease. **2019**, 736-740.e2
- 655 Cardiovigilance in Atrial Fibrillation âPrimordial to Quinary Prevention Intervention. **2019**, 5, 77
- 654 Role of Novel Oral Anticoagulant for Patient with Atrial Fibrillation Underwent Percutaneous Coronary Intervention. **2019**, 1, 19 1
- 653 Are There Enough Data to Safely Withdraw Anticoagulation After Atrial Fibrillation Catheter Ablation?. **2019**, 5, 82
- 652 Best Treatment Selection for Chronic Intracranial Artery Stenosis. **2019**, 28, 783-788
- 651 Consequences of Altered Cardiac Activity on Brain Activity. **2019**, 1-15
- 650 Prim3rpr3vention und Sekund3rpr3vention des Hirninfarkts. **2019**, 1-31
- 649 Novel Oral Anticoagulants âDo Real-world Data Support our Expectations?. **2019**, 5, 48
- 648 CHOICE OF DIRECT ORAL ANTICOAGULANTS BASED ON THE INDIVIDUAL APPROACH. **2019**, 5, 10-22
- 647 2018 Korean Heart Rhythm Society Guidelines for Non-Vitamin K Antagonist Oral Anticoagulants. **2019**, 94, 57-82 1
- 646 Impact of Hypertension in Patients with Atrial Fibrillation and Importance of Blood Pressure Management during Anticoagulation Therapy. **2019**, 15, 12-23
- 645 Hemorrhage in patients under oral anticoagulation for atrial fibrillation. The other side of the coin. **2019**, 54, 99-105 0
- 644 Cardiovascular Disease. **2019**, 101-151



- 643 Spectrophotometric Determination of Apixaban in Bulk Drug and Oral Dosage Formulation. **2019**, 377-385
- 642 POSSIBILITIES OF INHIBITING ANTICOAGULANT ACTIVITIES THAT INHIBIT XA-FACTOR. **2019**, 72-81
- 641 Anticoagulation Monitoring and Reversal. **2019**, 353-358
- 640 [Personalized approach for direct oral anticoagulant prescription: from theory to practice]. **2019**, 91, 111-120 3
- 639 (Cost-effectiveness analysis of first-line NOAC prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation). **2019**, 61, e354-e369 1
- 638 Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing. **2019**, 6, 142-159
- 637 [Thrombotic and hemorrhagic complications in atrial fibrillation patients, undergoing elective percutaneous coronary intervention]. **2019**, 91, 38-46 2
- 636 Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation. **2019**, 21, 259-275 2
- 635 Security profile of direct anticoagulants. Preferred use in atrial fibrillation. **2019**, 31, 263-270
- 634 [How to maintain an adherence to oral anticoagulant in a patient with atrial fibrillation?]. **2019**, 59, 76-83
- 633 Coagulation and Anticoagulants. **2020**, 1-53
- 632 Perioperative Management of Anticoagulation and Antiplatelet Therapy. **2020**, 267-286
- 631 (Anticoagulation therapy in patients with chronic kidney disease). **2019**, 61, 599-605 0
- 630 Anticoagulation in Cardiac Patients. **2020**, 77-102
- 629 Acute Stroke Emergency Management. **2020**, 273-282
- 628 Antithrombotika und Antihorrhagika. **2020**, 395-420
- 627 Ethnic Differences in Oral Antithrombotic Therapy. **2020**, 50, 645-657 4
- 626 [Risk of Coronary Events in Atrial Fibrillation]. **2020**, 60, 43-52

- 625 Bleeding During Oral Anticoagulation. **2020**, 117, 311
- 624 [Gastrointestinal Bleeding in Patients with Coronary Heart Disease: Preventive Options]. **2020**, 60, 125-135
- 623 Real-world outcomes of anticoagulant prescription in anticoagulant-naïve octogenarian patients with non-valvular atrial fibrillation. **2020**, 188-194
- 622 How to Manage Atrial Fibrillation in the Emergency Department: a Critical Appraisal. **2020**, 33, 55-66
- 621 Periprocedural Management of Oral Anticoagulation. **2020**, 104, 709-726 8
- 620 The Use of Direct Oral Anticoagulants in the Management of Venous Thromboembolism in Patients With Obesity. **2020**, 12, e10006 1
- 619 Reversal strategies and outcomes in patients with atrial fibrillation and warfarin-associated intracranial hemorrhage. **2020**, 29, 104903
- 618 [Direct Oral Anticoagulant Edoxaban in Patients with Non-Valvular Atrial Fibrillation: Results of Direct Comparison with Warfarin]. **2020**, 60, 124-129 1
- 617 EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). **2020**, 6-76 3
- 616 Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry. **2021**, 269, 470 1
- 615 Antithrombotic Therapy for Patients With Atrial Fibrillation and Bioprosthetic Valves - Real-World Data From the Multicenter, Prospective, Observational BPV-AF Registry. **2021**, 0
- 614 High-dose versus low-dose 4-factor prothrombin complex concentrate for factor Xa inhibitor reversal in intracranial hemorrhage. **2021**, 208, 112-116 1
- 613 Risk of Intracranial Hemorrhage Caused by Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation (from a Network Meta-Analysis of Randomized Controlled Trials). **2021**, 0
- 612 Meta-analysis comparing inappropriately low dose versus standard dose of direct oral anticoagulants in patients with atrial fibrillation. **2021**, 1
- 611 Edoxaban: de los ensayos clínicos a la evidencia de la vida real. **2021**, 57, 4-4
- 610 A proposed interval for evaluation of renal function during anticoagulation therapy using direct oral anticoagulants in patients with atrial fibrillation. **2021**,
- 609 Single facility analysis of cardioembolic stroke with atrial fibrillation Trend over the past 7 years after the introduction of DOACs . **2020**, 42, 73-79
- 608 Gerinnungsstörungen in der Neurologie. **2020**, 1727-1744

- 607 Anticoagulation in sub-saharan africa with the advent of non-vitamin K antagonist oral anticoagulants. **2020**, 29, 187 ○
- 606 Atrial Fibrillation and Atrial Flutter. **2020**, 41-58
- 605 Comparisons of Edoxaban Versus Warfarin on Levels of Plasma Prothrombin Fragment in Patients With Nonvalvular Atrial Fibrillation. **2020**, 136, 71-75
- 604 The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New?. **2020**, 16, 984-993
- 603 Clinical performance of the atrial fibrillation in the Russian population depending on the antithrombotic therapy: findings from the GLORIA-AF registry phase 2. **2020**, 25, 4179
- 602 The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation. **2020**, 28-43
- 601 New aspects of anticoagulant therapy in atrial fibrillation in patients with renal dysfunction. **2020**, 25, 4175
- 600 Prevention of Ischemic Stroke. **2021**, 581-609
- 599 The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis. **2020**, 18, ○
- 598 The prevention and treatment of bleeding associated with direct oral anticoagulants. **2020**, 96, 491-497
- 597 Rivaroxaban Experience at Tertiary Care Centre in Saudi Arabia:A Retrospective Observational Study. **2020**, 9, e1882
- 596 Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement. **2020**, 15, e0243866 1
- 595 Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. **2021**, 20, 103-107 ○
- 594 Consequences of Altered Cardiac Activity on Brain Activity. **2020**, 197-211
- 593 Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies. **2019**, 8, 212606 ○
- 592 Atrial Fibrillation and Other Supraventricular Tachycardias. **2020**, 125-130
- 591 Sekundärprävention. **2020**, 149-181
- 590 Dose Selection of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Non-Valvular Atrial Fibrillation. **2020**, 2, 1

589 Therapeutic anticoagulation. **2020**, 3729-3734

588 Soil Water Balance Response to Climate Change in Posavina Region. **2020**, 11-24

587 HEMATURIA AND OTHER KINDS OF BLEEDINGS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: AN UPDATED OVERVIEW ON OCCURRENCE, PATHOMECHANISMS AND MANAGEMENT. **2020**, 73, 2528-2534

586 The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis. **2021**, 25, 77-88 2

585 Devices for continuous embolic protection. **2020**, 979-1005

584 Hemorrhagic complication during anticoagulant therapy and antidote. **2020**, 31, 584-590

583 Atrial Fibrillation. **2020**, 141-168

582 ERKRANKUNGEN DES HERZENS UND DES KREISLAUFS. **2020**, D-1-D17-4

581 Assessment of the compatibility of the real-world nonvalvular atrial fibrillation patients in Turkey with the study population of Phase 3 novel oral anticoagulant trials: An auxiliary study of NOAC-TR. **2020**, 6, 12

580 Atrial Fibrillation and Atrial Flutter. **2020**, 185-196

579 Cardiac Arrhythmias. **2020**, 1-23

578 Primärprävention und Sekundärprävention des Hirninfarkts. **2020**, 883-913

577 Andexanet Alfa and its Clinical Application. **2020**, 14, 20

576 Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism. **2020**, 105, 2

575 Clinical Discussions in Antithrombotic Therapy Management : A Delphi Consensus Panel. **2020**, 12, 2159 1

574 Thrombolytic therapy and use of apixaban in a stroke patient. **2020**, 9,

573 Non-vitamin K oral antagonist failure and tailored treatment in patients with atrial fibrillation and stroke. **2020**, 4, 37-42

572 Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study. **2020**, 27, e28-e44 2

- 571 Medical and Device Therapy for Stroke Prevention in Patients With Atrial Fibrillation. **2021**, 48,
- 570 Residual Stroke Risk in Atrial Fibrillation. **2021**, 10, 147-153 1
- 569 Gastrointestinal Bleeding: a Cardiologist's Point of View. **2021**, 17, 771-778
- 568 Effectiveness and Safety of DOACs vs. VKAs in AF Patients With Cancer: Evidence From Randomized Clinical Trials and Observational Studies. **2021**, 8, 766377 1
- 567 Gastrointestinal Bleeding in Antithrombotic Therapy in Patients with Coronary Heart Disease: Risk Factors, Pathogenesis and Treatment. **2020**, 30, 14-23 0
- 566 La INR durante los ictus y las hemorragias en pacientes con fibrilaci3n auricular tratados con antagonistas de la vitamina K. **2020**, 55, 131-138
- 565 Institutional Experience of Using Andexanet Alfa. **2020**, 12, e9173 1
- 564 Efficacy and Safety of Direct Factor Xa Inhibitors Versus Warfarin in Prevention of Primary and Secondary Ischemic Strokes in Non-Valvular Atrial Fibrillation: A Literature Review. **2020**, 12, e9400
- 563 Perioperative outcomes of interrupted anticoagulation in patients with non-valvular atrial fibrillation undergoing non-cardiac surgery. **2020**, 37, 321-328 1
- 562 Atrial fibrillation and thrombophilia. DOAC as a valid alternative? A clinical case. **2020**, 62, 470-472 0
- 561 Cause of Death and Associated Factors in Elderly Patients With Atrial Fibrillation - Long-Term Retrospective Study. **2020**, 2, 490-498 0
- 560 Direct oral anticoagulant reversal. **2020**, 15, 18-29
- 559 [How to anticoagulate elderly and fragile patients?]. **2020**, 145, 1562-1568
- 558 Sekund3rprophylaxe der zerebralen Isch3mie. **2020**, 39, 644-650
- 557 Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. **2020**, 77, 11-21 0
- 556 Advances in the management of atrial fibrillation with a special focus on non-pharmacological approaches to prevent thromboembolism: a review of current recommendations. **2020**, 68, 1317-1333
- 555 Anticoagulation for Atrial Fibrillation in Advanced Chronic Kidney Disease. **2021**, 333-341
- 554 Risk management in patients with atrial fibrillation and comorbid conditions: potentialities of edoxaban. **2020**, 25, 4131

- 553 Edoxaban Treatment in routine clinical practice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data. **2020**, 39, 651-662
- 552 Novel Oral Anticoagulants in Renal Transplant Recipients: A Retrospective Cohort Study. **2020**, 41, 49-55 1
- 551 Patent Foramen Ovale, the Role of Antiplatelet Therapy Alone or Anticoagulant Therapy Alone Versus Device Closure for Cryptogenic Stroke: A Review of the Literature and Current Recommendations. **2020**, 18, 135-150
- 550 Electrophysiology and heart rhythm disorders in older adults. **2016**, 13, 645-651 5
- 549 Edoxaban: an investigational factor xa inhibitor. **2014**, 39, 686-715 1
- 548 Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. **2014**, 39, 858-80 6
- 547 Edoxaban (Savaysa): A Factor Xa Inhibitor. **2015**, 40, 651-95 8
- 546 Optimization Of Stroke Prophylaxis Strategies In Nonvalvular AF -Drugs, Devices Or Both?. **2015**, 8, 1156
- 545 Implications of Recent Drug Approvals for Older Adults. **2016**, 24, 25-30 5
- 544 Patient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding. **2015**, 8, 1218
- 543 The New Novel Oral Anticoagulants (NOACs) In Patients With Atrial Fibrillation: Dogma, Dilemmas, And Decisions On Dosing. **2014**, 6, 1037 1
- 542 How we treat bleeding associated with direct oral anticoagulants. **2016**, 14, 465-73 8
- 541 Ablation of Atrial Fibrillation in Combination with Left Atrial Appendage Occlusion in A Single Procedure. Rationale and Technique. **2016**, 8, 1346 2
- 540 Misleading Advertising by Attorneys Concerning NOACs is Adversely Costly to Our Patients and Our Society. **2016**, 8, 1393
- 539 Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?. **2016**, 9, 1481 5
- 538 Periprocedural Management of Non-Vitamin K Oral Anticoagulants in Chronic Kidney Disease: A Review of Existing Heterogeneity and Contemporary Evidence. **2015**, 8, 1230 1
- 537 Management of Atrial Fibrillation in Patients With Kidney Disease. **2014**, 6, 989
- 536 Atrial Fibrillation In Heart Failure: New Directions In Diagnosis, Risk Assessment And Risk Reduction. **2014**, 6, 1036

535	Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know. <b>2016</b> , 16, 531-541	4
534	Left Atrial Appendage Closure Device With Delivery System: A Health Technology Assessment. <b>2017</b> , 17, 1-106	1
533	Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding. <b>2017</b> , 23, S67-S80	17
532	New horizons in anticoagulation: Direct oral anticoagulants and their implications in oral surgery. <b>2017</b> , 22, e601-e608	3
531	Use of dabigatran and rivaroxaban in non-valvular atrial fibrillation: one-year follow-up experience in an Italian centre. <b>2018</b> , 16, 209-214	3
530	Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?. <b>2018</b> , 15, 229-234	1
529	Use of direct oral anticoagulants in daily practice. <b>2018</b> , 8, 57-72	17
528	Direct Comparison of Low-Dose Dabigatran and Rivaroxaban for Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation. <b>2019</b> , 35, 42-54	5
527	Spontaneous Hemopericardium Complicated with Hemothorax in a Patient Receiving Edoxaban Therapy: A Case Report. <b>2019</b> , 35, 342-344	0
526	Treatment of atrial fibrillation in nursing homes: A place for direct acting oral anticoagulants?. <b>2018</b> , 4, 15-19	3
525	Anticoagulant Utilization and Direct Oral Anticoagulant Prescribing in Patients with Nonvalvular Atrial Fibrillation. <b>2019</b> , 72, 428-434	2
524	Assessment of a Pharmacist-Led Direct Oral Anticoagulant Monitoring Clinic. <b>2021</b> , 74, 7-14	0
523	An algorithmic approach to gastrointestinal bleeding in patients receiving antithrombotic agents. <b>2020</b> , 13, S8-S17	
522	Bleeding Entity Recognition in Electronic Health Records: A Comprehensive Analysis of End-to-End Systems. <b>2020</b> , 2020, 860-869	1
521	Anticoagulation for atrial fibrillation in heart failure patients: balancing between Scylla and Charybdis. <b>2021</b> , 18, 352-361	0
520	Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management. <b>2021</b> , 18, 376-397	
519	STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. <b>2021</b> , 53, 97-124	1
518	A Scoping Review of Alternative Anticoagulation Strategies for Hemodialysis Patients with a Mechanical Heart Valve. <b>2021</b> , 52, 861-870	

517	Ginkgo, Ginseng und Gerinnung. <b>2021</b> , 42, 301-311	1
516	The safety and efficacy of the use of oral anticoagulant medications in patients with diabetes mellitus: A systematic review.. <b>2021</b> , 29, 1374-1382	0
515	The 2020 CCS atrial fibrillation guidelines for pharmacists: Top 10 takeaways.. <b>2022</b> , 155, 107-118	1
514	Thrombotic events and rebleeding after hemorrhage in patients taking direct oral anticoagulants for non-valvular atrial fibrillation. <b>2021</b> , 16, e0260585	1
513	Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice. <b>2021</b> , 10,	
512	Rationale, Design and Methods of the Prospective Record of the Use of Dabigatran in Patients with Acute Stroke or TIA (PRODAST) Study.. <b>2021</b> , 6, 438-444	
511	Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study. <b>2022</b> , 346, 93-99	1
510	Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis. <b>2021</b> , 10, e022628	0
509	2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. <b>2021</b> , 37, 1389-1426	8
508	Effect of Cancer on Clinical Outcomes in Elderly Patients With Non-Valvular Atrial Fibrillation - Substudy of the ANAFIE Registry. <b>2021</b> ,	0
507	Ischemic stroke in oral anticoagulated patients with atrial fibrillation. <b>2021</b> ,	0
506	Fibrilaci3 auricular. <b>2021</b> , 13, 2617-2626	
505	Direct oral anticoagulants: A review for the non-specialist.. <b>2021</b> , 13, 9239	
504	Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis. <b>2021</b> , 10,	2
503	Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin. <b>2021</b> , 10, e020904	1
502	Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants. <b>2021</b> , 11, 22403	0
501	Net clinical benefit of direct oral anticoagulants in atrial fibrillation patients with or without diabetes mellitus: A meta-analysis of outcome trials. <b>2021</b> , 182, 109147	1
500	Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity. <b>2021</b> , 37, 100913	0



- 499 Additional Effects of Antiplatelet Therapy on Anticoagulant Agents in Patients With Bioprosthetic Valves and Atrial Fibrillation. **2021**, 0
- 498 Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study. **2021**, 8,
- 497 Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily. **2021**, 1 0
- 496 Hemoptysis in Quadriplegia with Atrial Fibrillation Who Was Taking Edoxaban: a Case Report. **2021**, 14,
- 495 Medical Therapy for Ischemic Stroke : Current State and Problems. **2021**, 30, 778-784
- 494 Progress in the Use of Anticoagulant Drugs in Elderly Patients. **2021**, 11, 5911-5916
- 493 Antithrombotika und Antihorrhagika. **2021**, 299-326 0
- 492 Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation.. **2022**, 1 0
- 491 Edoxaban vs. Warfarin in High-risk Patients with Atrial Fibrillation: A Comprehensive Analysis of High-Risk Subgroups.. **2022**, 0
- 490 Hip fractures risks in edoxaban versus warfarin users: a propensity score-matched population-based cohort study with competing risk analyses.. **2021**, 156, 116303 0
- 489 The Characteristics and Clinical Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease: From the Database of A Single-Center Registry.. **2020**, 13, 2308
- 488 Antithrombotic Therapy in the Prevention of Stroke.. **2021**, 9, 0
- 487 A Multisite Retrospective Review of Direct Oral Anticoagulants Compared to Warfarin in Adult Fontan Patients.. **2022**, 1
- 486 Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation.. **2022**, 0
- 485 Use of Novel Antithrombotic Therapies for Patients With Atrial Fibrillation and Bioprosthetic Valves.. **2022**, 86, 0
- 484 Serum or Plasma for Quantification of Direct Oral Anticoagulants?. **2022**, 1
- 483 Off-Label Use and Inappropriate Dosing of Direct Oral Anticoagulants in Cardio-pulmonary Disease.. **2022**, 1
- 482 Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial.. **2022**, 1 0

481	Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex.. <b>2022</b> ,	5
480	Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm.. <b>2022</b> , 23,	0
479	No Time to Lose: Cases of Anticoagulant Reversal Before Thrombolysis in Acute Ischemic Stroke Patients.. <b>2022</b> , 14, e21406	1
478	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation.. <b>2022</b> , 1	0
477	Comparative Safety and Effectiveness of Apixaban vs. Warfarin in Oral Anticoagulant-Naïve Japanese Patients With Non-Valvular Atrial Fibrillation - A Retrospective Chart Review Study.. <b>2021</b> , 86,	0
476	2022 Update of the Korean Clinical Practice Guidelines for Stroke: Antithrombotic Therapy for Patients with Acute Ischemic Stroke or Transient Ischemic Attack.. <b>2022</b> , 24, 166-175	0
475	Differences Between Anticoagulated Patients With Ischemic Stroke Versus Intracerebral Hemorrhage.. <b>2021</b> , e023345	
474	Comparative Effectiveness and Safety of Direct Oral Anticoagulants vs Warfarin Among Obese Patients With Atrial Fibrillation.. <b>2022</b> , 4, 395-405	
473	Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation-A SWEDEHEART study.. <b>2022</b> , 17, e0262580	0
472	Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists.. <b>2022</b> , 1	0
471	Genetic Factors of Renin-Angiotensin System Associated with Major Bleeding for Patients Treated with Direct Oral Anticoagulants.. <b>2022</b> , 14,	0
470	A Patient-Level Meta-Analysis: The End of the Era of Direct Oral Anticoagulant Developmental Trials in Patients With Atrial Fibrillation?. <b>2022</b> , 145, 256-258	0
469	Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol.. <b>2022</b> , 11,	0
468	Cardiac Arrhythmias. <b>2022</b> , 1065-1086	
467	Atrial Fibrillation. <b>2022</b> , 294-318	
466	Choice of antithrombotic therapy for patients with atrial fibrillation undergoing carotid angioplasty and stenting: a nationwide population-based study.. <b>2022</b> , 12, 1417	0
465	Direct oral anticoagulants versus Vitamin K antagonists in the treatment of left ventricular thrombosis: a systematic review and meta-analysis.. <b>2022</b> ,	0
464	Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban.. <b>2022</b> ,	2

463	Systematic review and meta-analysis of randomized controlled trials on safety and effectiveness of oral anticoagulants for atrial fibrillation in older people.. <b>2022</b> , 1	0
462	Decision-Making Process for the Management of Acute Stroke in Patients on Oral Anticoagulant: From Guidelines to Clinical Routine.. <b>2021</b> , 12, 794001	0
461	Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D.	0
460	Atrial fibrillation: focus on monitoring strategies after cryptogenic stroke.. <b>2022</b> ,	0
459	Risks and Benefits of Early Rhythm Control in Patients With Acute Strokes and Atrial Fibrillation: A Multicenter, Prospective, Randomized Study (the RAFAS Trial).. <b>2022</b> , e023391	0
458	Newly developed modified diluted prothrombin time reagent: A multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy.. <b>2022</b> , 210, 87-90	0
457	Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study.. <b>2022</b> , STROKEAHA121036695	2
456	Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation. <b>2022</b> ,	0
455	Prior direct oral anticoagulant dosage and outcomes in patients with acute ischemic stroke and non-valvular atrial fibrillation: A sub-analysis of PASTA registry study.. <b>2022</b> , 434, 120163	0
454	Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States. <b>2022</b> , 2022, 1-9	3
453	Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase.. <b>2022</b> ,	4
452	Use of Non-Vitamin K Dependent Oral Anticoagulant in Ischemic Stroke. <b>2022</b> , 40, 1-14	
451	Edoxaban-Based Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Stable Coronary Disease: Rationale and Design of the Randomized EPIC-CAD Trial.. <b>2022</b> ,	0
450	Long-term risk of adverse outcomes according to atrial fibrillation type.. <b>2022</b> , 12, 2208	0
449	Direct oral anticoagulants are associated with potentially bleeding lesions in suspected mid-gastrointestinal bleeding.. <b>2021</b> , 1-7	2
448	Efficacy and Safety of Non-recommended Dose of New Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.. <b>2021</b> , 8, 774109	1
447	Management of Atrial Fibrillation in the Outpatient Setting. <b>2022</b> , 387-408	
446	Direct costs in patients with nonvalvular atrial fibrillation newly indicated to apixaban: a retrospective-prospective single-arm cohort study. <b>2022</b> , 68, 26-33	

- 445 Which Renal Function Equation Should Be Used for Prescribing DOACs in Patients With Atrial Fibrillation?. **2022**, 2, 59-61
- 444 Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease.. **2022**, 24, A19-A31 ○
- 443 Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort.. **2022**, 6, e12650 1
- 442 Exercise Training Outcomes in Patients with Chronic Heart Failure with Reduced Ejection Fraction Depend on Medications and Disease Conditions: Proposal of SEEM Score to Judge Exercise Suitability.
- 441 Access Site Bleeding Complications with NOACs versus VKAs in Patients with Atrial Fibrillation Undergoing Cardiac Implantable Device Intervention.. **2022**, 11,
- 440 Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation.. **2022**, 24, A1-A10 ○
- 439 Non-Vitamin K Oral Anticoagulants Assessment in High Risk of Bleeding Patients with Non-Valvular Atrial Fibrillation.. **2022**, 7,
- 438 Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation.. **2022**, 24, A42-A55 ○
- 437 The Connubium among diabetes, chronic kidney disease and atrial fibrillation.. **2022**, 1
- 436 Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases.. **2022**, 24, A11-A18
- 435 Use of Anticoagulant Therapy in Patients with Acute Myocardial Infarction and Atrial Fibrillation.. **2022**, 58,
- 434 Potential for replacing warfarin with a direct oral anticoagulant for endoscopic mucosal resection in the colorectum: A multicenter, open-label, randomized controlled trial. **2022**, 2,
- 433 Two-year outcomes of UK patients newly diagnosed with atrial fibrillation: findings from the prospective observational cohort study GARFIELD-AF.. **2022**,
- 432 Optimal therapy for stroke prevention in atrial fibrillation: Is it left atrial appendage closure?. **2022**,
- 431 Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation.. **2022**, 1
- 430 Treatment standards for direct oral anticoagulants in patients with acute ischemic stroke and non-valvular atrial fibrillation: A survey among German stroke units.. **2022**, 17, e0264122
- 429 Comorbidities and Antithrombotic Treatment Pattern in Patients With Atrial Fibrillation.. **2022**, 13, 761603
- 428 Post-Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation.. **2022**, e022849 ○

427	Higher heart rate variability as a predictor of atrial fibrillation in patients with hypertension.. <b>2022</b> , 12, 3702	0
426	The WOEST 2 registry : A prospective registry on antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention.. <b>2022</b> ,	0
425	Computed tomography measurement for left atrial appendage closure.. <b>2022</b> , 1	0
424	Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study.. <b>2022</b> ,	0
423	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.	
422	Management of Cardiac Diseases in Liver Transplant Recipients: Comprehensive Review and Multidisciplinary Practice-Based Recommendations.. <b>2022</b> ,	2
421	Monitoring of Direct Oral Anticoagulants Plasma Levels for Secondary Stroke Prevention.. <b>2022</b> ,	1
420	Comparison of the Efficacy and Safety of Non-vitamin K Antagonist Oral Anticoagulants with Warfarin in Atrial Fibrillation Patients with a History of Bleeding: A Systematic Review and Meta-Analysis.. <b>2022</b> , 1	0
419	Atrial Fibrillation Management: A Comprehensive Review with a Focus on Pharmacotherapy, Rate, and Rhythm Control Strategies.. <b>2022</b> , 1	
418	Real-world management of targeted therapies in chronic lymphocytic leukemia.. <b>2022</b> , 10781552221090869	1
417	Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.. <b>2022</b> , 1	0
416	Optimal Anticoagulant Strategy for Periprocedural Management of Atrial Fibrillation Ablation: A Systematic Review and Network Meta-Analysis.. <b>2022</b> , 11,	0
415	Association Between Inappropriately Dosed Anticoagulation Therapy With Stroke Severity and Outcomes in Patients With Atrial Fibrillation.. <b>2022</b> , e024402	
414	Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.. <b>2022</b> , e023907	0
413	Arrhythmias in Chronic Kidney Disease.. <b>2022</b> , 17, e05	0
412	Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting.. <b>2022</b> , 12,	1
411	Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document.. <b>2022</b> , 12,	1
410	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.. <b>2022</b> , CJ-20-1212	6

409	Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!. <b>2022</b> , 74, 18	1
408	Current Therapeutic Approach to Atrial Fibrillation in Patients with Congenital Hemophilia.. <b>2022</b> , 12,	0
407	Trends of anticoagulant use and outcomes of patients with non-valvular atrial fibrillation: Findings from the RAFFINE registry.. <b>2022</b> ,	0
406	Atrial fibrillation: trends in prevalence and antithrombotic prescriptions in the community.. <b>2022</b> , 1	
405	A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation.. <b>2022</b> , 11,	
404	Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.. <b>2022</b> , 1	0
403	Impact of different dose reduction criteria for anti-Xa direct oral anticoagulants on bleeding complications: A single center observational study.	
402	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <b>2022</b> ,	1
401	On-treatment follow-up in real-world studies of direct oral anticoagulants in atrial fibrillation: Association with treatment effects. <b>2022</b> , 101024	
400	Direct oral anticoagulants versus warfarin for secondary prevention of cerebral infarction and bleeding in older adults with atrial fibrillation.. <b>2022</b> ,	1
399	Oral Anticoagulant Use for Patients with Atrial Fibrillation with Concomitant Anemia and/or Thrombocytopenia.. <b>2022</b> ,	
398	Left Atrial Appendage Closure: What the Evidence Does and Does Not Reveal-A View from the Outside.. <b>2022</b> , 11, 171-183	
397	Are Ischemic Strokes the Same? The Special Case Argument of Atrial Fibrillation.. <b>2022</b> , 11, 113-119	
396	Efficacy and Safety Profile of Novel Oral Anticoagulants in the Treatment of Left Atrial Thrombosis: A Systematic Review and Meta-Analysis.. <b>2022</b> , 96, 100670	1
395	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <b>2022</b> ,	15
394	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <b>2022</b> , 101161CIR0000000000001063	35
393	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <b>2022</b> , 101161CIR0000000000001062	6
392	Risk of Stroke With Mitral Stenosis: The Underlying Mechanism, Treatment, and Prevention.. <b>2022</b> , 14, e23784	

391	How to handle a delayed or missed dose of edoxaban in patients with non-valvular atrial fibrillation? A model-informed remedial strategy.. <b>2022,</b>	0
390	Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.. <b>2022,</b>	1
389	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <b>2022,</b>	49
388	From ancient leech to direct thrombin inhibitors and beyond: New from old.. <b>2022,</b> 149, 112878	0
387	Clinical features and outcomes of patients in different age groups with non-valvular atrial fibrillation receiving oral anticoagulants.. <b>2022,</b> 40, 101009	
386	Impact of anemia on the clinical outcomes in elderly patients with atrial fibrillation receiving apixaban: J-ELD AF registry subanalysis.. <b>2022,</b> 40, 100994	0
385	The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <b>2021,</b>	
384	Treatment strategies for patients with atrial fibrillation and chronic heart failure. <b>2021,</b> 93, 1545-1550	1
383	Association of Direct Oral Anticoagulants (DOACs) and Warfarin With Haemorrhagic Risk by Applying Correspondence Analysis to Data From the Italian Pharmacovigilance Database - A Case Study.. <b>2021,</b> 12, 790740	0
382	The incidence of cardiovascular thrombotic complications after laparoscopic resection in colorectal cancer in Japanese hospitals: A large-scale clinical study.	0
381	Survival Benefit of Anticoagulation Therapy in End Stage Kidney Disease Patients with Atrial Fibrillation: A Single Center Retrospective Study.. <b>2021,</b> 58,	0
380	Changes of antithrombotic prescription in atrial fibrillation patients with acute coronary syndrome or percutaneous coronary intervention and the subsequent impact on long-term outcomes: a longitudinal cohort study.. <b>2021,</b> 19, 100	1
379	Is there consensus on the perioperative management of Xa inhibitors in patients undergoing elective spine surgery?-A survey of current spine surgeon practices.. <b>2021,</b> 7, 458-466	
378	Safety and efficacy of direct oral anticoagulants (DOAC) in patients with anaemia and atrial fibrillation: an observational nation-wide Danish cohort study.. <b>2021,</b>	1
377	Associations of anemia with death and major bleeding in patients with atrial fibrillation: A report from the Chinese Atrial Fibrillation Registry Study.. <b>2021,</b>	2
376	Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries. <b>2021,</b> 4, e2137288	4
375	Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis.. <b>2021,</b> 14, e007971	6
374	Commentary: Novel oral anticoagulants effectuating novel applications in cardiac surgery!. <b>2021,</b>	

- 373 Evaluation of adherence of patients with atrial fibrillation to anticoagulant therapy at the outpatient stage of treatment. **2021**, 50-56
- 372 Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Bioprosthetic Valves-A Systematic Review and Meta-analysis.. **2021**, 12, 4797-4805
- 371 Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min. **2021**, 0
- 370 Ischemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48.. **2021**, 1
- 369 New Oral Anticoagulant Versus Vitamin K Antagonists for Thoracoscopic Ablation in Patients with Persistent Atrial Fibrillation: A Randomized Controlled Trial. **2021**, 1
- 368 Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer.. **2021**, 8, 774072 0
- 367 Asymptomatic Stroke in the Setting of Percutaneous Non-Coronary Intervention Procedures.. **2021**, 58,
- 366 Clinical outcomes of dabigatran use in patients with non-valvular atrial fibrillation and weight >120 kg. **2021**, 208, 176-180 2
- 365 Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis.
- 364 Oral anticoagulants and relative risk of acute kidney injury in patients with atrial fibrillation: A systematic review and network meta-analysis. **2022**, 100132
- 363 Bleeding disorders in implant dentistry: a narrative review and a treatment guide.. **2022**, 8, 20 2
- 362 Evaluation and Interventional Management of Cardiac Dysrhythmias. **2022**,
- 361 Meaningful Evidence for Anticoagulation in the Gray (Elder) Zone.. **2022**,
- 360 [Changes in Prescription Patterns of Oral Anticoagulants in Family Practices after Marketing Approval of Direct Oral Anticoagulants].. **2022**,
- 359 Antiplatelet therapy indication in patients also prescribed direct oral anticoagulants.. **2022**, 1
- 358 Antithrombotic Therapy Following Transcatheter Aortic Valve Replacement.. **2022**, 11, 0
- 357 Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. **2022**, 1
- 356 Use of Non-Vitamin K-Dependent Oral Anticoagulants in Elderly and Fragile Patients with Atrial Fibrillation.



- 355 Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score-weighted study.. **2022**, o
- 354 Pharmacokinetics of Apixaban and Tacrolimus or Cyclosporine in Kidney and Lung Transplant Recipients.. **2022**,
- 353 Atrial Fibrillation in Heart Failure: Focus on Antithrombotic Management.. **2022**, 40, 245-258 o
- 352 Table\_1.DOCX. **2019**,
- 351 Data\_Sheet\_1.docx. **2020**,
- 350 Data\_Sheet\_1.DOCX. **2018**,
- 349 DataSheet\_1.doc. **2020**,
- 348 DataSheet1.docx. **2018**,
- 347 Image1.tif. **2018**,
- 346 Image2.tif. **2018**,
- 345 Table1.DOCX. **2018**,
- 344 Table2.DOCX. **2018**,
- 343 Table3.DOCX. **2018**,
- 342 Table4.DOCX. **2018**,
- 341 Table5.DOCX. **2018**,
- 340 DataSheet\_1.pdf. **2020**,
- 339 Table\_1.DOCX. **2018**,
- 338 DataSheet\_1.docx. **2019**,

- 337 Efficacy and Safety of Direct Oral Anticoagulants (DOACs) Versus Warfarin in Atrial Fibrillation Patients with Prior Stroke: a Systematic Review and Meta-analysis.. **2022**, 1 0
- 336 Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study.. **2022**, 1 1
- 335 Direct oral anticoagulation in atrial fibrillation and heart valve surgery-a meta-analysis and systematic review.. **2022**, 16, 17539447221093963
- 334 OUP accepted manuscript. 0
- 333 Safety and efficacy of treatment with vitamin K antagonists in patients managed in a network of anticoagulation services or as routine general care. **2022**, 1, 29-37
- 332 Effectiveness and Safety of Reduced and Standard Daily Doses of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: A Cohort Study Using National Database Representing the Japanese Population.. **2022**, 14, 623-639 0
- 331 Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study.. **2022**, 20, 25 1
- 330 Evaluating pharmacokinetic drug-drug interactions of direct oral anticoagulants in patients with renal dysfunction.. **2022**, 1-14
- 329 Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study.. **2022**, 101161STROKEAHA121038239 1
- 328 Intracerebral hemorrhage and thrombin-induced alterations in cerebral microvessel matrix.. **2022**, 271678X221099092
- 327 Clinical effects of off-label reduced doses of Direct Oral Anticoagulants: A systematic review and meta-analysis.. **2022**, 2
- 326 Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation.. **2022**, 0
- 325 Impact of treatment adherence on the effectiveness and safety of oral anticoagulants in patients with atrial fibrillation: A retrospective cohort study.. **2022**,
- 324 COMPARE LAAO: Rationale and design of the randomized controlled trial 'COMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagulation therapy'.. **2022**, 250, 45-45
- 323 Investigational drugs for ischemic stroke: what's in the clinical development pipeline for acute phase and prevention?. **2022**, 0
- 322 Important Risk Factors in Patients with Nonvalvular Atrial Fibrillation Taking Dabigatran Using Integrated Machine Learning Scheme—Post Hoc Analysis. **2022**, 12, 756 2
- 321 Statistical Essentials in the Design and Analysis of Clinical Trials. **2022**, 69-74
- 320 Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.. **2022**, 1 0

- 319 Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation.. **2022**, 79, 1785-1798 2
- 318 Restarting anticoagulant therapy after intracranial hemorrhage in patients with atrial fibrillation: A nationwide retrospective cohort study. **2022**, 40, 101037
- 317 Coagulation factors XI and XII as possible targets for anticoagulant therapy.. **2022**, 214, 53-62 0
- 316 Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study.. **2022**, 31, 106520
- 315 Anticoagulants: dose control methods and inhibitors. **2022**, 16, 158-175 0
- 314 Echocardiographic Evaluation of the Patient with a Systemic Embolic Event. **2017**, 802-821
- 313 The Role of Echocardiography in Patients with Atrial Fibrillation and Flutter. **2017**, 822-836
- 312 Rationale design and efficacy of a smartphone application for improving self-awareness of adherence to edoxaban treatment: study protocol for a randomised controlled trial (adhere app).. **2022**, 12, e048777
- 311 Thromboembolism and bleeding in patients with atrial fibrillation and liver disease â a nationwide register-based cohort study. **2022**, 101952 1
- 310 XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia.
- 309 Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data. **2022**, 20, 1
- 308 Comparative Risks of Fracture Among Direct Oral Anticoagulants and Warfarin: A Systematic Review and Network Meta-Analysis. **2022**, 9,
- 307 Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy. **2022**, 5, e2213945 0
- 306 Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation. **2022**, 1, 100039 1
- 305 Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY. **2022**, 215, 37-40
- 304 An Approach to Combining Adherence-to-Therapy and Patient Preference Models for Evaluation of Therapies in Patient-Centered Care. **2022**, 425-440
- 303 Coagulation in Kidney Disease. **2022**, 1253-1272
- 302 Antithrombotic strategies after transcatheter aortic valve implantation: A systematic review and network meta-analysis of randomized controlled trials. **2022**, 1

- 301 Drug Interactions Affecting Oral Anticoagulant Use. 3
- 300 Off-label underdosing of four individual NOACs in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
- 299 ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes. **2022**, 24, C254-C271
- 298 ANMCO position paper "Appropriateness of prescribing direct oral anticoagulants in stroke and systemic thromboembolism prevention in adult patients with non-valvular atrial fibrillation" **2022**, 24, C278-C288
- 297 The use of non-vitamin K oral anticoagulants in dialysis patients—a systematic review.
- 296 Clinical outcomes of gastrointestinal bleeding management during anticoagulation therapy. **2022**, 17, e0269262 0
- 295 Frailty and oral anticoagulant prescription in adults with atrial fibrillation: A systematic review.
- 294 Five Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions from the Italian National Pharmacovigilance Network. **2022**, 11, 3207
- 293 Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting.
- 292 In Search of the Optimal Antithrombotic Regimen for Intracerebral Hemorrhage Survivors with Atrial Fibrillation.
- 291 Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. 2
- 290 Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis. 9,
- 289 A Review of Direct-acting Oral Anticoagulants and Their Use in Solid Organ Transplantation. Publish Ahead of Print,
- 288 Beneficial Effect of Edoxaban on Preventing Atrial Fibrillation and Coagulation by Reducing Inflammation via HBG1/HBD Biomarkers. 13,
- 287 Anticoagulants in Use. **2022**, 327-345
- 286 Monitoring Anticoagulation. **2022**, 417-429
- 285 Neurological Complications of Anticoagulation. **2022**, 549-560
- 284 Reaching Frail Elderly Patients to Optimize Diagnosis and Management of Atrial Fibrillation (REAFEL): A Feasibility Study of a Cross-Sectoral Shared-Care Model. **2022**, 19, 7383

- 283 Clinical Characteristics, Outcomes, and Risk Factors for Adverse Events in Elderly and Non-Elderly Japanese Patients With Non-Valvular Atrial Fibrillation âCompeting Risk Analysis From the Hokuriku-Plus AF Registry â2022, 0
- 282 A Watch-Type Electrocardiography Is a Reliable Tool for Detecting Paroxysmal Cardiac Arrhythmias. 2022, 11, 3333
- 281 Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis. 9, 0
- 280 Orale Antikoagulation bei Vorhofflimmern und stark eingeschränkter Nierenfunktion. 2022, 41, 411-415
- 279 Association of direct oral anticoagulant-proton pump inhibitor cotherapy with adverse outcomes: protocol for a population-based cohort study. 2022, 12, e057991
- 278 Leaflet thickening and motion after transcatheter aortic valve replacement: Design and rationale of the Rotterdam edoxaban trial. 2022,
- 277 Antithrombotic dilemmas in stroke medicine: new data, unsolved challenges. jnnp-2020-325249
- 276 Neue Ansätze zur Früherkennung von Vorhofflimmern. 2022, 41, 381-389
- 275 Effectiveness and safety of non-vitamin K direct oral anticoagulants in atrial fibrillation patients with bioprosthetic valve. 2022, 17, e0268113
- 274 Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: A survey among physicians. 2022, 28, 101861
- 273 First case of thrombolysis with non-immunogenic staphylokinase in a patient with ischemic stroke receiving dabigatran etexilate followed by thrombectomy. 2022, 122, 145 0
- 272 Use of a mobile application for the control of anticoagulation with warfarin: a cluster randomized controlled clinical trial - Ijuí/RS/Brazil. 58,
- 271 Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH AC Registry): A Nationwide Prospective Cohort Study in Japan.
- 270 Atrial Fibrillation and Stroke.
- 269 Timing of anticoagulation after acute ischemic stroke in patients with atrial fibrillation. 1-33
- 268 Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art. 2022, 18, 332-341
- 267 Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants. 9, 0
- 266 Acute Stroke and Atrial Fibrillation: Risk of Incorrect NOAC Dosage When Estimating Renal Function From Plasma Creatinine Only. 13,

- 265 Comparison of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and an Aortic Bioprosthetic Valve. **2022**, 0
- 264 Factor Xa inhibitors, Era to replace traditional anticoagulants. **2022**, 10, 17-21
- 263 Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study. **2022**, 20,
- 262 Left Atrial Appendage Occlusion: Current Stroke Prevention Strategies and a Shift Toward Data-Driven, Patient-Specific Approaches. **2022**, 100405
- 261 Hospitalization rates, stroke unit care, and recurrence rates in Austriaâs stroke cohort Epidemiologic analysis of 102,107 patients in a nation-wide acute stroke cohort between 2015 and 2019. 239698732211088 0
- 260 Risk of Venous Thromboembolic Complications in Patients with Atrial Fibrillation: a Systematic Review and Meta-analysis. **2022**, 18, 236-241
- 259 Prescribing direct-acting oral anticoagulants âMind the evidence gap.
- 258 Perioperative Management of Direct Oral Anticoagulants in Cardiac Surgery: Practice Recommendations Based on Current Evidence. **2022**,
- 257 Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.
- 256 Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry. 0
- 255 Effectiveness and safety of oral anticoagulant therapy in patients with atrial fibrillation with prior gastrointestinal bleeding: A systematic review and meta-analysis. 9,
- 254 Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial - KABUKI trial. **2022** , 12, e061225 1
- 253 Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions and Pharmacogenetics. 1
- 252 Evidence gaps pertaining to high-risk medications - Commentary on anticoagulation in new onset postoperative atrial fibrillation. **2022**,
- 251 A Practical Guide to Ordering and Interpreting Coagulation Tests for Patients on Direct Oral Anticoagulants in Singapore. **2016**, 45, 98-105 4
- 250 Cerebral venous thrombosis. **2022**, 80, 53-59
- 249 Wie antikoaguliert man Ätere und fragile Patienten?. **2022**, 04, 161-172
- 248 Stroke pathway âAn evidence base for commissioning âAn evidence review for NHS England and NHS Improvement. 2, 43

- 247 Polypharmacy and major adverse events in atrial fibrillation. **2022**, Publish Ahead of Print,
- 246 Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus. 2
- 245 Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry.
- 244 Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study. **2022**, 23,
- 243 Analysis of the trend in Oral Anticoagulation Overdose from 2010 to 2020 –Ireland.
- 242 Managing thrombotic risk in patients with diabetes. **2022**, 21, 0
- 241 Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients –A Subanalysis of the ENVISAGE-TAVI AF Trial –**2022**, 0
- 240 Apixaban for Anticoagulation after Robotic Mitral Valve Repair. **2022**, 0
- 239 Clinical and neuroimaging risk factors associated with the development of intracerebral hemorrhage while taking direct oral anticoagulants.
- 238 Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulant Among patients with nonvalvular atrial fibrillation and Cancer: A Systematic Review and Network Meta-analysis. **2022**, 101346 0
- 237 Drug-induced intracerebral hemorrhage. **2022**, 55-68
- 236 Prevalence, risk factors, and prediction of inappropriate use of non-vitamin K antagonist oral anticoagulants in elderly Chinese patients with atrial fibrillation: A study protocol. 9, 0
- 235 A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry. 1-9 0
- 234 A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation. 1
- 233 The complex interplay between diabetes mellitus and atrial fibrillation. 1-11 0
- 232 Adherence, persistence and switching rates of apixaban, dabigatran and rivaroxaban in non-valvular atrial fibrillation: a multicentre real-life analysis at 3 years. ejhpharm-2022-003338
- 231 Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies. 0
- 230 Drug-related problem characterization and the solved status associated factor analysis in a pharmacist-managed anticoagulation clinic. **2022**, 17, e0270263

- 229 Stroke Prevention in Atrial Fibrillation. **2022**, 2, 395-411
- 228 Left Atrial Appendage Closure for Stroke Prevention.
- 227 Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis. ○
- 226 Anticoagulación en pacientes con valvulopatía, más allá del ritmo. **2022**,
- 225 Warfarin is associated with higher rates of upper but not lower gastrointestinal bleeding compared to direct oral anticoagulants: a population-based propensity-weighted cohort study. **2022**, ○
- 224 Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care.
- 223 Bioequivalence and Pharmacokinetic Study of 2 Edoxaban Tablets in Healthy Chinese Subjects.
- 222 Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin-naïve or warfarin-experienced patients.
- 221 Comparison of the Efficacy and Safety of Apixaban and Warfarin in the Prevention of Stroke in Patients With Non-valvular Atrial Fibrillation: A Meta-Analysis. **2022**,
- 220 Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration?. ○
- 219 Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes. **2022**, 21,
- 218 Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis. 1-25
- 217 Stroke Prevention in Atrial Fibrillation. **2022**,
- 216 Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population: updated analysis. 1-10
- 215 Another possible determinant for ischemic stroke with nonvalvular atrial fibrillation other than conventional oral anticoagulant treatment: The relationship between whole blood viscosity and stroke?. **2022**, 31, 106687
- 214 Direct-acting oral anticoagulants in patients with atrial fibrillation and valvular heart disease. **2022**, 35, 17-18
- 213 Direct oral anticoagulants or vitamin K antagonists after TAVR: A systematic review and meta-analysis. **2022**, 365, 123-130 ○
- 212 Biochemistry of hemostasis. **2023**, 727-751



- 211 Antithrombotic therapy after transcatheter aortic valve replacement. ○
- 210 A Historical Perspective on the Reversal of Anticoagulants. ○
- 209 Twice- or once-daily dosing of direct oral anticoagulants and gastrointestinal bleeding in patient with atrial fibrillation. **2022**, 22, 100203 ○
- 208 Direct oral anticoagulants for the treatment of left ventricular thrombosis: an updated systematic review and meta-analysis. **2022**, 23, 672-677 ○
- 207 Cancer and stroke: What do we know and where do we go?. **2022**, 219, 133-140 ○
- 206 Intervenções para o Controle do Ritmo em Pacientes com Fibrilação Atrial – Anticoagulação Pré- Procedimento e Utilidade da Avaliação por Imagem do Vórtice Esquerdo. **2022**, 119, 520-521 ○
- 205 Effectiveness and Safety of Direct Oral Anticoagulants in Thai Patients with Atrial Fibrillation: A Real-World Retrospective Cohort Study. **2022**, 28, 107602962211300 1
- 204 Bleeding events in the emergency department with warfarin versus novel oral anticoagulants: A five-year analysis. **2022**, 25, 1308 ○
- 203 Rastreamento, Diagnóstico e Manejo da Fibrilação Atrial em Pacientes com Câncer: Evidências Atuais e Perspectivas Futuras. **2022**, 119, 328-341 ○
- 202 Sex differences in neurovascular disorders. **2022**, 69-99 ○
- 201 Safety and efficacy of non-vitamin K antagonist oral anticoagulants compared with well-controlled warfarin in Thai patients with atrial fibrillation. **2022**, 16, 131-136 ○
- 200 Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation – in-group comparison. **2022**, 20, 26-31 ○
- 199 Safety of a single bolus administration of heparin without the measurement of activated clotting time during cryoballoon ablation: a prospective randomized controlled trial. ○
- 198 Current Use of Oral Anticoagulation Therapy in Elderly Patients with Atrial Fibrillation: Results from an Italian Multicenter Prospective Study – The ISNEP Study. **2022**, 12, 1419 ○
- 197 Comparison of efficacy and safety between VKAs and DOACs in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis. ○
- 196 Left atrial appendage occlusion should be offered only to select atrial fibrillation patients. **2022**, 3, 448-454 ○
- 195 Residual Stroke Risk Despite Oral Anticoagulation in Patients with Atrial Fibrillation. **2022**, ○
- 194 Oral anticoagulants, time in therapeutic range and renal function over time in real-life patients with atrial fibrillation and chronic kidney disease. **2022**, 9, e002043 ○

193	GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide.	0
192	Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries.	0
191	Evaluation of newly-developed modified diluted prothrombin time reagent in non-valvular atrial fibrillation patients with direct oral anticoagulants: A comparative study with conventional reagents.	1
190	Direct Oral Anticoagulation Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves: a Retrospective, Real-World Cohort Study.	0
189	The association of non-vitamin K antagonist oral anticoagulants vs. warfarin and the risk of fractures for patients with atrial fibrillation: a systematic review and meta-analysis. 1-13	0
188	Prevention of Cardioembolic Complications in Patients with Atrial Fibrillation: Efficacy and Safety of Left Atrial Appendage Isolation and Oral Anticoagulants. <b>2022</b> , 18, 439-448	0
187	Dual therapy with oral anticoagulation and single antiplatelet agent versus monotherapy with oral anticoagulation alone in patients with atrial fibrillation and stable ischemic heart disease: a systematic review and meta-analysis.	0
186	Incidence of stroke in the first year after diagnosis of cancer—a systematic review and meta-analysis. 13,	0
185	Prediction of atrial fibrillation using a home blood pressure monitor with a high-resolution system. <b>2022</b> , 9, e002006	0
184	Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding. <b>2022</b> , 8, 645-647	0
183	Outcomes by Class of Anticoagulant Use for Nonvalvular Atrial Fibrillation in Patients With Active Cancer. <b>2022</b> , 4, 341-350	0
182	Real-time data on the prognosis of acute ischemic stroke patients in the Tochigi Clinical ObservatioNal registry for 1-year mortality of aCute ischEmic stRoKe patieNt (T-CONCERN) study.	0
181	Stroke Prevention in Atrial Fibrillation.	0
180	Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation.	0
179	Efficacy and safety of novel oral anticoagulants in patients with atrial nonvalvular atrial fibrillation and diabetes mellitus: a systematic review and meta-analysis. <b>2022</b> , 20,	0
178	Stroke genetics informs drug discovery and risk prediction across ancestries.	5
177	Efficacy and Safety of Anticoagulants in Patients with Atrial Fibrillation and History of Falls or Risk of Falls: A Systematic Review and Multilevel Meta-Analysis.	0
176	Privacy-aware multi-institutional time-to-event studies. <b>2022</b> , 1, e0000101	0

- 175 Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events. 13, 0
- 174 Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer. **2022**, 4, 351-353 0
- 173 Risk of bleeding among individuals on direct acting oral anticoagulants: an academic medical center cohort study.. **2022**, Publish Ahead of Print, 0
- 172 Comparison of Outcomes in Patients With Atrial Fibrillation Under Oral Anticoagulation Therapy Analyzed by Body Weight (<60, 60 to 100, and >100 kg). **2022**, 0
- 171 Evaluation of bleeding and anticoagulation markers by edoxaban and low-dose cyclosporine: A case series study. 0
- 170 Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. **2022**, 146, 1056-1066 3
- 169 The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function – A systematic review. **2022**, 107123 0
- 168 Orale Antikoagulation nach Klappeneingriffen – Was ist der Standard?. **2022**, 11, 477-483 0
- 167 Impact of anticoagulants on the clinical outcomes of colonic diverticular bleeding comparing warfarin and direct oral anticoagulants. **2022**, 12, 0
- 166 Off-label dose direct oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation: A new evidence of Asian dose. **2022**, 0
- 165 Hypertension and atrial fibrillation. Publish Ahead of Print, 0
- 164 Percutaneous Left Atrial Appendage Occlusion in Comparison to Non-Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation. **2022**, 11, 1
- 163 Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants. **2022**, 0
- 162 Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review. 0
- 161 Clinical features of ischemic stroke on recommended doses of direct oral anticoagulants. **2022**, 0
- 160 Antithrombotic treatment beyond one year after percutaneous coronary intervention in patients with atrial fibrillation. 0
- 159 Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known. 0
- 158 Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review. 1

- 157 Vitamin-K Antagonists vs. Direct Oral Anticoagulants on Severity of Upper Gastrointestinal Bleeding: A Retrospective Analysis of Italian and UK Data. **2022**, 11, 6382 ○
- 156 Impact of baseline renal function on the efficacy and safety of different Anticoagulants in Atrial Fibrillation Patients – A cohort study. **2022**, 20, ○
- 155 Putting external validation performance of major bleeding risk models into context. 2, ○
- 154 Factor XI inhibitors: cardiovascular perspectives. 2 ○
- 153 Efficacy and safety of oral anticoagulants in elderly patients with stable coronary artery disease and atrial fibrillation. **2022**, 20, ○
- 152 UK prescribing practice of anticoagulants in patients with chronic kidney disease: A nephrology and haematology-based survey. ○
- 151 Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19. **2022**, 2 ○
- 150 Kidney function and the comparative effectiveness and safety of direct oral anticoagulants versus warfarin in adults with atrial fibrillation: a multicenter observational study. ○
- 149 Impact of Integrating Machine Learning in Comparative Effectiveness Research of Oral Anticoagulants in Patients with Atrial Fibrillation. **2022**, 19, 12916 ○
- 148 Direct oral anticoagulants (DOACs): From the laboratory point of view. **2022**, 72, 459-482 ○
- 147 Impact of off-label under-dose direct oral anticoagulant on coagulation and fibrinolytic markers in patients with atrial fibrillation. ○
- 146 Direct Oral Anticoagulants vs Vitamin-K Antagonists in Thrombotic Antiphospholipid Syndrome: Meta-analysis of Randomized Controlled Trials. **2022**, ○
- 145 Effects of a Pharmacist-Led Educational Interventional Program on Electronic Monitoring – Assessed Adherence to Direct Oral Anticoagulants: A Randomized, Controlled Trial in Patients with Nonvalvular Atrial Fibrillation. **2022**, ○
- 144 Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. *heartjnl-2022-321114* ○
- 143 Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study. **2022**, 12, e064662 ○
- 142 Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors. ○
- 141 The importance of dosing frequency on the safety of DOACs. **2022**, 23, 100216 ○
- 140 Challenges in managing patients on anticoagulation: Thrombocytopenia, resumption after bleeding and recurrent thrombosis. 147827152211347 ○

- 139 International, Large-Scale, Real-World Clinical Data Confirm the Safety Profile of Rivaroxaban. 82-88 ○
- 138 Bayesian Meta-analysis of Direct Oral Anticoagulation Versus Vitamin K Antagonists With or Without Concomitant Antiplatelet After Transcatheter Aortic Valve Implantation in Patients With Anticoagulation Indication. 000331972211216 ○
- 137 Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage. **2022**, 5, e2240145 ○
- 136 Oral Anticoagulants in Very Elderly Nonvalvular Atrial Fibrillation Patients With High Bleeding Risks. **2022**, 2, 720-733 ○
- 135 Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms. **2022**, 23, 13955 ○
- 134 Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020. **2022**, 11, ○
- 133 Effect of direct oral anticoagulants in patients with atrial fibrillation with mitral or aortic stenosis: A review. 9, ○
- 132 Comparison of primary and secondary stroke prevention in patients with nonvalvular atrial fibrillation: Results from the RAFFINE registry. **2022**, 31, 106871 ○
- 131 Interpreting Findings with Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Collective Views on Data from Seminal Studies to Present in Clinical Practice. 34-41 ○
- 130 Outcomes of On-Label Reduced-Dose Edoxaban in Patients With Atrial Fibrillation: The LEDIOS Registry. **2022**, 37, ○
- 129 Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAf) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database. ○
- 128 Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions. ○
- 127 Efficacy and Safety of NOACs Compared With VKAs for Patients With Atrial Fibrillation After Transcatheter Aortic Valve Implantation: A System Review and Meta-Analysis. **2022**, 28, 107602962211451 ○
- 126 Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry. 64, ○
- 125 Minimisation of Bleeding Risks Due to Direct Oral Anticoagulants. 78-90 ○
- 124 Prescribing Patterns of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Retrospective Cohort Analysis. **2022**, 27, 107424842211422 ○
- 123 Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation. 14, 576-598 ○
- 122 Exploring the potential cost-effectiveness of a novel platelet assay for guiding dual antiplatelet therapy duration in acute coronary syndrome patients following percutaneous coronary intervention. **2023**, 34, 24-33 ○

121	Direct Oral Anticoagulants. An Updated Systematic Review of its Clinical Pharmacology and Clinical Effectiveness and Safety in Patients with Nonvalvular Atrial Fibrillation.	0
120	Development of Interstitial Lung Disease Among Patients With Atrial Fibrillation Receiving Oral Anticoagulants in Taiwan. <b>2022</b> , 5, e2243307	1
119	Sociodemographic Determinants of Oral Anticoagulant Prescription in Patients With Atrial Fibrillations: Findings From the PINNACLE Registry Using Machine Learning. <b>2022</b> ,	0
118	Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.	1
117	Patient Education Strategies to Improve Risk of Stroke in Patients with Atrial Fibrillation. <b>2022</b> , 16, 249-258	0
116	The Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients Hospitalized With Acute Kidney Injury. 106002802211392	0
115	The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. <b>2022</b> ,	0
114	Antithrombotic Therapy After Heart Valve Surgery, Contemporary Practice in the United Kingdom.	0
113	Temporal trends in admissions for atrial fibrillation and severe bleeding in England: an 18-year longitudinal analysis. <b>2023</b> , 57, 40-47	0
112	Feasibility, effectiveness, and safety of edoxaban administration through percutaneous endoscopic gastrostomy: 12-months follow up of the ORIGAMI study. 9,	0
111	Can warfarin be replaced by non-vitamin K anticoagulants in prosthetic valves?. <b>2022</b> , 20, 905-909	0
110	Atrial fibrillation and stroke.	1
109	Oral Anticoagulant Use and Appropriateness in Elderly Patients with Atrial Fibrillation in Complex Clinical Conditions: ACONVENIENCE Study. <b>2022</b> , 11, 7423	0
108	Acute, periprocedural and longterm antithrombotic therapy in older adults.	0
107	How Did We Get Here? Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement: A Review.	0
106	Stroke Prevention with Anticoagulant in Cardiovascular Problem: Focus in Atrial Fibrillation. <b>2023</b> , 269-292	0
105	Comparison of the effectiveness and safety of direct oral anticoagulants: nationwide propensity score-weighted study.	0
104	PrevAleNce and Associated factors of inappropriate dosing of direct Oral anticoagulants In patients with Atrial Fibrillation: the ANATOLIA-AF Study.	0

- 103 The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. **2022**, ○
- 102 Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis. **2022**, 51, ○
- 101 Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: An updated traditional and Bayesian network meta-analysis. 13, ○
- 100 UK prescribing practice of anticoagulants in patients with chronic kidney disease: a nephrology and haematology-based survey. **2023**, 24, 1
- 99 Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis. **2023**, 18, 624-629 ○
- 98 Analysis of Cerebrovascular Events after Coil Embolization of Unruptured Cerebral Aneurysms in Patients Taking Anticoagulants. **2022**, ○
- 97 Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Moderate to Severe Mitral Stenosis: A Systematic Review. **2023**, ○
- 96 Vitamin-K-antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: a real-world analysis of German claims data. **2023**, 13, e063490 ○
- 95 Clinical Studies with Anticoagulants that Have Changed Clinical Practice. ○
- 94 Arrhythmia Management in the Elderly. **2023**, 193-235 ○
- 93 Direct Oral Anticoagulants for Stroke Prevention in Special Populations: Beyond the Clinical Trials. **2023**, 11, 131 ○
- 92 Andexanet alfa (ONDEXXYA<sup>®</sup> for Intravenous Injection 200 mg), a reversal agent for direct factor Xa inhibitors: pharmacological characteristics and clinical evidence. **2023**, 158, 89-100 ○
- 91 Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation. ○
- 90 The optimum anticoagulation time after endovascular thrombectomy for atrial fibrillation-related large vessel occlusion stroke: a real-world study. ○
- 89 Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation. ○
- 88 Causes of Death in Elderly Patients With Non-Valvular Atrial Fibrillation âResults From the ANAFIE Registry â**2023**, ○
- 87 Oral anticoagulants: A plausible new treatment for Alzheimerâ disease?. ○
- 86 Comparison OF The Treatment Persistence Among Four Direct Oral Anticoagulants In Patients With Non-Valvular Atrial Fibrillation: A 5-Year Retrospective Cohort Study. ○

- 85 Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. **2023**, 23, 101-112 ○
- 84 Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D. ○
- 83 Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis. **2023**, 10, 13 ○
- 82 Real-world comparison of in-hospital complications after catheter ablation for atrial fibrillation between non-antivitamin K anticoagulants and warfarin: A propensity-matched analysis using nation-wide database. **2023**, 44, 101174 ○
- 81 Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness. **2023**, 12, 860 ○
- 80 Comparison of Early Complications of Oral Anticoagulants after Totally Thoracoscopic Ablation: Warfarin versus Non-vitamin K Antagonist Oral Anticoagulants. **2023**, ○
- 79 Retrospective analysis of gastrointestinal bleedings with direct oral anticoagulants reported to EudraVigilance. ○
- 78 Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAf) Patients with Diabetes in a US Population. ○
- 77 Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response. **2023**, 59, 254 ○
- 76 Edoxaban vs low molecular weight heparin in COVID-19 hospitalized patients with atrial fibrillation. ○
- 75 Cardiovascular assessment before liver transplantation. **2023**, 309-326 ○
- 74 Effects of direct oral anticoagulants vs. vitamin K antagonists on acute kidney injury in patients with atrial fibrillation: A systematic review. 10, ○
- 73 A Cost-Effectiveness Analysis of Biomarkers for Risk Prediction in Atrial Fibrillation. ○
- 72 Clinical significance of the rivaroxabanâ€¦ronedarone interaction: insights from physiologically based pharmacokinetic modelling. ○
- 71 Efficacy and safety outcomes of patients with atrial fibrillation compared between warfarin and non-vitamin K antagonist oral anticoagulants based on SAME-TT2R2 score. **2023**, 23, ○
- 70 Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing. 142-159 ○
- 69 Comparing Vitamin K Antagonists and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement: A Meta-Analysis. **2023**, 29, 107602962311585 ○
- 68 Hyperacute Medical Management of Intracerebral Haemorrhage. **2023**, 22, 16-19 ○



- 67 Head-to-head comparison between left atrial appendage occlusion and non-vitamin K oral anticoagulants in non-valvular atrial fibrillation patients: A systematic review and meta-analysis study. **2023**, ○
- 66 Direct oral anticoagulants in patients with a left-sided bioprosthetic heart valve: a systematic review and meta-analysis. **2023**, 18, 535-547 ○
- 65 The use of eponyms in medical case reports: etymological, quantitative, and structural analysis. **2023**, 17, ○
- 64 Management of Left Ventricular Thrombus. **2023**, 194, 111-112 ○
- 63 Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Treatment of Left Ventricular Thrombi—Insights from a Swiss Multicenter Registry. **2023**, 194, 113-121 ○
- 62 Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method. **2023**, 260, 124-140 ○
- 61 Left Atrial Appendage Closure. **2023**, 15, 169-181 ○
- 60 Safety and efficacy of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation electrical cardioversion: An update systematic review and meta-analysis. **2023**, 379, 40-47 ○
- 59 Long-term stroke and major bleeding risk in patients with non-valvular atrial fibrillation: A comparative analysis between non-vitamin K antagonist oral anticoagulants and warfarin using a clinical data warehouse. 14, ○
- 58 Anticoagulation for Atrial Fibrillation. Publish Ahead of Print, ○
- 57 Antithrombotische Therapie. **2022**, 233-263 ○
- 56 Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study. 14, ○
- 55 Safety of Direct Oral Anticoagulants for Gastrointestinal Hemorrhage in Patients With Nonvalvular Atrial Fibrillation. Publish Ahead of Print, ○
- 54 Development and refinement of diagnostic and therapeutic strategies for managing patients with cardiogenic stroke: An arduous journey. 11, 719-724 ○
- 53 Direct Oral Anticoagulants as the First Choice of Anticoagulation for Patients with Peripheral Artery Disease to Prevent Adverse Vascular Events: A Systematic Review and Meta-Analysis. **2023**, 10, 65 ○
- 52 Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country. **2023**, 23, 173-183 ○
- 51 Application of rivaroxaban in patients with non-valvular atrial fibrillation and end-stage kidney disease: A systematic review and meta-analysis. 10, ○
- 50 Potentially inappropriate medication among older patients with diabetic kidney disease. 14, ○

- 49 Emergent external ventricular drain placement in patients with factor Xa inhibitor-associated intracerebral hemorrhage after reversal with andexanet alfa. **2023**, 226, 107621 ○
- 48 Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study. **2023**, 147, 782-794 1
- 47 Aneurysmal Subarachnoid Hemorrhage in Hospitalized Patients on Anticoagulants—A Two Center Matched Case-Control Study. **2023**, 12, 1476 ○
- 46 Survival Benefit of Anticoagulation in Patients with End-Stage Kidney Disease and Atrial Fibrillation: A National Population-Based Study. ○
- 45 Initial Japanese Multicenter Experience and Age-Related Outcomes Following Left Atrial Appendage Closure. **2023**, 3, 272-284 ○
- 44 DOAC versus VKA in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis. **2023**, ○
- 43 Relation between laxative use and risk of major bleeding in patients with atrial fibrillation and heart failure. ○
- 42 Clinical Evaluation of Factor XIa Inhibitor Drugs. **2023**, 81, 771-779 ○
- 41 Direct Oral Anticoagulants: Laboratory Challenges and Antidotes. **2023**, 43, 037-043 ○
- 40 Two-Year Outcomes With a Next-Generation Left Atrial Appendage Device: Final Results of the PINNACLE FLX Trial. **2023**, 12, 1
- 39 Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes. **2023**, ○
- 38 Recurrent embolic stroke associated with adenomyosis: A single case report and literature review. ○
- 37 Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data. **2023**, 18, e0279297 ○
- 36 Evolving Trends in Consumption of Direct Oral Anticoagulants in 65 Countries/Regions from 2008 to 2019. **2023**, 83, 315-340 ○
- 35 Comparison of Efficacy and Safety of Direct Oral Anticoagulants and Warfarin between Patients in Asian and Non-Asian Regions: A Systematic Review and Meta-Regression Analysis. ○
- 34 Drug-drug interactions with direct oral anticoagulants for the prevention of ischemic stroke and embolism in atrial fibrillation: a narrative review of adverse events. **2023**, 16, 313-328 ○
- 33 Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review. **2023**, 62, 351-373 ○
- 32 Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach. ○

- 31 Secondary Ischemic Stroke Prevention. ○
- 30 Use of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Liver Disease. **2023**, 147, 795-797 ○
- 29 Sex Differences Among Patients Receiving Edoxaban vs Vitamin K Antagonist for Atrial Fibrillation After TAVR. **2023**, 2, 100259 ○
- 28 Atrial fibrillation: Primary prevention, secondary prevention, and prevention of thromboembolic complications: Part 2. 9, ○
- 27 Stroke Prevention with Left Atrial Appendage Closure in Patients with Atrial Fibrillation and Prior Intracranial Haemorrhage. **2023**, ○
- 26 Evaluation of the timing of using direct oral anticoagulants after ischemic stroke for patients with atrial fibrillation. **2023**, 9, e14456 ○
- 25 Spezifische Pharmakotherapie bei intrazerebralen Blutungen unter oraler Antikoagulation. **2023**, 18, 81-98 ○
- 24 Risk of hemorrhagic transformation with early use of direct oral anticoagulants after acute ischemic stroke: A pooled analysis of prospective studies and randomized trials. 174749302311648 ○
- 23 Increased major bleeding incidence in atrial fibrillation patients with apixaban: a review of Japanese post-marketing surveillance studies of direct oral anticoagulants. **2023**, 79, 579-588 ○
- 22 Direct oral anticoagulants for atrial fibrillation in early postoperative valve repair or bioprosthetic replacement. **2023**, ○
- 21 Clinical experience with idarucizumab in patients with atrial fibrillation taking dabigatran etexilate. **2023**, 28, 54-61 ○
- 20 Incidence and Predictors of Switching and Dose Change of Direct Oral Anticoagulants among Elderly Patients with Nonvalvular Atrial Fibrillation: A 5-Year Analysis of a Large Administrative Database. **2023**, 12, 2379 ○
- 19 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with  $\beta$ -Thalassemia. **2023**, 12, 491 ○
- 18 The association between direct oral anticoagulant concentration upon acute stroke and stroke outcome. **2023**, ○
- 17 Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation. **2023**, 6, e234086 ○
- 16 Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation. ○
- 15 Is There a Role for Vitamin K Antagonist in the Management of Atrial Fibrillation in 2023?. ○
- 14 Promising zone two-stage design for a single-arm study with binary outcome. 096228022311647 ○

- 13 Clinical Outcomes of Left Atrial Appendage Occlusion Versus Switch of Direct Oral Anti-coagulant in Atrial Fibrillation. ○
- 12 ACOD frente a AVK en pacientes con fibrilaci3n auricular y biopr3tesis: revisi3n sistem3tica y metan3lisis. **2023**, ○
- 11 Atrial fibrillation as a contributor to the mortality in patients with dementia: A nationwide cohort study. **10**, ○
- 10 The contribution of competing mechanisms in stroke despite anticoagulation in patients with atrial fibrillation. 239698732311683 ○
- 9 Challenges of Anticoagulant Therapy in Atrial Fibrillation—Focus on Gastrointestinal Bleeding. **2023**, **24**, 6879 ○
- 8 Ninety-Day Stroke or Transient Ischemic Attack Recurrence in Patients Prescribed Anticoagulation in the Emergency Department With Atrial Fibrillation and a New Transient Ischemic Attack or Minor Stroke. **2023**, **12**, ○
- 7 Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines. ○
- 6 Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study. **2023**, ○
- 5 Treatment of Persistent Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation on Adequate Oral Anticoagulation: Pathways of Care for All-comers and Heart Failure Patients. **9**, ○
- 4 Are Ischemic Strokes the Same? The Special Case Argument of Atrial Fibrillation. **2023**, **15**, 111-117 ○
- 3 Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study. **2023**, **18**, e0284425 ○
- 2 DOACs and rheumatic valvulopathy: always a red light?. **2023**, **25**, B41-B45 ○
- 1 Assessment of delayed bleeding after endoscopic submucosal dissection of early-stage gastrointestinal tumors in patients receiving direct oral anticoagulants. **29**, 2916-2931 ○